Use these links to rapidly review the document
TABLE OF CONTENTS

Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.            )

Filed by the Registrantý

Filed by a Party other than the Registranto

Check the appropriate box:

o

 

Preliminary Proxy Statement

o

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

ý

 

Definitive Proxy Statement

o

 

Definitive Additional Materials

o

 

Soliciting Material under §240.14a-12

 

IRONWOOD PHARMACEUTICALS, INC.

(Name of Registrant as Specified In Its Charter)

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

ý

 

No fee required.

o

 

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
  (1) Title of each class of securities to which transaction applies:
         
  (2) Aggregate number of securities to which transaction applies:
         
  (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
         
  (4) Proposed maximum aggregate value of transaction:
         
  (5) Total fee paid:
         

o

 

Fee paid previously with preliminary materials.

o

 

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

 

 

(1)

 

Amount Previously Paid:
        
 
  (2) Form, Schedule or Registration Statement No.:
         
  (3) Filing Party:
         
  (4) Date Filed:
         

Table of Contents

LOGOGRAPHIC


Table of Contents

GRAPHIC


100 Summer Street, Suite 2300
Boston, Massachusetts 02110

301 Binney Street
Cambridge, Massachusetts 02142

NOTICE OF 20192020 ANNUAL MEETING OF STOCKHOLDERS OF
IRONWOOD PHARMACEUTICALS, INC.

Date: Thursday, May 30, 2019Wednesday, June 3, 2020

Time:

 

9:00 a.m. Eastern Time

Place:

Location:


Ironwood Pharmaceuticals, Inc.
301 Binney Street
Cambridge, MA 02142Our 2020 annual meeting of stockholders will be a "virtual meeting." You will be able to attend the annual meeting, vote and submit questions via live webcast by visiting
www.virtualshareholdermeeting.com/IRWD2020.

Purpose:

 

We are holding the annual meeting for stockholders to consider fivethree company sponsored proposals:

 

 

1.

 

To elect our Class IIII directors, Andrew Dreyfus, Julie H. McHughMark G. Currie, Ph.D., Jon Duane and Edward P. Owens,Mark Mallon, each for a three-yearone-year term;

 

 

2.

 

To hold an advisory vote on named executive officer compensation; and

 


3.

 

To amend our Certificate of Incorporation to declassify the board of directors;



4.


To approve our 2019 Equity Incentive Plan; and



5.3.

 

To ratify our audit committee's selection of Ernst & Young LLP as our auditors for 2019.



We will also consider action on any other matter that may be properly brought before the meeting or any postponement(s) or adjournment(s) thereof.
2020.

We will also consider action on any other matter that may be properly brought before the meeting or any postponement(s) or adjournment(s) thereof.

Our board of directors recommends you vote "for" each of the nominees for Class IIII director (proposal no. 1), "for" on an advisory vote on named executive officer compensation (proposal no. 2), "for" the proposed amendment to our certificate of incorporation (proposal no. 3), "for" our 2019 Equity Incentive Plan (proposal no. 4), and "for" ratification of our selection of auditors (proposal no. 5)3). Only stockholders of record at the close of business on April 9, 201913, 2020 are entitled to notice of and to vote at the meeting.

        YouWe are cordially invitedpleased to attendtake advantage of the Securities and Exchange Commission rules that allow us to furnish proxy materials to our stockholders on the internet. We believe these rules allow us to provide you with the information that you need while lowering the costs of delivery and reducing the environmental impact of the annual meeting.

The safety of our stockholders is important to us and given the current guidance by public health officials and protocols that federal, state and local governments have imposed surrounding the coronavirus (COVID-19) pandemic, at the time of this filing we believe it is not advisable to hold our annual meeting in person. Our virtual stockholder format uses technology designed to provide our stockholders rights and opportunities to participate in the virtual meeting similar to an in-person meeting. You may attend the meeting, vote and submit questions electronically during the meeting via live webcast by visiting the website provided above. A list of shareholders of record will be available electronically during the meeting. The website can be accessed on a computer, tablet, or phone with internet connection. To ensurebe admitted to the meeting atwww.virtualshareholdermeeting.com/IRWD2020, you must enter the 16-digit control number found on your proxy card, voting instruction form or notice that your vote is counted at the annual meeting, however, please vote as promptly as possible.you received.


Proxy Material Mailing Date:

April 26, 201921, 2020

 

Sincerely,



LOGOGRAPHIC

Chief Executive Officer

Table of Contents


TABLE OF CONTENTS
GRAPHIC
Table of Contents

GRAPHIC

Letter From Our CEO

General Information

  1 

Security Ownership of Certain Beneficial Owners and Management


About Ironwood


 

53

 

Certain Relationships and Related Person Transactions


Our Board of Directors


 

95

 

Directors and Corporate Governance


12


Proposal No. 1—1Election of Directors


 

 

2625

 

Our Executives




27


Executive Compensation


 

 

2730

 

Proposal No. 2—2Advisory Vote on Named Executive Officer Compensation

  
5465
 
Our Stockholders

Proposal No. 3—Amendment to our Certificate of Incorporation to Declassify the Board of Directors

  
5567
 
Certain Relationships and Related Person Transactions

Proposal No. 4—Approval of our 2019 Equity Incentive Plan

  
5770
 

Proposal No. 5—3Ratification of our Selection of Auditors

  
6574
 
User's Guide

Section 16(a) Beneficial Ownership Reporting Compliance

  
6676
 

Stockholder Communications, Proposals and Nominations for Directorships

  
6680
 

SEC Filings

  
6781
 

Appendix A—Proposed Amendment to Our Certificate of Incorporation


A-1

Appendix B—2019 Equity Incentive Plan


B-1

2020  Proxy Statement    i


Table of Contents

LOGOGRAPHIC
Letter From Our CEO
LOGO

Dear Ironwood stockholders,

I want to begin by commenting on the COVID-19 pandemic. We are experiencing unprecedented times in modern history both in the U.S. and around the world. This pandemic is causing substantial disruption to our healthcare systems and severely impacting the global economy. At Ironwood, we are focused on doing our part to help mitigate the spread of COVID-19 and protect the safety and well-being of those around us, including our employees, healthcare providers, patients and broader communities, while striving to ensure that patients continue to gain access to the medications that they need. We have taken important actions to-date, and are regularly evaluating any potential impact on our business and assessing our preparedness and our plans to address the evolving circumstances.

Turning to the business: I became CEO of Ironwood just over a year ago now, and what a remarkable year it has been. Following the separation from Cyclerion Therapeutics, Inc., or the Separation, Ironwood became a GI-focused healthcare company dedicated to advancing the treatment of GI diseases and redefining the standard of care for GI patients. There are approximately 70 million people in the U.S. suffering from GI diseases today - that is one in every five Americans. The GI landscape represents an area of substantial unmet need, and one where we believe we can achieve real impact for patients.

We are now in the early stages of executing on our post-Separation strategy and our priorities are clear: drive LINZESS® (linaclotide) growth, advance our GI pipeline, and deliver sustainable profits.

LINZESS is now the number one prescription medicine in the U.S. for treating irritable bowel syndrome with constipation, or IBS-C, or chronic idiopathic constipation, or CIC, with growth of 14% in prescription demand in 2019 versus 2018. This strong performance translated to $803 million in 2019 U.S. net sales, which we benefit from through our 50-50 profit share with Allergan plc (together with its affiliates), or Allergan, in the U.S. We are proud of the successful execution of our strategy for LINZESS; we are one of the few pharmaceutical companies to have successfully discovered, developed and commercialized a product that has become the prescription market leader in its category. We look forward to working with our partner to continue to drive the LINZESS franchise forward for many years to come.

2020  Proxy Statement    1


Table of Contents

GRAPHIC

But LINZESS is only the first installment of the Ironwood story. We have two innovative GI product candidates in our pipeline that we believe, if approved, could make a huge difference in improving the lives of millions of patients. IW-3718 is our bile sequestering agent designed to treat the eight to 10 million adult patients suffering from refractory gastroesophageal reflux disease despite treatment on proton pump inhibitors. MD-7246 is our delayed release formulation of linaclotide that, together with Allergan, is being evaluated as an oral, non-opioid, pain-relieving agent for patients suffering from abdominal pain associated with certain GI diseases.

The company achieved strong financial results in 2019, reporting full year net income for the first time in Ironwood's history. We also met or exceeded all of our 2019 financial guidance metrics and took several important actions post-Separation, including relocating our headquarters to Boston, restructuring our debt and amending our ex-U.S. linaclotide partnerships for China (including Hong Kong and Macau) and Japan.

We have a remarkable team, that as of April 21, 2020, includes approximately 137 employees based in our Boston headquarters and another 170 customer-facing employees based around the country. I am proud of what this team accomplished in 2019 and believe strongly in the opportunities we have in front of us.

I encourage you to read the pages that follow that tell you more about our board, our team, our strategy, our pay, and our culture—all of the things that contributed to our strong results in 2019 and, we believe, position us well for the future. We ask for your voting support on the items described in this proxy statement so we can have the opportunity to continue to deliver for you and for all of our stockholders.

Sincerely,

GRAPHIC


Mark Mallon
Chief Executive Officer and Director

2    Ironwood


Table of Contents

301 BinneyGRAPHIC
About Ironwood

2019 was a transformational year for Ironwood.

We are a gastrointestinal, or GI, healthcare company dedicated to advancing the treatment of GI diseases and redefining the standard of care for millions of GI patients. We are focused on the development and commercialization of innovative GI product opportunities in areas of large unmet need, leveraging our demonstrated expertise and capabilities in GI diseases. Our flagship product is linaclotide, which is trademarked under the names LINZESS® and CONSTELLA®, and is approved to treat adult patients suffering from IBS-C or CIC in more than 35 countries around the world.

We also have two innovative late-stage development programs that we believe, if approved, could be important treatment options for millions of patients. MD-7246 is our delayed release formulation of linaclotide that we are advancing with our partner Allergan, as an oral, intestinal, non-opioid, pain-relieving agent for patients with abdominal pain associated with certain GI diseases. IW-3718 is our gastric retentive formulation of a bile acid sequestrant that we are developing for the potential treatment of refractory gastroesophageal reflux disease, or refractory GERD.

On April 1, 2019, we completed a tax-free spin-off of our soluble guanylate cyclase, or sGC, business into a separate publicly traded company, Cyclerion Therapeutics, Inc., or Cyclerion. In completing the separation of our sGC business into Cyclerion, or the Separation, in 2019 we advanced our vision of becoming the leader in U.S. GI healthcare, building on our commercial success with LINZESS and advancing our GI development portfolio. Our strategy is focused on three core priorities: drive LINZESS growth, advance our GI development portfolio and strengthen our financial profile. We made significant progress on each of these priorities in 2019:

1.
Drive LINZESS Growth

We grew our share of collaborative arrangements revenue related to sales of LINZESS in the U.S. by over 20% to $325.5 million for the year ended December 31, 2019.

We reported positive topline data from our Phase IIIb clinical trial evaluating LINZESS 290 mcg on overall abdominal symptoms (bloating, pain and discomfort) in adult patients with IBS-C. We and Allergan began communicating these additional benefits of LINZESS to healthcare practitioners in July 2019 and submitted a Supplemental New Drug Application, or sNDA, with the U.S. Food and Drug Administration, or U.S. FDA, in November 2019 to seek a more comprehensive description of the effects of LINZESS on its approved label.

2.
Advance GI Development Portfolio

We continued enrollment in our two pivotal Phase III clinical trials of IW-3718 for the potential treatment of refractory GERD.

We initiated a Phase II clinical trial with Allergan to evaluate the safety and efficacy of MD-7246 in adult patients with abdominal pain associated with IBS-D. The trial completed enrollment in December 2019 and completed patient dosing in March 2020.

We expanded our GI development organization through key roles including Chief Medical Officer, Head of Regulatory and Head of Biostatistics.

3.
Strengthen Financial Profile

We restructured our debt by issuing $200.0 million in 0.75% Convertible Senior Notes due 2024 and $200.0 million in 1.50% Convertible Senior Notes due 2026. The proceeds of these issuances were used to pay

2020  Proxy Statement    3


Table of Contents

GRAPHIC

PROXY STATEMENT FORWe demonstrated strong progress across our corporate goals in 2019, ANNUAL MEETING OF STOCKHOLDERS


GENERAL INFORMATION

        Ourexceeding some goals and achieving certain stretch goals. As a result, our 2019 company performance achievement multiplier, which we used as a key consideration in determining executive compensation for 2019 performance, was 130%, as determined by the compensation and HR committee of our board of directors is soliciting proxies fordirectors. Please see the 2019 annual meeting of stockholders. ThisCompensation Discussion and Analysis section included elsewhere in this proxy statement explains the agenda, votingfor detailed information and procedures for the meeting. Please read it carefully. This proxy statement and accompanying proxy card are first being mailedon compensation to the stockholders on or about April 26, 2019. All stockholders will also have the ability to access the proxy materials online through the Investors section of our website atwww.ironwoodpharma.com, under the heading Featured Reports.2019 named executive officers.

In this proxy statement, references to "the company" or "Ironwood" and, except within the Audit Committee Report and the Compensation Committee Report, references to "we", "us" or "our" mean Ironwood Pharmaceuticals, Inc. LINZESS® is a trademarkand CONSTELLA® are trademarks of Ironwood Pharmaceuticals, Inc. ZURAMPIC® and DUZALLO® are trademarks of AstraZeneca AB. Any other trademarks referred to in this proxy statement are the property of their respective owners. All rights reserved.

The contents of our website are not incorporated into this document and you should not consider information provided on our website to be part of this document.

        Who can vote.4    Ironwood

    Only stockholders of record of our common stock at the close of business on April 9, 2019 can vote at the meeting.

        Quorum.    In order to hold and complete the business of the annual meeting, we must have a majority of the votes entitled to be cast represented in person or by proxy at the meeting. On our record date, April 9, 2019, we had 155,621,305 shares of our common stock outstanding and entitled to vote. With respect to all matters that will come before the meeting, each share is entitled to one vote.

        Voting procedures—stockholders of record and beneficial owners.    You are a stockholder of record if your shares of our stock are registered directly in your own name with our transfer agent, Computershare Trust Company, N.A., or Computershare. You are a beneficial owner if a brokerage firm, bank, trustee or other agent, called a "nominee", holds your stock. This is often called ownership in "street name" because your name does not appear in the records of Computershare. If you hold your shares in street name, you should receive a voting instruction form from your broker nominee.

How to vote your shares.

        If you are a stockholder of record, there are four ways to vote:


Table of Contents

        If you are a beneficial owner of shares held in street name, there are four ways to provide voting instructions:

        How you may revoke your proxy or voting instructions.    If you are a stockholder of record, you may revoke or amend your proxy before it is voted at the annual meeting by writing to us directly in a timely manner "revoking" your earlier proxy, submitting a new proxy in a timely manner with a later date by mail, over the telephone or on the internet, or by attending the meeting and voting in person. Your last dated proxy timely received prior to or vote cast at the annual meeting will be counted.

        What if you receive more than one proxy card or voting instruction form?    This means that you may have more than one account at Computershare and/or with a nominee. Your proxy card or voting instruction form lists the number of shares you are voting. Please vote all proxy cards and voting instruction forms that you receive.

        We recommend you consolidate your holdings under the same name, address and tax identification number, if possible. This will eliminate some duplication of mailings and reduce costs. Please contact your nominee to consolidate accounts, or our transfer agent, Computershare, at (800) 662-7232, as applicable.

        Abstentions and "broker non-votes."    If you are a stockholder of record and you vote "abstain" or "withhold" on any matter, your shares will not be voted on that matter and will not be counted as votes cast in the final tally of votes on that matter. However, your shares will be counted for purposes of determining whether a quorum is present. If you are a beneficial owner holding shares through a broker nominee, you may instruct your broker nominee that you wish to abstain from voting on a proposal or withhold authority to vote for one or more nominees for director.

        A broker nominee generally may not vote on "non-routine" matters without receiving your specific voting instructions. A "broker non-vote" occurs when a broker nominee holding shares in street name votes shares on some matters at the meeting but not others. Like abstentions, broker non-votes are counted as present and entitled to vote for quorum purposes, but are not counted as votes cast. At the annual meeting, your broker nominee will not be able to submit a vote on the election of directors, the advisory votes on named executive officer compensation, the amendment to our certificate of


Table of Contents

incorporation or the approval of our 2019 Equity Incentive Plan unless it receives your specific instructions. If your broker nominee does not receive your specific instructions for these proposals, it will submit a broker non-vote. The broker nominee will, however, be able to vote on the ratification of the selection of our independent auditors even if it does not receive your instructions, so we do not expect any broker non-votes will exist in connection with such proposal.

        Discretionary authority.    If you are a stockholder of record and you properly submit your proxy card without making any specific selections, your shares will be voted on each matter before the annual meeting in the manner recommended by our board. If other matters not included in this proxy statement properly come before the annual meeting, the persons named on the proxy card, or otherwise designated, will have the authority to vote on those matters for you as they determine, to the extent permitted by Rule 14a-4(c)(1) of the Securities Exchange Act of 1934, as amended, or the Exchange Act. If you are a beneficial owner of shares held in street name, please see the discussion above regarding broker non-votes and the rules related to voting by broker nominees.

        Vote required.    The required vote for each of the proposals expected to be acted upon at the annual meeting is described below.


Table of Contents

        Results of the voting.    We expect to announce the preliminary voting results at the annual meeting. The final voting results will be tallied by the inspector of election and published in a Current Report on Form 8-K, which we are required to file with the Securities and Exchange Commission, or the SEC, within four business days following the annual meeting.

        Costs of solicitation and solicitation participants.    We will pay the costs of soliciting proxies. We will solicit proxies by email from stockholders who are our employees or who previously requested to receive proxy materials electronically. Our directors, our officers and our employees also may solicit proxies on our behalf, personally, electronically or by telephone, facsimile or mail or other means, without additional compensation. We may request that brokerage firms, banks and other agents forward proxy materials to beneficial owners and we would reimburse such institutions for their out-of-pocket expenses incurred.

        We may also utilize the assistance of third parties in connection with our proxy solicitation efforts, and we would compensate such third parties for their efforts. We have engaged one such third party, MacKenzie Partners, to assist in the solicitation of proxies and provide related advice and informational support, for service fees of up to $20,000 and the reimbursement of certain expenses.


Table of Contents


SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
GRAPHIC

        The following table sets forth certain information with respect to the beneficial ownership

Our Board of our common stock at April 2, 2019 for:

    each person whom we know beneficially owns more than five percent of our common stock;Directors

    each of our directors;

    each of our named executive officers; and

    all of our directors and executive officers as a group.

        The number of shares beneficially owned by each stockholder is determined under rules issued by the SEC. Under these rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power. Each of the stockholders listed has sole voting and investment power with respect to the shares beneficially owned by the stockholder unless noted otherwise, subject to community property laws where applicable.

        The percentage of common stock beneficially owned by each person is based on 155,621,305 shares of common stock outstanding on April 2, 2019. Shares of common stock that may be acquired within 60 days following April 2, 2019 pursuant to the exercise of options or the vesting of restricted stock units, or RSUs, are included in the holdings of each stockholder, as applicable, and are deemed to be outstanding for the purpose of computing the percentage ownership of such holder. Such amounts, however, are not included in the holdings of any other stockholder in the table and are not deemed to be outstanding for computing the percentage ownership of any other holder shown in the table. Beneficial ownership representing less than one percent is denoted with an "*."


Table of Contents

        Unless otherwise indicated, the address for each of the stockholders in the table below is c/o Ironwood Pharmaceuticals, Inc., 301 Binney Street, Cambridge, Massachusetts 02142.

Name of Beneficial Owner
 Number of
Shares of our
Common Stock(1)
 Percentage 

Officers and Directors(2)

       

Peter M. Hecht(3)

  5,430,772  3.4%

Gina Consylman(4)

  166,857  * 

Mark G. Currie(5)

  1,426,698  * 

Thomas A. McCourt(6)

  1,111,492  * 

William Huyett(7)

  149,185  * 

Andrew Dreyfus

  58,107  * 

Jon Duane

  2,995  * 

Marla Kessler

  2,995  * 

Mark Mallon

  0  * 

Julie H. McHugh

  88,131  * 

Catherine Moukheibir

  2,995  * 

Lawrence S. Olanoff

  37,553  * 

Edward P. Owens

  199,528  * 

All executive officers and directors as a group (14 persons)(8)

  9,294,741  5.9%

5% Security Holders

       

Wellington Management Group LLP(9)

  19,600,069  12.6%

FMR LLC (Fidelity)(10)

  14,872,366  9.6%

The Vanguard Group(11)

  13,360,554  8.6%

BlackRock, Inc.(12)

  12,317,565  7.9%

Brown Capital Management, LLC(13)

  10,129,331  6.5%

UBS Group AG(14)

  8,591,679  5.5%

(1)
The share numbers referenced in this table give effect to certain adjustments made on April 1, 2019 to outstanding equity awards in connection with the Separation (as defined below).

(2)
Marsha H. Fanucci, Amy W. Schulman, Dr. Hecht and Terrance G. McGuire transitioned off the Ironwood board of directors and joined the Cyclerion (as defined below) board of directors on April 1, 2019 in connection with the Separation. Douglas E. Williams transitioned off of the Ironwood board of directors on April 1, 2019 in connection with the Separation. In addition, Dr. Hecht and Dr. Currie transitioned from Ironwood to Cyclerion on April 1, 2019 in connection with the Separation, Dr. Currie joined the Ironwood board of directors, and Mr. Mallon became the chief executive officer of Ironwood and joined the Ironwood board of directors.

(3)
Includes 3,213,406 shares of common stock issuable to Dr. Hecht upon the exercise of options that are exercisable within 60 days following April 2, 2019.

(4)
Includes (i) 125,564 shares of common stock issuable to Ms. Consylman upon the exercise of options that are exercisable within 60 days following April 2, 2019 and (ii) 13,483 restricted stock units that vest on May 9, 2019.

(5)
Includes (i) 893,740 shares of common stock issuable to Dr. Currie upon the exercise of options that are exercisable within 60 days following April 2, 2019 and (ii) 13,483 restricted stock units that vest on May 9, 2019.

Table of Contents

(6)
Includes (i) 1,056,230 shares of common stock issuable to Mr. McCourt upon the exercise of options that are exercisable within 60 days following April 2, 2019 and (ii) 13,483 restricted stock units that vest on May 9, 2019.

(7)
Includes (i) 121,639 shares of common stock issuable to Mr. Huyett upon the exercise of options that are exercisable within 60 days following April 2, 2019 and (ii) 13,483 restricted stock units that vest on May 9, 2019.

(8)
Includes (i) 5,948,723 shares of common stock issuable upon the exercise of options that are exercisable within 60 days following April 2, 2019 and (ii) 67,415 restricted stock units that vest on May 9, 2019.

(9)
Based upon the information provided by Wellington Management Group LLP, or Wellington, Wellington Group Holdings LLP, or Wellington Group, Wellington Investment Advisors Holdings LLP, or Wellington Investment, and Wellington Management Company LLP, or Wellington Management and, collectively with Wellington, Wellington Group and Wellington Investment, the Wellington Entities, in a Schedule 13G/A filed on February 12, 2019, reporting as of December 31, 2018. According to this Schedule 13G/A, (i) Wellington has sole voting and sole dispositive power with respect to none of these shares, shared voting power with respect to 11,839,894 of these shares, and shared dispositive power with respect to all of these shares, (ii) Wellington Group has sole voting and sole dispositive power with respect to none of these shares, shared voting power with respect to 11,839,894 of these shares, and shared dispositive power with respect to all of these shares, (iii) Wellington Investment has sole voting and sole dispositive power with respect to none of these shares, shared voting power with respect to 11,839,894 of these shares, and shared dispositive power with respect to all of these shares, and (iv) Wellington Management has sole voting and sole dispositive power with respect to none of these shares, shared voting power with respect to 11,445,939 of these shares, and shared dispositive power with respect to 18,079,233 of these shares. The address of the Wellington Entities is c/o Wellington Management Company LLP, 280 Congress Street, Boston, MA 02210.

(10)
Based upon the information provided by FMR LLC, or FMR, and Abigail P. Johnson in a Schedule 13G/A filed on February 13, 2019, reporting as of December 31, 2018. According to this Schedule 13G/A, (i) FMR has sole voting power with respect to 3,466,218 of these shares, sole dispositive power with respect to all of these shares, and neither shared voting nor shared dispositive power with respect to these shares, and (ii) Ms. Johnson has neither sole nor shared voting power with respect to these shares, sole dispositive power with respect to all of these shares, and shared dispositive power with respect to none of these shares. The address of FMR and Ms. Johnson is 245 Summer Street, Boston, MA 02210.

(11)
Based upon the information provided by The Vanguard Group, or Vanguard, in a Schedule 13G/A filed on February 13, 2019, reporting as of December 31, 2018. According to this Schedule 13G/A, Vanguard has sole voting power with respect to 291,521 of these shares, sole dispositive power with respect to 13,063,404 of these shares, shared voting power with respect to 19,406 of these shares and shared dispositive power with respect to 297,150 of these shares. The address of Vanguard is 100 Vanguard Blvd., Malvern, PA 19355.

(12)
Based upon the information provided by BlackRock, Inc., or BlackRock, in a Schedule 13G/A filed on February 4, 2019, reporting as of December 31, 2018. According to this Schedule 13G/A, Blackrock has sole voting power with respect to 11,874,500 of these shares, sole dispositive power with respect to all of these shares, and shared voting and shared dispositive power with respect to none of these shares. The address of BlackRock is 55 East 52nd Street, New York, NY 10055.

(13)
Based upon the information provided by Brown Capital Management, LLC, or Brown Capital, in a Schedule 13G filed on February 14, 2019, reporting as of December 31, 2018. According to this

Table of Contents

(14)
Based upon the information provided by UBS Group AG, or UBS, in a Schedule 13G filed on February 13, 2019, reporting as of December 31, 2018. According to this Schedule 13G, UBS has sole voting power with respect to 7,632,375 of these shares, shared dispositive power with respect to all of these shares, and shared voting power and sole dispositive power with respect to none of these shares. The address of UBS is Bahnhofstrasse 45, Zurich, Switzerland.

Who We Are

Table of Contents


CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS

        Since January 1, 2018, except as described below, there has not been, nor is there currently proposed, any transaction or series of similar transactions to which we were or are a party in which the amount involved exceeded or exceeds $120,000 and in which any of our directors, executive officers, holders of more than 5% of any class of our voting securities, or any member of the immediate family of any of the foregoing persons, had or will have a direct or indirect material interest, other than compensation arrangements with directors and executive officers, which, with respect to our directors and named executive officers are described under the captionsDirectors and Corporate Governance—How We Are Paid andExecutive Compensation appearing elsewhere in this proxy statement.

Indemnification Agreements

        We have entered into indemnification agreements with each of our current directors and certain of our officers. These agreements require us to indemnify these individuals to the fullest extent permitted under Delaware law against liabilities that may arise by reason of their service to us, and to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified. We intend to enter into indemnification agreements with our future directors and executive officers.

The Separation

        On April 1, 2019, we completed the previously-announced separation of our soluble guanylate cyclase, or sGC, stimulators business and certain other assets and liabilities into an independent, publicly traded company, or the Separation. This Separation was effected by means of a distribution of all of the outstanding shares of common stock of Cyclerion Therapeutics, Inc., or Cyclerion, through a dividend in-kind of Cyclerion's common stock, with no par value, to our stockholders of record as of the close of business on March 19, 2019. In connection with the separation, we and Cyclerion have entered into certain agreements that effect the separation of Cyclerion's business from us and govern our relationship with Cyclerion after the Separation. The following is a summary of the terms of the material agreements that we have entered into with Cyclerion in connection with the Separation.

Separation Agreement

        In connection with the Separation, Ironwood entered into a separation agreement with Cyclerion, dated as of March 30, 2019, that, among other things, set forth our agreements with Cyclerion regarding the principal actions to be taken in connection with the Separation, including the distribution. The separation agreement identified assets to be transferred, liabilities to be assumed and contracts to be assigned to each of Ironwood and Cyclerion as part of the Separation, and it provided for when and how these transfers, assumptions and assignments would occur. The separation agreement was intended to provide for those transfers of assets and assumptions of liabilities that were necessary so that after the Separation, Ironwood and Cyclerion would have the assets necessary to operate their respective businesses and retain or assume the liabilities related to those assets. Each of Ironwood and Cyclerion agreed to releases, with respect to pre-distribution claims, and cross indemnities, with respect to post-distribution claims, that, except as otherwise provided in the separation agreement, were principally designed to place financial responsibility for the obligations and liabilities allocated to Ironwood under the separation agreement with Ironwood and financial responsibility for the obligations and liabilities allocated to Cyclerion under the separation agreement with Cyclerion.

        Ironwood and Cyclerion are also each subject to two-year non-solicit and non-hire restrictions. In addition, the parties agreed to certain non-competition restrictions, including Ironwood's agreement not to engage, for three years following the Separation, in the business of discovering, researching, developing, importing, exporting, manufacturing, marketing, distributing, promoting or selling any pharmaceutical product (a) for the diagnosis, prevention or treatment of diabetic nephropathy, heart


Table of Contents

failure with preserved ejection fraction or sickle cell disease or (b) that contains one or more sGC stimulators.

Development Agreement

        We entered into a development agreement with Cyclerion pursuant to which it provides us with certain research and development services with respect to certain of our products and product candidates, including without limitation MD-7246 (linaclotide delayed release) and IW-3718. Such research and development activities are governed by a joint steering committee comprised of representatives from both Cyclerion and Ironwood. We pay Cyclerion fees for such research and development services as mutually agreed upon by us and Cyclerion as provided under this development agreement with certain allowances for specified overages.

Transition Services Agreements

Ironwood Transition Services.    Prior to the Separation, we provided Cyclerion with significant corporate and shared services and resources related to corporate functions such as finance, human resources, internal audit, research and development, financial reporting and information technology, which we refer to collectively as the "Ironwood Services." Pursuant to this agreement, each of the Ironwood Services will continue for an initial term of up to two years (as applicable), unless earlier terminated or extended according to the terms of the transition services agreement. Cyclerion pays us fees for the Ironwood Services as mutually agreed upon by us and Cyclerion as provided under this transition services agreement, which fees are based on our cost of providing the Ironwood Services.

Cyclerion Transition Services.    We also entered into a second transition services agreement whereby Cyclerion provides certain finance, procurement and facilities services to us, which we refer to herein collectively as the "Cyclerion Services." Pursuant to this agreement, each of the Cyclerion Services will continue for an initial term of up to one year, unless earlier terminated or extended according to the terms of such transition services agreement. We pay Cyclerion fees for the Cyclerion Services, as mutually agreed upon by us and Cyclerion as provided under this transition services agreement, which fees are based on Cyclerion's cost of providing the Cyclerion Services.

Intellectual Property License Agreement

        We entered into an intellectual property license agreement with Cyclerion pursuant to which each party granted a license to certain know-how. We granted Cyclerion a perpetual, worldwide, non-exclusive, royalty-free, fully paid-up license to certain know-how to allow Cyclerion to use such know-how in connection with Cyclerion's ongoing and future research and development activities related to sGC stimulator products in any field. Cyclerion granted us a perpetual, worldwide, non-exclusive, royalty-free, fully paid-up license to certain know-how for use outside of the research and development of sGC stimulator products, including in our existing products and product candidates. Such licenses between the parties generally allow current or future uses of the know-how in connection with each party's respective fields.

Tax Matters Agreement

Allocation of taxes.    We entered into a tax matters agreement with Cyclerion that governs Ironwood's and Cyclerion's respective rights, responsibilities and obligations with respect to taxes (including taxes arising in the ordinary course of business and taxes, if any, incurred as a result of any failure of the distribution of Cyclerion common stock to Ironwood stockholders and certain related transactions to qualify as tax-free for U.S. federal income tax purposes), tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings and assistance and cooperation in respect of tax matters.


Table of Contents

Preservation of the tax-free status of certain aspects of the Separation.    The tax matters agreement imposed certain restrictions on Cyclerion and its subsidiaries (including restrictions on share issuances, business combinations, sales of assets and similar transactions) designed to preserve the tax-free status of the distribution and certain related transactions. The tax matters agreement also provided special rules that allocate tax liabilities in the event the distribution, together with certain related transactions, is not tax-free. In general, under the tax matters agreement, each party is expected to be responsible for any taxes imposed on Ironwood or Cyclerion that arise from the failure of the distribution, together with certain related transactions, to qualify as a transaction that is generally tax-free, for U.S. federal income tax purposes, under Sections 355 and 368(a)(1)(D) and certain other relevant provisions of the Code, to the extent that the failure to so qualify is attributable to an acquisition of stock or assets of, or certain actions, omissions or failures to act of, such party. If both Cyclerion and Ironwood are responsible for such failure, liability will be shared according to relative fault. U.S. tax otherwise resulting from the failure of the distribution, together with certain related transactions, to qualify as a transaction that is tax-free generally is the responsibility of Ironwood.

Employee Matters Agreement

        We entered into an employee matters agreement with Cyclerion, which allocated assets, liabilities and responsibilities relating to the employment, compensation, and employee benefits of Ironwood and Cyclerion employees, and other related matters in connection with the Separation, including the treatment of outstanding incentive equity awards and certain retirement and welfare benefit obligations. The employee matters agreement generally provided that, unless otherwise specified, Cyclerion is responsible for liabilities associated with employees who transferred to Cyclerion and employees whose employment terminated prior to the Separation but who primarily supported the Cyclerion business, whether incurred prior to or after the Separation, and Ironwood is responsible for liabilities associated with other employees, including employees retained by Ironwood.

The Private Placement

        On February 25, 2019, Cyclerion, which was Ironwood's wholly owned subsidiary at the time, and various investors entered into an amended and restated common stock purchase agreement pursuant to which these investors agreed to make an aggregate cash investment in Cyclerion. These investors included the following, each of whom was either an Ironwood director, an Ironwood executive officer, an immediate family member of an Ironwood director or executive officer, an entity related to such a director, executive officer or immediate family member, or beneficially owned at least 5% of Ironwood's common stock: accounts managed by direct or indirect subsidiaries of FMR LLC, a donor advised fund created by Peter M. Hecht, Ph.D., our former chief executive officer, Mark Currie, our former senior vice president, chief scientific officer and president of research and development and current member of our board of directors, and certain members of Dr. Hecht's immediate family, including through a trust or donor advised fund. Pursuant to this agreement, accounts managed by direct or indirect subsidiaries of FMR LLC agreed to invest up to $17,500,004, the donor advised fund created by Dr. Hecht agreed to invest up to $34,000,000, Dr. Currie agreed to invest up to $4,000,000 and Dr. Hecht's immediate family agreed to invest up to $6,800,000 in the aggregate. This investment closed on April 2, 2019.

Procedures for Related Party Transactions

        Under our code of business conduct and ethics, our employees, officers and directors are discouraged from entering into any transaction that may create or give the appearance of a conflict of interest. In addition, they must report any potential conflict of interest, including related party transactions, to certain members of our management or the chair of our audit committee. Pursuant to its charter, our audit committee must approve any related party transactions, including those


Table of Contents

transactions involving our directors. In approving or rejecting a proposed transaction, the audit committee considers the relevant facts and circumstances available to and deemed relevant by the audit committee, including the material terms of the transaction, risks, benefits, costs, availability of other comparable services or products and, if applicable, the impact on a director's independence. Our audit committee will approve only those transactions that, in light of known circumstances, are in, or are not inconsistent with, our best interests, as our audit committee determines in the good faith exercise of its discretion. A copy of our code of business conduct and ethics and our audit committee charter are available through the Investors section of our website atwww.ironwoodpharma.com, under the heading Corporate Governance.


DIRECTORS AND CORPORATE GOVERNANCE

Who We Are

The following table sets forth certain information, as of April 26, 2019,21, 2020, with respect to each of our directors:

Name
 Age Class Year
term
expires
 Audit
committee
 Governance
and Nominating
committee
 Compensation
and HR
committee

Andrew Dreyfus(1)

  60 III  2019     C

Julie H. McHugh, Chair(1)

  54 III  2019 ü ü  

Edward P. Owens

  72 III  2019 ü    

Mark G. Currie, Ph.D. 

  64 I  2020      

Jon Duane

  60 I  2020   ü ü

Mark Mallon, Chief Executive Officer

  56 I  2020      

Marla Kessler

  49 II  2021     ü

Catherine Moukheibir

  59 II  2021 C    

Lawrence S. Olanoff, M.D., Ph.D. 

  67 II  2021   C  

Name

 Age Class Year Term
Expires
 Audit
Committee
 Governance
and Nominating
Committee
 Compensation & HR
Committee

Mark G. Currie, Ph.D.

 65 I 2020   

Jon R. Duane

 61 I 2020    

Mark Mallon, Chief Executive Officer

 57 I 2020   

Marla L. Kessler

 50 II 2021     

Catherine Moukheibir

 60 II 2021 C  

Lawrence S. Olanoff, M.D., Ph.D.

 68 II 2021   C  

Andrew Dreyfus

 61 III 2022   C

Julie H. McHugh, Chair

 55 III 2022    

Edward P. Owens

 73 III 2022   
​ ​ ​ ​ ​ ​ 

"C" indicates chair of the committee.

(1)
On April 1, 2019, Mr. Dreyfus and Ms. McHugh, who had previously served as

2020  Proxy Statement    5


Table of Contents

GRAPHIC

Class I directors, resigned from the board of directors and were reappointed as Class III directors.

Class III Directors (accepted nomination(nominated for election at the 20192020 annual meeting)




MARK G.
CURRIE, Ph.D.

President and Chief Scientific Officer, Cyclerion
Therapeutics, Inc.

Age: 65

Director since 2019

Dr. Currie has served as president and chief scientific officer of Cyclerion Therapeutics, Inc. since April 2019, and previously served as senior vice president, chief scientific officer and president of R&D at Ironwood Pharmaceuticals, Inc. from 2002 to April 2019.

Prior to joining Ironwood, Dr. Currie directed cardiovascular and central nervous system disease research as vice president of discovery research at Sepracor, Inc.

Previously, Dr. Currie initiated, built and led discovery pharmacology and also served as director of arthritis and inflammation at Monsanto Company.

Dr. Currie earned a B.S. in biology from the University of South Alabama and holds a Ph.D. in cell biology from the Bowman-Gray School of Medicine of Wake Forest University.

We believe that Dr. Currie's vast experience leading the research and development efforts of an international biotechnology company will prove instrumental in guiding us through the research and development of novel therapies.

Andrew Dreyfus, 60, Independent
Director since 2016
Compensation and HR Committee, Chair6    Ironwood


        Mr. Dreyfus has served as president and chief executive officer for Blue Cross Blue Shield of Massachusetts, or BCBSMA, one of the largest independent, not-for-profit Blue Cross Blue Shield plans in the country, since September 2010. From July 2005 to September 2010, Mr. Dreyfus served as the executive vice president of health care services of BCBSMA. Prior to joining BCBSMA, he served as the first president of the Blue Cross Blue Shield of Massachusetts Foundation. Mr. Dreyfus also previously served as executive vice president of the Massachusetts Hospital Association and held a number of senior positions in Massachusetts state government, including undersecretary of consumer affairs and business regulation.

        Mr. Dreyfus is chair of the board of the National Institute for Health Care Management and serves on the board of directors of BCBSMA, the Blue Cross Blue Shield Association, Jobs for Massachusetts, Boys & Girls Club of Boston, RIZE Massachusetts and NACD New England Chapter, and the advisory board of Ariadne Labs. Mr. Dreyfus received a B.A. in English from Connecticut


Table of Contents

College. Mr. Dreyfus brings to our board of directors significant expertise in the healthcare payer and reimbursement market, and broad management and executive leadership experience, providing valuable insight as we continue to develop and commercialize medicines in an evolving healthcare landscape.

GRAPHIC



JON R.
DUANE

Senior Partner Emeritus, McKinsey & Company

Age: 61

Director since 2019

Board Committees

Governance and Nominating Committee

Compensation and HR Committee

Mr. Duane is senior partner emeritus at McKinsey & Company, or McKinsey. Before his retirement in December 2017, Mr. Duane had served as a partner at McKinsey since 1992.

At McKinsey, Mr. Duane founded and led the firm's biotech practice. In that role, Mr. Duane advised both private and public companies in the pharmaceutical, medical device and life science industries, as well as academic research centers, on various strategic initiatives.

Mr. Duane has served as the executive chair on the board of Nashville Biosciences since 2017.

Mr. Duane graduated from Wesleyan University with a B.A. in government and received an M.B.A from Harvard Business School.

Mr. Duane brings to the board of directors significant experience advising academic research centers and companies across the life science and medical device industries.




MARK MALLON

Chief Executive Officer,
Ironwood Pharmaceuticals, Inc.

Age: 57

Director since 2019

Prior to joining Ironwood in January 2019 as executive senior advisor and becoming chief executive officer of Ironwood in April 2019, Mr. Mallon was a member of the senior executive team of AstraZeneca PLC and led certain key strategic functions: global product and portfolio strategy, global medical affairs, and corporate affairs.

After joining AstraZeneca in 1994, Mr. Mallon held a number of senior sales and marketing roles, including executive vice president, international from January 2013 to April 2017 and executive vice president, global product and portfolio strategy from August 2016 to December 2018.

Mr. Mallon started his career in the biopharmaceutical industry in management consulting.

Mr. Mallon earned his B.S. in chemical engineering from the University of Pennsylvania and his M.B.A. in marketing and finance from the Wharton School of Business.

Given his role as our chief executive officer, we believe Mr. Mallon brings unique and in-depth insight on the operations and management of the company, which together with Mr. Mallon's extensive experience building and shaping businesses, and his deep knowledge of GI, is valuable to our board of directors.

Julie H. McHugh, 54, Chair, Independent
Director since 2014
Audit Committee member
Governance and Nominating Committee member2020  Proxy Statement    7


        Ms. McHugh most recently served as chief operating officer for Endo Health Solutions, Inc., from March 2010 through May 2013, where she was responsible for the specialty pharmaceutical and generic drug businesses. Prior to joining Endo, Ms. McHugh was the chief executive officer of Nora Therapeutics, Inc., a venture capital backed biotech start-up company focused on developing novel therapies for the treatment of infertility disorders. Before that she served as company group chairman for Johnson & Johnson's (J&J) worldwide virology business unit, and previously she was president of Centocor, Inc., a J&J subsidiary. While at J&J, Ms. McHugh oversaw the development and launches of several products, including Remicade® (infliximab), Prezista® (darunavir) and Intelence® (etravirine), and she was responsible for oversight of a research and development portfolio including compounds for HIV, hepatitis C, and tuberculosis. Prior to joining Centocor, Ms. McHugh led the marketing communications for gastrointestinal drug Prilosec® (omeprazole) at Astra-Merck Inc.

        She currently serves on the board of visitors for the Smeal College of Business of the Pennsylvania State University as well as on the board of directors of Aerie Pharmaceuticals, Inc., Lantheus Holdings, Inc. and Trevena, Inc., all publicly held companies, and The New Xellia Group, a privately held company. She previously served on the board of directors for ViroPharma Inc., Epirus Biopharmaceuticals, Inc., the Biotechnology Industry Organization (BIO), the Pennsylvania Biotechnology Association and the New England Healthcare Institute (NEHI).

        Ms. McHugh received her masters of business administration degree from St. Joseph's University and her Bachelor of Science degree from Pennsylvania State University. Ms. McHugh's experience as a chief executive officer and a chief operating officer at large multinational pharmaceutical companies make her a valuable member of our board of directors, particularly as we evolve as a company and seek to maximize our current products and execute on our corporate strategy and associated pipeline.

Edward P. Owens, 72, Independent
Director since 2013
Audit Committee member

        Mr. Owens was previously partner, portfolio manager and global industry analyst with Wellington Management Company, LLP where he worked in investment management since 1974. He was the portfolio manager of the Vanguard Health Care Fund for 28 years from its inception in May 1984 until his retirement from Wellington in December 2012.

        Mr. Owens serves on the board of directors of Stealth BioTherapeutics Corp. He has a B.S. in physics from the University of Virginia and an M.B.A. from Harvard Business School. He brings to our board extensive experience in evaluating and investing in life sciences companies, providing valuable insight as we continue to strive towards our goal of maximizing long-term stockholder value.

Class I Directors (term expires at the 2020 annual meeting)

Mark G. Currie, Ph.D., 64
Director since 2019

        Dr. Currie has served as president of Cyclerion Therapeutics, Inc. since April 2019, and previously served as senior vice president, chief scientific officer and president of research and development at


Table of Contents

Ironwood Pharmaceuticals, Inc. from 2002 to April 2019. Prior to joining Ironwood, Dr. Currie directed cardiovascular and central nervous system disease research as vice president of discovery research at Sepracor Inc. Previously, Dr. Currie initiated, built and led discovery pharmacology and also served as director of arthritis and inflammation at Monsanto Company. Dr. Currie earned a B.S. in biology from the University of South Alabama and holds a Ph.D. in cell biology from the Bowman-Gray School of Medicine of Wake Forest University. We believe that Dr. Currie's vast experience leading the research and development efforts of an international biotechnology company will prove instrumental in guiding us through the research and development of novel therapies.

GRAPHIC

Jon R. Duane, 60, Independent
Director since 2019
Governance and Nominating Committee member
Compensation and HR Committee member

        Mr. Duane is senior partner emeritus at McKinsey & Company, or McKinsey. Before his retirement in December 2017, Mr. Duane had served as a partner at McKinsey since 1992. At McKinsey, Mr. Duane founded and led the firm's biotech practice. In that role, Mr. Duane advised both private and public companies in the pharmaceutical, medical device and life science industries, as well as academic research centers, on various strategic initiatives. Mr. Duane has served as the executive chair on the board of Nashville Biosciences since 2017.

        Mr. Duane graduated from Wesleyan University with a B.A. in government and received an M.B.A from Harvard Business School. Mr. Duane brings to the board of directors significant experience advising academic research centers and companies across the life science and medical device industries.

Mark Mallon, 56
Director and chief executive officer since 2019

        Prior to joining Ironwood in January 2019 as executive senior advisor and becoming chief executive officer of Ironwood in April 2019, Mr. Mallon was a member of the senior executive team of AstraZeneca PLC (AstraZeneca) and led its strategic functions, global product and portfolio strategy, global medical affairs, and corporate affairs. After joining AstraZeneca in 1994, Mr. Mallon held a number of senior sales and marketing roles, including executive vice president, international from January 2013 to April 2017 and executive vice president, global product and portfolio strategy from August 2016 to present. Mr. Mallon started his career in the biopharmaceutical industry in management consulting.

        Mr. Mallon earned his B.S. in chemical engineering from the University of Pennsylvania and his M.B.A. in marketing and finance from the Wharton School of Business. Mr. Mallon's extensive experience building and shaping businesses, combined with his deep knowledge of GI, will be valuable to our board of directors.

Class II Directors (term expires at the 2021 annual meeting)




MARLA L.
KESSLER

Senior Vice President for Strategy, Marketing and Communications, IQVIA, Inc.

Age: 50

Director since 2019

Board Committees

Compensation and HR Committee

Ms. Kessler has been the senior vice president for strategy, marketing and communications for IQVIA Holdings Inc., or IQVIA, (formerly IMS Health and Quintiles) since October 2016.

Previously, Ms. Kessler served in various roles for IQVIA, including vice president for global services marketing and knowledge management from June 2013 to September 2016, regional leader of the IMS Consulting Group in Europe from 2011 to 2013, location manager for the London IMS Consulting Group from 2009 to 2011 and senior principal from 2008 to 2009.

Before joining IQVIA, Ms. Kessler led several marketing efforts for Pfizer, Inc. from 2004 to 2007 and worked in consulting for McKinsey & Company from 1996 to 2004.

Ms. Kessler received a B.S. in economics from Arizona State University and an M.B.A. from the Fuqua School of Business at Duke University.

Ms. Kessler provides an important commercial perspective to our board of directors given her expertise in strategic marketing, evidence-based research and customer experience in the life science industry.




CATHERINE
MOUKHEIBIR

Chief Executive Officer,
MedDay Pharmaceuticals

Age: 60

Director since 2019

Board Committees

Audit Committee, Chair

Ms. Moukheibir currently serves as chief executive officer, as well as chairman of the board of directors, of MedDay Pharmaceuticals, or MedDay.

Prior to that, Ms. Moukheibir served as the senior advisor for finance and a member of the executive board of directors at Innate Pharma SA from March 2011 to December 2016, and as the chief financial officer for Movetis N.V. from 2008 to 2010, when it was acquired.

Ms. Moukheibir previously served as the director of capital markets for Zeltia Group S.A. from 2001 to 2007.

In addition to her service on the board of directors of MedDay, Ms. Moukheibir also serves on the board of directors of Orphazyme A/S, Genkyotex SA, and Kymab Group Limited. She also held past directorships on the boards of directors of Ablynx NV, Cerenis Therapeutics SA and Creabilis S.A.

Ms. Moukheibir has an M.A. in economics and an M.B.A. from Yale University.

Ms. Moukheibir's long leadership career in the biopharmaceutical industry, as well as her deep background in international finance, provide her with valuable business and financial expertise in support of our corporate objectives.

Marla L. Kessler, 49, Independent
Director since 2019
Compensation and HR Committee member8    Ironwood


        Ms. Kessler has been the senior vice president for strategy, marketing and communications for IQVIA (formerly IMS Health and Quintiles) since October 2016. Previously, Ms. Kessler served in various roles for IQVIA, including vice president for global services marketing and knowledge management from June 2013 to September 2016, regional leader of the IMS Consulting Group in Europe from 2011 to 2013, location manager for the London IMS Consulting Group from 2009 to 2011 and senior principal from 2008 to 2009. Before joining IQVIA, Ms. Kessler led several marketing


Table of Contents

GRAPHIC

efforts for Pfizer, Inc. from 2004 to 2007 and worked in consulting for McKinsey & Company from 1996 to 2004.

        Ms. Kessler received a B.S. in economics from Arizona State University and an M.B.A. from the Fuqua School of Business at Duke University. As a result of her marketing expertise in the life sciences and technology industries, Ms. Kessler provides an important outside perspective to our board of directors as we continue to execute our corporate goals on delivering treatments to patients.




LAWRENCE S.
OLANOFF, M.D., Ph.D.

Former Chief Operating Officer, Forest Laboratories, Inc.

Age: 68

Director since 2015

Board Committees

Governance and Nominating Committee, Chair

Dr. Olanoff most recently served as chief operating officer for Forest Laboratories, Inc., or Forest, (acquired by Allergan plc) from October 2006 to December 2010. Dr. Olanoff also served as a director of Forest from October 2006 to July 2014.

From July 2005 to October 2006, Dr. Olanoff was president and chief executive officer and a director at Celsion Corporation. He also served as executive vice president and chief scientific officer of Forest from 1995 to 2005.

Catherine Moukheibir, 59, Independent
Director since 2019
Audit Committee, Chair

        Ms. Moukheibir most recently served as the senior advisor for finance and a member of the executive board at Innate Pharma from March 2011 to December 2016. Prior to that, Ms. Moukheibir was the chief financial officer for Movetis N.V. from 2008 to 2010, when it was acquired. Ms. Moukheibir previously served as the director of capital markets for Zeltia Group S.A. from 2001 to 2007. Ms. Moukheibir presently serves on the board of directors of Orphazyme, GenKyoTex, MedDay Pharmaceuticals and Zealand Pharma A/S. She also held past directorships on the boards of Ablynx, Cerenis and Creabilis S.A.

        Ms. Moukheibir has an M.A. in economics and an M.B.A. from Yale University. Ms. Moukheibir's long leadership career in the biopharmaceutical industry, as well as her deep background in international finance, provide her with valuable business and financial expertise in support of our corporate objectives.

Lawrence S. Olanoff, M.D., Ph.D., 67, Independent
Director since 2015
Governance and Nominating Committee, Chair

        Dr. Olanoff most recently served as chief operating officer for Forest Laboratories, Inc. (acquired by Allergan plc) from October 2006 to December 2010. Dr. Olanoff also served as a director of Forest from October 2006 to July 2014. From July 2005 to October 2006, Dr. Olanoff was president and chief executive officer and a director at Celsion Corporation. He also served as executive vice president and chief scientific officer of Forest from 1995 to 2005. Prior to joining Forest in 1995, Dr. Olanoff served as senior vice president of clinical research and development at Sandoz Pharmaceutical Corporation (now a division of the Novartis Group) and at the Upjohn Company in a number of positions, including corporate vice president of clinical development and medical affairs.

In addition, he is currently an adjunct assistant professor and special advisor to the president for corporate relations at the Medical University of South Carolina (MUSC), an ex-officio director of the MUSC Foundation for Research Development, chairman of the board of directors of Mitochondria in Motion, and a member of the board of directors of Clinical Biotechnology Research Institute at Roper St. Francis Hospital, the Westedge Project, and the Zucker Institute for Applied Neurosciences. Dr. Olanoff also held past directorships on the boards of directors of Axovant Sciences Ltd. and Celsion Corporation.

Dr. Olanoff received his Ph.D. in biomedical engineering and M.D. degree from Case Western Reserve University.

Dr. Olanoff's detailed knowledge of the pharmaceutical industry, his broad operational experience and his research and development leadership over the course of his career make him an important asset to our board of directors.

Class III Directors (term expires at the Upjohn Company2022 annual meeting)




ANDREW
DREYFUS

President and Chief Executive Officer for Blue Cross Blue Shield of Massachusetts

Age: 61

Director since 2016

Board Committees

Compensation and HR Committee, Chair

Mr. Dreyfus has served as president and chief executive officer for Blue Cross Blue Shield of Massachusetts, or BCBSMA, one of the largest Blue Cross Blue Shield plans in the country, since September 2010. From July 2005 to September 2010, Mr. Dreyfus served as the executive vice president of health care services of BCBSMA.

Prior to joining BCBSMA, he served as the first president of the Blue Cross Blue Shield of Massachusetts Foundation. Mr. Dreyfus also previously served as executive vice president of the Massachusetts Hospital Association and held a number of senior positions in Massachusetts state government, including undersecretary of consumer affairs and business regulation.

Mr. Dreyfus serves on the board of directors of BCBSMA, the Blue Cross Blue Shield Association, Jobs for Massachusetts, Boys & Girls Club of Boston, RIZE Massachusetts and NACD New England Chapter, and the advisory board of Ariadne Labs.

Mr. Dreyfus received a B.A. in English from Connecticut College.

Mr. Dreyfus brings to our board of directors significant expertise in the healthcare payer and reimbursement market, and broad management and executive leadership experience, providing valuable insight as we continue to develop and commercialize medicines in an evolving healthcare landscape.

2020  Proxy Statement    9


Table of positions including corporate viceContents

GRAPHIC





JULIE H.
McHUGH, CHAIR

Former Chief Operating Officer, Endo Health Solutions, Inc.

Age: 55

Director since 2014

Board Committees

Audit Committee

Governance and Nominating Committee

Ms. McHugh most recently served as chief operating officer for Endo Health Solutions, Inc., or Endo, from March 2010 through May 2013, where she was responsible for the specialty pharmaceutical and generic drug businesses.

Prior to joining Endo, Ms. McHugh was the chief executive officer of Nora Therapeutics, Inc.

Before that she served as company group chairman for the worldwide virology business unit of Johnson & Johnson, or J&J, and previously she was president of Centocor, Inc., a J&J subsidiary. While at J&J, Ms. McHugh oversaw the development and launches of several products, including Remicade® (infliximab), Prezista® (darunavir) and Intelence® (etravirine), and she was responsible for oversight of a research and development portfolio including compounds targeting HIV, hepatitis C, and tuberculosis.

Prior to joining Centocor, Inc., Ms. McHugh led the marketing communications for gastrointestinal drug Prilosec® (omeprazole) at Astra-Merck Inc.

She currently chairs the board of visitors for the Smeal College of Business of Pennsylvania State University as well as serves on the board of directors of Aerie Pharmaceuticals, Inc., Lantheus Holdings, Inc. and Trevena, Inc., all publicly held companies, and The New Xellia Group, a privately held company. She previously served on the board of directors for ViroPharma Inc., Epirus Biopharmaceuticals, Inc., the Biotechnology Industry Organization, the Pennsylvania Biotechnology Association and the New England Healthcare Institute.

Ms. McHugh received her M.B.A. degree from St. Joseph's University and her B.S. degree from Pennsylvania State University.

Ms. McHugh's experience as a chief executive officer and a chief operating officer at large multinational pharmaceutical companies makes her a valuable member of our board of directors, particularly as we evolve as a company and seek to maximize our current products and execute on our corporate strategy and associated pipeline.





EDWARD P.
OWENS

Former Partner, Portfolio Manager and Global Industry Analyst, Wellington Management Company, LLP

Age: 73

Director since 2013

Board Committees

Audit Committee

Mr. Owens was previously partner, portfolio manager and global industry analyst with Wellington Management Company, LLP where he worked in investment management from 1974 to 2012. He was the portfolio manager of the Vanguard Health Care Fund for 28 years from its inception in May 1984 until his retirement from Wellington in December 2012.

Mr. Owens serves on the board of directors of Stealth BioTherapeutics Corp. He has a B.S. in physics from the University of Virginia and an M.B.A. from Harvard Business School.

He brings to our board of directors extensive experience in evaluating and investing in life sciences companies, providing valuable insight as we continue to strive towards our goal of maximizing long-term stockholder value.

10    Ironwood


Table of clinical development and medical affairs.Contents

        In addition, he is currently an adjunct assistant professor and special advisor to the president for corporate relations at the Medical University of South Carolina (MUSC), an ex-officio director of the MUSC Foundation for Research Development, chairman of the board of Mitochondria in Motion, a biopharmaceutical company and a board member of the Clinical Biotechnology Research Institute at Roper St. Francis Hospital, the Westedge Project, and the Zucker Institute for Applied Neurosciences, and a former board member of Axovant Sciences Ltd. and Celsion Corporation.

        Dr. Olanoff received his Ph.D. in biomedical engineering and M.D. degree from Case Western Reserve University. Dr. Olanoff's detailed knowledge of the pharmaceutical industry, his broad operational experience and his research and development leadership over the course of his career make him an important asset to our board of directors.

How We are Selected and EvaluatedGRAPHIC

How We are Selected and Evaluated

We believe that our board of directors should be comprised of individuals with sophistication and experience in many substantive areas that will help us achieve our goalsvision of creatingbecoming a leading GI company dedicated to advancing treatments for GI diseases and commercializing medicines that make a differenceadvancing care for patients, building value for our fellow stockholders, and empowering our passionate team.


Tablemillions of ContentsGI patients.

The core criteria that we use in evaluating each nominee to our board consists of the following: (a) an owner-oriented attitude and a commitment to represent the interests of our stockholders, demonstrated, in part, through ownership of our capital stock; (b) strong personal and professional ethics, integrity and values; (c) strong business acumen and savvy; (d) a deep, genuine passion for our business and the patients whom we serve; (e) demonstrated achievement in the nominee's field of expertise; (f) the absence of conflicts of interest that would impair the nominee's ability to represent the interests of our stockholders; (g) the ability to dedicate the time necessary to regularly participate in meetings of the board and committees of our board; and (h) the potential to contribute to the diversity of our board of directors, as a result of the nominee's professional background, expertise, gender, age or ethnicity.

As illustrated in the matrix below, we believe our current directors possess the professional and personal qualifications and necessary expertise both within and outside of the healthcare industry to maintain an effectivea diverse and experienced board of directors that can effectively represent stockholders.

 
 








Broader Business Healthcare Industry
Ironwood Board of Directors

 Capital
Allocation /
Finance /
Accounting

 Strategic
Transactions

 Risk
Management

 Human
Capital

 Public
Company
Board

 Senior
Leadership
(small (small
biotech)

 Senior
Leadership
(large (large
pharma)

 Customer /
Market Insights
(patient, payer,
physician)

Julie H. McHugh

 ü ü  ü ü ü ü ü

Andrew Dreyfus

 ü ü ü ü       ü

Lawrence S. Olanoff, M.D., Ph.D. Ph.D.

  ü ü ü ü ü ü ü

Mark Mallon. Mallon

 ü ü ü ü     ü ü

Jon R. Duane

 ü ü ü     ü

Edward P. Owens

 ü ü ü   ü      

Mark G. Currie

 ü ü ü ü  ü ü ü

Marla L. Kessler

   ü ü ü     ü ü

Catherine Moukheibir. Moukheibir

 ü ü ü ü ü ü  

Director Succession Planning

We refresh our board of directors and assess our board succession plans regularly with the aim of balancing tenure and expertise.regularly. As of April 26, 2019,21, 2020, the average age of our independent directors is 60directors' was 61 years, and the average tenure of our independent directors is 2.5was approximately 3.5 years. All seven independentFive of our nine directors (including Mr. Mallon) joined our board of directors in 2013 or later, including three who were newly appointed in 2019.

Annual Evaluations

Our directors conduct annual evaluations to assess the performance and effectiveness of the board of directors and each committee in which they are a member. In addition, each director completes a self-evaluation as well as a peer evaluation of each other director. For 2018,2019, each director completed a written questionnaire which solicited open-ended and candid feedback on an anonymous basis. In addition to the director evaluations, we also solicit annual feedback from senior management concerning the board's performance on an anonymous basis. After the collective board and

2020  Proxy Statement    11


Table of Contents

GRAPHIC

committee evaluations and comments (including those from senior management) and the self and peer evaluations and comments were compiled, and summarized, the chair of the governance and nominating committee provided the committeemet with a summary of the individual evaluations for the Class III directors up for election at the 2019 annual meeting. Theour chair of the committee then met with our currentboard and chief executive officer to discuss the board and committee evaluations and individual evaluations for directors who were staying on our board following the Separation.directors. The chair of the committee also conducted individual feedback sessions with each such director to discuss the results of his or her individual evaluation.evaluation and then provided the committee with a summary of the individual evaluations for the Class I directors up for election at the 2020 annual meeting of stockholders. The chair of the committee then presented a summary of the collective board and committee evaluations and comments (including those from senior management) are then compiled, summarized and presented to the governance and nominating committee and full board of directors.


Table of Contents

Director Nomination Process

Our governance and nominating committee identifies potential director candidates through referrals and recommendations, including byfrom incumbent directors, management and stockholders, as well as through business and other organizational networks. We and our board of directors retained and paid third party firms to assist in identifying and evaluating potential director nominees forto join our board of directors followingupon the completion of the Separation, including our chief executive officer. Stockholders who wish to recommend candidates may contact the governance and nominating committee in the manner described inStockholder Communications, Proposals and Nominations for Directorships—Communications. Stockholder-recommended candidates whose recommendations comply with these procedures will be evaluated by the governance and nominating committee in the same manner as candidates identified by the governance and nominating committee.

How We are Organized and Governed

Board Size and GovernedTerms

Key governance structures

        As we have grown and evolved, our governance profile has grown with us. As you will read in more detail in the pages that follow, our dual-class stock structure expired at the end of fiscal year 2018 and we are in the process of de-classifying our board, subject to stockholder approval at the annual meeting. We separate the roles of chair of the board and chief executive officer and rotate the chair approximately every five years.

Board size and terms

Our Eleventh Amended and Restated Certificate of Incorporation, as amended, or our Certificate of Incorporation, states that our board of directors shall consist of between one and 15 members, and the precise number of directors shall be fixed by a resolution of our board.board of directors. Our board of directors currently consists of nine members. Each director holds office until his or her successor is duly elected and qualified or until his or her death, resignation or removal. Our Certificate of Incorporation currently provides that our directors may be removed only for cause by the stockholders. If the proposed amendment to our Certificate of Incorporation is adopted, our directors will be removable with or without cause by our stockholders following the declassification of our board of directors.

        Our board of directors currently consists of nine members, seven of whom are independent members. On April 1, 2019, we completed the previously-announced Separation. Our board of directors consisted of nine members prior to the Separation and nine members immediately thereafter. Mses. Fanucci and Schulman, Dr. Hecht and Mr. McGuire transitioned off of our board of directors on April 1, 2019 in connection with their appointment to the Cyclerion board of directors. Additionally, Dr. Williams transitioned off of the board of directors on April 1, 2019 in connection with the Separation. SeeCertain Relationships and Related Person Transactions—The Separation for more information about the Separation.

        In accordance with the terms of our Certificate of Incorporation, our board of directors is currently divided into three classes, and the directors in each class serve for three-year terms. Any vacancy on the board of directors, including a vacancy that results from an increase in the number of directors, may be filled by a vote of the majority of the directors then in office. Any additional directorships resulting from an increase in the number of directors will be apportioned by our board of directors among the three classes.classes until the declassification of our board of directors, as described further below.

In accordance with the terms of our Certificate of Incorporation, our board of directors is currently divided into three classes, which has resulted in staggered elections. Upon the expiration of the term of a class of directors, directors in that class will be eligible to be nominated and elected for a new three-year term at the annual meeting in the year in which their term expires. The current members of each class are set forth in the table above underWho We Are. The classification of the board of directors results in staggered elections, with each class of directors standing for election every third year. One class consists of members whose terms expire upon the election and qualification of their successors at the 2019 Annual Meeting, or the Class III directors,


Table of Contents

one class consistsOn the recommendation of members whose terms expire at the 2020 annual meeting of stockholders, or the Class I directors, and one class consists of members whose terms expire at the 2021 annual meeting of stockholders, or the Class II directors.

        After careful consideration, our board of directors, has determined that it is advisable and in the best interestsour stockholders voted at our 2019 annual meeting of the company and its stockholders to amend our Certificate of Incorporation to declassify theour board of directors to allow the company's stockholders to vote on the election of the entire board of directors on an annual basis, rather than on a staggered basis, and our board of directors has recommended thatbasis. Consistent with the company's stockholders vote in favor of such a proposal. SeeProposal No. 3—Amendmentamendment to our Certificate of Incorporation to Declassifythat was approved by our stockholders, the Boarddeclassification of Directorsthe board of directors will be phased in as follows:

    at our 2020 annual meeting of stockholders, the Class I directors will stand for election for a one-year term;

    at our 2021 annual meeting of stockholders, the Class I and Class II directors will stand for more information aboutelection for a one-year term; and

    at our 2022 annual meeting of stockholders, and at each annual meeting of stockholders thereafter, all directors will stand for election for one-year terms.

12    Ironwood


Table of Contents

GRAPHIC

For so long as our board of directors is classified, directors may be removed by our stockholders only for cause. Following the proposed amendment todeclassification of our Certificateboard of Incorporation.directors, our directors will be removable with or without cause by our stockholders.

We separate the roles of chair of the board of directors and chief executive officer and rotate the chair approximately every five years, unless the governance and nominating committee recommends otherwise. Our board of directors believes that this structure enhances the board'sboard of directors' oversight of, and independence from, management, and enables the board of directors to carry out its responsibilities on behalf of our stockholders. This leadership structure also allows Mr. Mallon, our chief executive officer, to focus his time and energy on operating and managing the company, while leveraging the experience and perspective of Ms. McHugh, the current chair of our board.board of directors. We expect the next chair rotation will take place in 2024.

Director Independence

Under Nasdaq Rule 5605, a majority of a listed company's board of directors must be comprised of independent directors. In addition, Nasdaq rules require that, subject to specified exceptions, each member of a listed company's audit, compensation and governance and nominating committees be independent, and that audit and compensation committee members satisfy the additional independence criteria set forth in Rule 10A-3 and 10C-1, respectively, under the Securities Exchange Act of 1934, as amended, or the Exchange Act. Under Nasdaq Rule 5605(a)(2), a director will only qualify as an "independent director" if, in the opinion of that company's board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.

Our board of directors determined that none of Messrs. Dreyfus, Duane and Owens, Mses. Kessler, McHugh and Moukheibir, and Dr. Olanoff, representing seven of our eight non-employee directors and seven of our nine current directors, has a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is "independent" as that term is defined under Nasdaq Rule 5605(a)(2). Mr. Mallon, our current chief executive officer, and Dr. Currie, who served as our senior vice president, chief scientific officer and president of research and developmentR&D until the Separation, were not determined to be independent due to their current or recent employment with the company. Our board of directors also determined that each of the current members of our audit committee, our governance and nominating committee, and our compensation and HR committee satisfies the independence standards for such committee established by Rule 10A-3 and 10C-1 under the Exchange Act, the Securities and Exchange Commission, or the SEC, rules and the Nasdaq rules, as applicable. In making such determinations, our board of directors considered the information requested from and provided by each director concerning their background, employment and affiliations, including family relationships, the relationships that each such non-employee director has with Ironwood and all other facts and circumstances the board of directors deemed relevant in determining their independence. As part of such determination, the board of directors considered: (a) Dr. Olanoff's service on our Pharmaceutical Advisory Committee, or the PAC, and any payments for such services (however, his service on the PAC has since concluded and he currently serves as the board representative to the PAC, and receives no compensation for such representation); (b) the volume of business between BCBSMA, the company in which Mr. Dreyfus serves as president and chief executive officer, and Ironwood, which amounted to less than 1% of the annual revenues of each


Table of Contents

company; company in 2019; and (c)(b) payments made by Ironwood to IQVIA, the company in which Ms. Kessler serves as a senior vice president, which amounted to less than 1% of the annual revenues of IQVIA.IQVIA in 2019.

Risk Oversight

Our board of directors retains ultimate responsibility for risk oversight and our management retains the responsibility for risk management. In carrying out its risk oversight responsibilities, our board of directors reviews the long- and short-term internal and external risks facing the company through its participation in long-range strategic planning, and the annual review and evaluation of corporate risks that the audit committee reports. Our board of directors also believes that separating the roles of chair of the board of directors and chief executive officer enhances the board'sboard of directors' ability to oversee risk in an objective manner.

We have implemented and continue to refine a formalized enterprise risk management process. On an ongoing basis, we identify key risks, assess their potential impact and likelihood, and, where appropriate, implement operational

2020  Proxy Statement    13


Table of Contents

GRAPHIC

measures and controls or purchase insurance coverage in order to help ensure adequate risk mitigation. Together with our board of directors, we are closely monitoring the developments and impact of COVID-19 on our business and operations, including employees, and are working to quickly address and mitigate risks in the evolving and dynamic environment.

On a quarterly basis, key risks, status of mitigation activities, and potential new or emerging risks are reported to and discussed with senior management and further addressed with our board of directors, as necessary. On at least an annual basis, a long-term comprehensive enterprise risk management update is provided to our board.board of directors. The long-term goal of our enterprise risk management process is to ingrain a culture of risk awareness and mitigation throughout the organization that can be applied to our current business activities as well as our assessment and pursuit of future business opportunities.

As set forth in its charter, our audit committee discusses with management and our independent registered public accounting firm any significant risks or exposures facing Ironwood, evaluates the steps management has taken or proposes to take to mitigate such risks, and reviews our compliance with such mitigation plans. As part of fulfilling these responsibilities, the audit committee meets regularly with Ernst & Young LLP, our independent registered public accounting firm, and members of our management, including our chief executive officer and chief financial officer,officer. Our audit committee also discusses with Ernst & Young LLP any significant risks or exposures facing the company to the extent that such risks or exposures relate to accounting and chief administrative officer.financial reporting, and reviews related mitigation plans with Ernst & Young LLP. In addition, our audit committee reviews the risk factors presented in our annual reports on Form 10-K and our quarterly reports on Form 10-Q that we file with the SEC.

As part of our board'sboard of directors' risk oversight role, our compensation and HR committee reviews and evaluates the risks associated with our compensation programs and succession plans, as it is responsible under its charter for approving the compensation of all of our executive officers and overseeing the maintenance and presentation to our board of directors, of succession planningplans for members of our senior management. Likewise, our governance and nominating committee is responsible for evaluating the performance, operations and composition of our board of directors and the sufficiency of our corporate governance guidelines, either of which may impact our risk profile from a governance perspective.

In performing their risk oversight functions, each committee of our board of directors has full access to management, as well as the ability to engage outside advisors.

Hedging and Pledging Policy

As part of our insider trading prevention policy, our directors and executive officers are prohibited from engaging in any hedging or monetization transactions of our company securities, including through the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds. In addition, our insider trading prevention policy generally prohibits our directors and executive officers from holding company securities in a margin account or pledging company securities as collateral for a loan.


Table of Contents

Corporate Governance Guidelines

We have adopted corporate governance guidelines which are accessible through the Investors section of our website atwww.ironwoodpharma.com, under the heading Corporate Governance, and which also are available in print to any stockholder who requests them from our Secretary.secretary. Our board of directors believes that sound governance practices and policies provide an important framework to assist it in fulfilling its duties to stockholders, and relies on these guidelines to provide that framework. Among other things, the guidelines help to ensure that our board of directors is independent from management, that our board of directors adequately performs its oversight functions, and that the interests of our board of directors and management align with the interests of our stockholders.

Sunset14    Ironwood


Table of Dual Class Voting StructureContents

GRAPHIC

Board Meetings

        From the time of our initial public offering, or IPO, until December 31, 2018, we maintained a dual class equity voting structure, which provided holders of our Class B common stock with significant influence over certain limited matters requiring stockholder approval, including a merger involving Ironwood, a sale of substantially all Ironwood assets and a dissolution or liquidation of Ironwood. In accordance with the terms of our Certificate of Incorporation, each outstanding share of Class B common stock converted into one share of Class A common stock on December 31, 2018, resulting in the company having only one class of common stock. Throughout this proxy statement, unless otherwise noted, we refer to our Class A common stock as our "common stock."

Board Meetings

Our board of directors held eight17 meetings during 2018.2019. As stated in our corporate governance guidelines, we expect our board membersdirectors to rigorously prepare for, attend, and participate in all board and applicable committee meetings. Each board memberdirector is expected to ensure that other existing and planned future commitments do not materially interfere with his or her service as a director. We also expect that all of our board membersdirectors up for election at, or who have a term that continues after, an annual meeting of stockholders will attend such annual meeting. In 2018,2019, each incumbent director attended at least 75% of all meetings of the board of directors and all committees of the board of directors on which he or she served that were held during the period that such director was a member of the board of directors or the applicable committee. All nine of our directors at the time of our 20182019 annual meeting of stockholders attended suchthis meeting.

Committees

Our board of directors has established an audit committee, a governance and nominating committee and a compensation and HR committee. In addition, our board of directors established a capital allocation committee in 2018 to oversee and monitor the company's business mix and capital allocation decisions in order to make recommendations to the board of directors, as well as advise on the Separation. This committee was disbanded upon completion of the Separation. Each of the audit committee, the governance and nominating committee and the compensation and HR committee operates under a charter that has been approved by our board.board of directors. Copies of each charter are accessible through the Investors section of our website atwww.ironwoodpharma.com, under the heading Corporate Governance, and are also available in print to any stockholder who requests them from our Secretary.secretary. The chair of each of our committees is expected to rotate approximately every three to five years, unless the governance and nominating committee recommends otherwise.

Audit Committee.Committee

We have a separately designated standing audit committee established by our board of directors for the purpose of overseeing our accounting and financial reporting processes and audits of our financial statements. The members of our audit committee are Mses. Moukheibir and McHugh and Mr. Owens, with each of Ms. Moukheibir and Mr. Owens being appointed to the committee upon


Table of Contents

completion of the Separation.Owens. Ms. Moukheibir chairs the audit committee. Prior to the Separation, the audit committee was comprised of Mses. McHugh and Fanucci and Mr. Dreyfus. Our audit committee met sevensix times during 2018.2019. Our audit committee assists our board of directors in its oversight of significant risks facing Ironwood, the integrity of our financial statements and our independent registered public accounting firm's qualifications, independence and performance.

Our audit committee's responsibilities include:

    reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly financial statements, earnings releases and related disclosures;

    reviewing and discussing with management and our independent registered public accounting firm and, as needed, internal auditors or any relevant third party, our internal controls and internal auditing procedures, including any material weaknesses in either;

    discussing our accounting policies and all material correcting adjustments with our management and our independent registered public accounting firm;

    discussing with our management any significant risks or exposures facing the company and the related mitigation plans, and discussing with our independent registered public accounting firm any significant risks or exposures facing the company to the extent that such risks or exposures relate to accounting and thefinancial reporting and related mitigation plans, as well as plans;

    monitoring our internal control over financial reporting and disclosure controls and procedures;

    working with management to formulate a mitigation plan and reviewing the company's compliance with such mitigation plan in the event of a significant breakdown or security breach affecting the information technology systems of the company or a third party;

2020  Proxy Statement    15


Table of Contents

GRAPHIC
    appointing, retaining, evaluating, overseeing, and approving the compensation for and, when necessary, terminating our independent registered public accounting firm;

    approving all audit services and all permitted non-audit, tax and other services to be performed by our independent registered public accounting firm, in each case, in accordance with the audit committee's pre-approval policy;

    discussing with the independent registered public accounting firm its independence and ensuring that it receives the written disclosures regarding these communications required by the Public Company Accounting Oversight Board;Board, or PCAOB;

    reviewing with the independent registered public accounting firm, to the extent applicable, any matter arising from the audit of the financial statements that was communicated or required to be communicated that both relates to accounts or disclosures that are material to the financial statements and involves especially challenging, subjective or complex auditor judgment;

    reviewing and approving all transactions or series of similar transactions to which we were or are a party in which the amount involved exceeded or exceeds $120,000 and in which any of our directors, executive officers, holders of more than 5% of any class of our voting securities, or any member of the immediate family of any of the foregoing persons, had or will have a direct or indirect material interest, other than compensation arrangements with directors and executive officers;

    recommending whether the audited financial statements should be included in our annual report and preparing the audit committee report required by SEC rules;

    reviewing with our independent registered public accounting firm all material communications between our management and our independent registered public accounting firm;

    reviewing, updating and recommending to our board of directors approval of our code of business conduct and ethics; and

    establishing procedures for the receipt, retention, investigation and treatment of accounting related complaints and concerns.

Our board of directors has determined that Ms. Moukheibir is an audit committee financial expert, as defined in Item 407(d)(5) of Regulation S-K.


16    Ironwood


Table of Contents

    GRAPHIC

    Audit Committee Report

In the course of our oversight of Ironwood's financial reporting process, we have (i) reviewed and discussed with management the company's audited financial statements for the fiscal year ended December 31, 2018,2019, (ii) discussed with Ernst & Young LLP, the company's independent registered public accounting firm, the matters and communications required to be discussed pursuant toby the applicable auditing standards,requirements of the PCAOB and the SEC, and (iii) received the written disclosures and the letter from Ernst & Young LLP, the company's independent registered public accounting firm, required by applicable requirements of the Public Company Accounting Oversight BoardPCAOB regarding the independent registered public accounting firm's communications with us concerning independence, discussed with the independent registered public accounting firm its independence, and considered whether the provision of non-audit services by the independent registered public accounting firm is compatible with maintaining its independence.

Based on the foregoing review and discussions, we recommended to the board of directors of the company that the audited financial statements be included in the company's Annual Report on Form 10-K for the year ended December 31, 20182019 for filing with the SEC.

  By the Audit Committee,

 

 

Andrew DreyfusCatherine Moukheibir, Chair
Julie H. McHugh
Edward P. Owens

2020  Proxy Statement    17


Table of Contents

GRAPHIC

Governance and Nominating Committee.Committee

The members of our governance and nominating committee are Messrs. Olanoff and Duane and Ms. McHugh. Mr. Duane joined the governance and nominating committee upon the completion of the Separation. Mr. Olanoff chairs the governance and nominating committee. Prior to the completion of the Separation, Mr. McGuire was a member of the committee. Our governance and nominating committee met two times during 2018.2019.

Our governance and nominating committee's responsibilities include:

    assisting our board of directors in identifying and recruiting individuals qualified to become members of our board of directors;

    recommending to our board of directors the persons to be nominated for election as directors;

    assisting our board of directors in recruiting such nominees;

    recommending to our board of directors qualified individuals to serve as committee members;

    performing an annual evaluation of our board of directors and each committee of the board of directors;

    evaluating the need and, if necessary, creating a plan for the continuing education of our directors;

    assessing and reviewing our corporate governance guidelines and recommending any changes to our board of directors;

    considering any potential conflicts of interest of members of our board of directors;

    considering our policies with respect to their impact on significant issues of corporate social responsibility; and

    evaluating and approving any requests from our executives to serve on the board of directors of another for-profit company.

Compensation and HR Committee.Committee

The members of our compensation and HR committee are Messrs. Dreyfus and Duane and Ms. Kessler, each of whom was appointed to the committee upon completion of the Separation.Kessler. Mr. Dreyfus chairs our compensation and HR committee. Prior to the completion of the Separation, the compensation and HR committee consisted of Mr. Owens, Ms. Schulman and Dr. Williams. Our compensation and HR committee met sixseven times during 2018.2019. Our compensation and HR committee assists our board of directors in fulfilling its responsibilities relating to the compensation of our board of directors and our executive officers.


Table of Contents

Our compensation and HR committee's responsibilities include:

    reviewing and approving corporate goals and objectives relevant to executive officer compensation and evaluating the performance of executive officers in light of those goals and objectives;

    reviewing and approving executive officer compensation, including salary, bonus and incentive compensation, deferred compensation, perquisites, equity compensation, benefits provided upon retirement, severance or other termination of employment, and any other forms of executive compensation;

    reviewing and approving our chief executive officer's compensation based on its evaluation of the chief executive officer's performance;

    reviewing and approving our peer companies to evaluate our compensation competitiveness and mix of compensation elements;

    overseeing and administering our incentive compensation plans and equity-based plans and recommending the adoption of new incentive compensation plans and equity-based plans to our board of directors;

    reviewing, accessing and making recommendations to our board of directors with respect to director compensation;

    reviewing and discussing with management the compensation discussion and analysis required to be included in our filings with the SEC and recommending whether the compensation discussion and analysis should be included in such filings;

    preparing the compensation and HR committee report required by the SEC; and

    making recommendations to our board of directors with respect to management succession planning, including planning with respect to our chief executive officer.officer;

18    Ironwood


Table of Contents

GRAPHIC
    overseeing compliance with applicable laws and regulations affecting employee compensation and benefits, including regarding stockholder approval of certain executive compensation matters; and

    reviewing the risks associated with our compensation policies and practices.

Compensation Committee Interlocks and Insider Participation

None of the members of our compensation and HR committee is or has at any time during the past fiscal year been an officer or employee of Ironwood. None of the members of our compensation and HR committee has formerly been an officer of Ironwood. None of our executive officers serve, or in the past fiscal year has served, as a member of the board of directors or compensation committee of any other entity that has one or more executive officers serving as a member of our board of directors or compensation and HR committee. None of the members of our compensation and HR committee had any relationship with us that requires disclosure under any paragraph of Item 404 of Regulation S-K under the Exchange Act.

How We Are Paid

How We Are Paid

The vast majority of the compensation that our non-employee directors receive for service on our board of directors is paid in the form of restricted shares of our Class A common stock. Vesting of these shares of restricted stock is contingent on each non-employee director continuing to serve as a member of the board of directors on the last day of each applicable vesting period. Further, whetherIf a director ceases serving as a member of our board of directors at any time during the sharesvesting period of a restricted stock are vestedaward, or not, no director may transfer anyRSA, unvested shares will be forfeited on the date of restricted stock while such person is a directordirector's termination of Ironwood, subjectservice.

Director Compensation Plan, effective January 2014

From January to limited exceptions. We believe these forfeiture and transfer restrictions underMay 2019, our directors were compensated pursuant to our prior director compensation plan, effectively create stock ownership guidelines for our directors in that they ensure that the interests of our directors, each of whom has equity in the business, are aligned with those of our stockholders and they focus our directors on maximizing long-term value.

        Under our director compensation plan,which became effective January 1, 2014, or the 2014 Director Compensation Plan. Under this plan, at each annual meeting of stockholders, our non-employee directors receivereceived an annual grant of the number of restricted shares of


Table of Contents

our Class A common stock calculated by dividing (i) the dollar amount for total director compensation approximating the 25th percentile of our current peer group on the date of grant, by (ii) the average closing price of our Class A common stock on the Nasdaq Global Select Market for the six months preceding the month in which the applicable annual meeting of stockholders occurs. Such restricted shares vestvested 25% on each three-month anniversary of the grant date over a nine-month period and the remaining 25% on the day before the date of the annual meeting of stockholders for the next calendar year. For 2018, our compensation and HR committee determined that the 25th percentile for total director compensation for our peer group was approximately $250,000. Accordingly, on May 31, 2018, the date of our 2018 annual meeting of stockholders, each of our non-employee directors received a grant of restricted stock consistent with the foregoing terms and valuation.

Under our director compensation plan,2014 Director Compensation Plan, if a non-employee director iswas elected other than at an annual meeting of our stockholders, on the start date of such non-employee directors service on the board of directors, such non-employee director will bewas granted the number of restricted shares of our Class A common stock granted to non-employee directors at the most recent annual meeting of our stockholders, prorated based on the number of days between the last annual meeting of our stockholders and the date on which the non-employee director began service with us. In connection with their election to the board, on April 1, 2019, each of Mses. Kessler and Moukheibir, Dr. Currie and Mr. Duane were issued 2,995 restricted shares of our Class A common stock, which are scheduled to vestvested in full on the day before the date of thisour 2019 annual meeting of stockholders.

In addition, pursuant to our director compensation plan,2014 Director Compensation Plan, the chair of our board and each of the committee chairs receivesreceived annual compensation of $10,000, payable quarterly in unrestricted stock or cash at the individual director's election. Shares of our Class A common stock issued to our directors under our director compensation plan are2014 Director Compensation Plan were granted under our Amended and Restated 2010 Employee, Director and Consultant Equity Incentive Plan, or the 2010 Plan. Further, whether the shares of restricted stock are vested or not, no director may transfer any shares of restricted stock granted pursuant to our 2014 Director Compensation Plan while such person is a director of Ironwood, subject to limited exceptions.

2020  Proxy Statement    19


Table of Contents

GRAPHIC

Under our 2014 Director Compensation Plan, non-employee directors also were reimbursed for reasonable travel and other expenses incurred in connection with attending meetings of the board of directors and its committees.

Non-Employee Director Compensation Policy, effective May 2019

Following a competitive assessment of market data related to non-executive director compensation provided by Pearl Meyer & Partners, LLC, or Pearl Meyer, our compensation consultant at the time, our compensation and HR committee approved our non-employee director compensation policy, or the 2019 Director Compensation Policy, effective in May 2019. Under our 2019 Director Compensation Policy, at each annual meeting of stockholders, our non-employee directors are granted restricted shares of our Class A common stock with a grant date fair value of $250,000, determined based on the average closing price of our Class A common stock on the Nasdaq Global Select Market (or the stock exchange on which our stock is being actively traded) for the six months preceding the month in which the award is granted, rounded down to the nearest whole share. Such restricted shares vest in full on the date immediately preceding the date of the next annual meeting of stockholders.

Under our directors are eligible2019 Director Compensation Policy, if a non-employee director is elected other than at an annual meeting of our stockholders, then upon his or her initial election to participate. If a director ceases serving as a member of our board of directors, such director will be granted the number of restricted shares of our Class A common stock granted to non-employee directors at any time during the vesting periodmost recent annual meeting of aour stockholders, prorated based on the number of days between the last annual meeting of our stockholders and the date on which the non-employee director began service with us. Such restricted stock award, unvested shares will be forfeitedvest in full on the date immediately preceding the date of the next annual meeting of stockholders. In addition, each non-employee director who is first elected to our board of directors will, upon his or her initial election, be granted restricted shares of our Class A common stock with a grant date fair value of $250,000, determined based on the average closing price of our Class A common stock on the Nasdaq Global Select Market (or the stock exchange on which our stock is being actively traded) for the six months preceding the month in which the award is granted, rounded down to the nearest whole share. Such restricted shares vest in three equal installments on the first three anniversaries of the grant date.

Shares of restricted stock that were granted to our directors under our 2019 Director Compensation Policy in connection with our 2019 annual meeting of stockholders were granted under our 2010 Plan. After May 2019, shares of restricted stock granted to directors under our 2019 Director Compensation Policy will be granted under our 2019 Equity Incentive Plan, or our 2019 Plan.

In addition to equity grants, each non-employee director receives an annual retainer under our 2019 Director Compensation Policy for his or her service on our board of directors, as well as additional fees for board chair, committee or committee chair service as follows:




Fees
Annual retainer for members of the board of directors$50,000 ($80,000 for the chair)
Additional annual retainer for members of the audit committee$10,000 ($20,000 for the chair)
Additional annual retainer for members of the compensation and HR committee$7,500 ($15,000 for the chair)
Additional annual retainer for members of the governance and nominating committee$5,000 ($10,000 for the chair)

20    Ironwood


Table of Contents

GRAPHIC

All cash fees are payable quarterly in arrears and will be prorated for any quarter of partial service, and fees payable under our 2019 Director Compensation Policy were retroactive to April 1, 2019. Each non-employee director may elect, prior to January 1 of the year with respect to which such director's terminationelection will be effective, to receive fully vested shares of service.our Class A common stock at no cost in lieu of his or her annual cash retainer and any additional cash retainers for board chair, committee or committee chair service set forth above. The number of shares of our Class A common stock to be issued will be determined by dividing the applicable cash retainer(s) the director would be eligible to receive by the closing price of our Class A common stock on the Nasdaq Global Select Market (or the stock exchange on which our stock is being actively traded) on the date the cash fees would otherwise be paid, rounded down to the nearest whole share. Further, non-employee directors are reimbursed for reasonable travel and other expenses incurred in connection with attending meetings of the board of directors and its committees.

Director Stock Ownership Guidelines

In May 2019, we instituted stock ownership guidelines that provide that each non-employee director must accumulate and continuously hold shares of our Class A common stock with a value equal to or greater than three times the amount of the then-current annual retainer paid to the non-employee director for service on our board of directors (excluding any additional board chair, committee, or committee chair retainers). Non-employee directors are required to achieve this level of ownership by the later of (a) May 30, 2021 (the date which is two years from the date of our 2019 annual meeting of stockholders) and (b) two years from the date the individual began service with us, or the Ownership Date.

Compliance with the stock ownership requirements will be measured on the date of the annual meeting of stockholders each year based on the annual retainer then in effect. Following the Ownership Date, until a non-employee director holds the required ownership level and if such director does not hold the number of shares of our Class A common stock to meet the stock ownership requirements at any time thereafter, such director will be required to retain 100% of any shares of our Class A common stock held or received upon the vesting or settlement of equity awards or the exercise of stock options, in each case, net of shares sold to cover applicable taxes and the payment of any exercise or purchase price (if applicable). Further, following the Ownership Date, to the extent a non-employee director does not hold the number of shares of our Class A common stock that meets this threshold, such director will be automatically deemed to have elected to receive any cash retainer for service on our board of directors or a committee thereof in the form of shares of our Class A common stock in an amount that satisfies the threshold shortfall.

In addition to the stock ownership guidelines described above, the non-employee director share transfer restrictions described above under our 2014 Director Compensation Plan remain in effect with respect to any shares granted under that plan.

We believe our stock ownership guidelines and other transfer restrictions ensure that the interests of our directors, each of whom has equity in the business, are aligned with those of our stockholders and further focus our directors on maximizing long-term value.

Director Compensation Table

The following table sets forth information regarding the compensation earned during the year ended December 31, 20182019 by each of our directors who served in 2019 other than (i) Mr. Mallon, our current chief executive officer and current member of our board of directors, (ii) Peter Hecht, our former chief executive officer and former member of board of directors, and (iii) Mark Currie, our former senior vice president, chief scientific officer and president of R&D and current member of our board of directors. Neither Mr. Mallon nor Dr. Hecht who did not receivereceived compensation for his service as a director.on our board of directors, and Dr. Hecht'sCurrie's compensation for his service ason our chief executive officerboard of directors is described in ourCompensation Discussion and Analysis andincluded in theSummary Compensation Table and related footnotes includedavailable elsewhere in this proxy statement.

Name
 Fees Earned or
Paid in Cash
($)
 Stock Awards
($)(1)
 All Other
Compensation ($)
 Total ($) 

Andrew Dreyfus

    301,423    301,423 

Marsha H. Fanucci

  10,000(2) 301,423    311,423 

Terrance G. McGuire

  9,965(3) 301,423    311,388 

Julie H. McHugh

  10,000(4) 301,423    311,423 

Lawrence S. Olanoff, M.D., Ph.D. 

    301,423  6,250(5) 307,673 

Edward P. Owens

  10,000(6) 301,423    311,423 

Amy W. Schulman

  7,299(7) 301,423    308,722 

Douglas E. Williams, Ph.D. 

    301,423    301,423 

 
  
  
  
 
Name*
 Fees Earned or
Paid in
Cash ($)

 Stock Awards
($)(1)

 Total
($)

 

Andrew Dreyfus

 $48,736(2)$244,317 $293,053 

Jon R. Duane

 $45,795(3)$286,306 $332,101 

Marsha H. Fanucci

 $2,500(4)$ $2,500 

Marla L. Kessler

 $43,125(5)$286,306 $329,431 

Terrance G. McGuire

 $2,492(6)$ $2,492 

Julie H. McHugh

 $73,750(7)$244,317 $318,067 

Catherine Moukheibir

 $52,500(8)$286,306 $338,806 

Lawrence S. Olanoff

 $45,000(9)$244,317 $289,317 

Edward P. Owens

 $47,500(10)$244,317 $291,817 

Amy W. Schulman

 $2,492(11)$ $2,492 

Douglas E. Williams, Ph.D.

 $ $ $ 
*
Mses. Fanucci and Schulman and Mr. McGuire transitioned off of the Ironwood board of directors and joined the Cyclerion board of directors on April 1, 2019, in connection with the Separation. Dr. Williams transitioned off of the Ironwood board of directors on April 1, 2019 in connection with the Separation.

(1)
On May 31, 2018, each non-employee member ofApril 1, 2019, in connection with their election to our board of directors, each of Mses. Kessler and Moukheibir, Dr. Currie and Mr. Duane received a restricted stock grant in the amount of 2,995 shares of our Class A common stock, which vested in full on the day before the date of our 2019 annual meeting of stockholders. The number of shares subject to such restricted stock grant was determined by prorating the restricted stock grant of 16,223 shares of our Class A common stock awarded to the board of directors in connection with our 2018 annual meeting of stockholders by the number of days served on our board of directors between April 1, 2019, the date Mses. Kessler and Moukheibir, Dr. Currie and Mr. Duane joined our board of directors, and the date of our 2019 annual meeting of stockholders. Each such award of restricted stock had a grant date fair value of $14.02 per share and was granted pursuant to the terms of our 2014 Director Compensation Plan and our 2010 Plan.


On May 29, 2019, each non-employee member of our board of directors who was serving on such date received a restricted stock grant in the amount of 22,706 shares of our Class A common stock for service to Ironwoodon our board of directors from the date of our 20182019 annual meeting of stockholders to the date of our 20192020 annual meeting of stockholders.

Tablestockholders, which shares will vest in full on the date immediately preceding the date of Contents

    our 2020 annual meeting of stockholders. The number of shares subject to the restricted stock grant was determined by dividing (i) $250,000 (the dollar amount for the total director compensation approximating the 25th percentile of our current peer group on the date of grant), by (ii) the average closing price of our Class A common stock on the Nasdaq Global Select Market for the six months preceding the month of the 20182019 annual meeting of stockholders.stockholders (which price was adjusted for the impact of the Separation). Each such award of restricted stock had a grant date fair value of $18.58$10.46 per share and was granted pursuant to the terms of our director compensation plan2019 Director Compensation Policy and our 2010 Plan. As of December 31, 2018, 8,1122019, each non-employee director held 22,706 restricted shares underlying each suchof Class A common stock as a result of this grant and held no other unvested equity awards.



    Amounts in the table represent the fair value of these restricted stock award remained unvested.

grants on the date of grant calculated in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718,Compensation—Stock Compensation. For a discussion of the assumptions used in the valuation of awards made in 2019, see Note 15 to our consolidated financial statements for the year ended December 31, 2019 included in our Annual Report on Form 10-K that we filed with the SEC on February 13, 2020. All values reported exclude the effects of potential forfeitures.

(2)
Mr. Dreyfus received this compensation for his service on our board of directors and as chair of the compensation and HR committee from April 1, 2019 through December 31, 2019. Mr. Dreyfus elected to receive this compensation in unrestricted shares of our Class A common stock. Mr. Dreyfus received a total of 4,529 shares of our Class A common stock for such service in 2019.

(3)
Mr. Duane received this compensation for his service on our board of directors and as a member of our governance and nominating and compensation and HR committees from April 1, 2019 through December 31, 2019.

(4)
Ms. Fanucci received this compensation for her servicesservice as the chair of our audit committee in 2018.from January 1, 2019 through March 31, 2019.

2020  Proxy Statement    21


Table of Contents

GRAPHIC
(5)
Ms. Kessler received this compensation for her service on our board of directors and as a member of our compensation and HR committee from April 1, 2019 through December 31, 2019.

(3)(6)
Mr. McGuire received this compensation for his service as the chair of our board in 2018. Pursuant to our director compensation plan,of directors from January 1, 2019 through March 31, 2019. Mr. McGuire elected to receive this compensation in unrestricted shares of our Class A common stock. Mr. McGuire received a total of 645183 shares of our Class A common stock for such chair service in 2018.2019.

(4)(7)
Ms. McHugh received this compensation for her service as the chair of our governance and nominating committee in 2018.from January 1, 2019 through March 31, 2019, and for her service as chair of our board of directors and service on our audit and compensation and HR committees from April 1, 2019 through December 31, 2019.

(5)(8)
Ms. Moukheibir received this compensation for her service on our board of directors and as chair of our audit committee from April 1, 2019 through December 31, 2019.

(9)
Dr. Olanoff received this compensation for his service on our board of directors and as a memberchair of our Pharmaceutical Advisory Committee for a portion of 2018.governance and nominating committee from April 1, 2019 through December 31, 2019.

(6)(10)
Mr. Owens received this compensation for his servicesservice as the chair of our compensation and HR committee in 2018.from January 1, 2019 through March 31, 2019, and for his service on our audit committee from April 1, 2019 through December 31, 2019.

(7)(11)
Ms. Schulman received this compensation for her service as the chair of our capital allocation committee for a portion of 2018. Pursuant to our director compensation plan,from January 1, 2019 through March 31, 2019. Ms. Schulman elected to receive this compensation in unrestricted shares of our Class A common stock. Ms. Schulman received a total of 474183 shares of our Class A common stock for such chair service in 2018.2019.

22    Ironwood


Table of Contents

GRAPHIC

On April 1, 2019, each of the non-employee directors who was on our board of directors prior to the date of the Separation held 4,056 unvested shares of our Class A common stock, which represented 25% of the annual restricted stock award of 16,223 shares of our Class A common stock granted on the date of our 2018 annual meeting of stockholders. In connection with the Separation, on April 1, 2019, each such director received a dividend of 405 shares of unrestricted shares of Cyclerion common stock, which amount was determined according to a fixed ratio of one share of Cyclerion common stock for every 10 shares of unvested Ironwood Class A common stock. In addition to receiving 405 shares of Cyclerion common stock, the Separation had the following impact on unvested restricted stock held by directors at the time of the Separation:




Directors
Ironwood
Cyclerion
Directors who remained on Ironwood's board of directors following the Separation (Ms. McHugh, Messrs. Dreyfus and Owens and Dr. Olanoff)Retained the 4,056 shares of Ironwood Class A common stock that were unvested as of April 1, 2019, which shares vested in full on the date of our 2019 annual meeting of stockholders
Directors who transitioned to Cyclerion's board of directors in connection with the Separation (Mses. Fanucci and Schulman and Mr. McGuire)Forfeited the 4,056 shares of Ironwood Class A common stock shares that were unvested as of April 1, 2019Received 3,279 shares of unvested Cyclerion common stock, which were granted on substantially the same terms and vesting conditions as were applicable to the 4,056 forfeited shares of Ironwood Class A common stock(1)
Director who transitioned off of Ironwood's board of directors and did not join Cyclerion's Board of Directors (Dr. Williams)Forfeited 4,056 Ironwood shares that were unvested as of April 1, 2019

(1)  The 3,279 shares of unvested Cyclerion common stock granted in connection with the Separation were calculated by dividing (i) $13.45 (the volume-weighted average price of Ironwood's Class A common stock for the 10 days preceding the Separation) by (ii) $14.81 (the purchase price of Cyclerion common stock as of the date of the Separation), then multiplying the quotient by (iii) 4,056 shares.

Furthermore, the directors who joined Ironwood's board of directors in connection with the Separation (Mses. Kessler and Moukheibir, Dr. Currie and Mr. Duane) also received 405 shares of Cyclerion common stock in addition to the award of 2,995 shares of restricted Ironwood Class A common stock granted on April 1, 2019 in connection with joining our board of directors. Further information on the impact of the Separation on directors' equity is available elsewhere in this proxy statement under the captionCompensation Discussion and Analysis—Equity Impact of the Separation.

2020  Proxy Statement    23


Table of Contents


PROPOSAL NO. 1—ELECTION OF DIRECTORS
GRAPHIC


Table of Contents

GRAPHIC

Proposal No. 1

Our board recommends that you vote for each of the
Class III directors up for election.

        Our board has nominated each of our current Class IIII directors—Dr. Currie and Messrs. OwensDuane and Dreyfus and Ms. McHugh—Mallon—for election at the 20192020 annual meeting. Each of Dr. Currie and Messrs. OwensDuane and Dreyfus and Ms. McHughMallon has indicated his or her willingness to serve if elected and has consented to be named in the proxy statement. Should any nominee become unavailable for election at the annual meeting, the persons named on the enclosed proxy card as proxy holders may vote all proxies given in response to this solicitation for the election of a substitute nominee chosen by our board.board of directors.

Vote Required

The three nominees for director with the highest number of affirmative votes will be elected as directors to serve for three yearsone year and until their successors are duly elected and qualified or until their death, resignation or removal. Because there is no minimum vote required, abstentions and broker non-votes will not affect the outcome of this proposal.


26    Ironwood


Table of Contents

GRAPHIC
Our Executives

Who We Are

The following table sets forth certain information, as of April 21, 2020, with respect to each of our executive officers, other than Mr. Mallon, whose biographical information is included elsewhere in this proxy statement under the captionOur Board of Directors:

Name

AgePosition(s)

Gina Consylman, CPA

48Senior Vice President, Chief Financial Officer

Conor Kilroy

38Senior Vice President, General Counsel

Thomas A. McCourt

62President

Jason Rickard

49Senior Vice President, Chief Operating Officer

Michael Shetzline, M.D., Ph.D.

61Chief Medical Officer, Senior Vice President and Head of Drug Development
​ ​ 





GINA
CONSYLMAN, CPA

Senior Vice President, Chief Financial Officer of Ironwood Pharmaceuticals, Inc.

Age: 48

Joined Ironwood 2014

Ms. Consylman has served as our senior vice president, chief financial officer since November 2017. Ms. Consylman previously served as our interim chief financial officer from September 2017 to November 2017, and as our vice president of finance and chief accounting officer from August 2015 to November 2017. She also previously served as our vice president, corporate controller and chief accounting officer from June 2014 to July 2015.

Prior to joining Ironwood, Ms. Consylman served as vice president, corporate controller and principal accounting officer of Analogic Corporation, or Analogic, (which was acquired by funds affiliated with Altaris Capital Partners, LLC) from February 2012 to June 2014, where she oversaw Analogic's global accounting team.

Prior to joining Analogic, Ms. Consylman served in various finance roles at Biogen Inc., or Biogen, from November 2009 to February 2012, culminating in her service as senior director, corporate accounting where she was responsible for the accounting teams for the corporate and U.S. commercial business units.

Before joining Biogen, Ms. Consylman also served as corporate controller at Varian Semiconductor Equipment Associates, Inc. (subsequently acquired by Applied Materials, Inc.)

Ms. Consylman currently serves on the board of directors, including as chair of the audit committee, of Verastem, Inc. Ms. Consylman, a Certified Public Accountant, began her career in public accounting at Ernst & Young LLP. She holds a B.S. in accounting from Johnson & Wales University and a M.S. in taxation from Bentley University.

2020  Proxy Statement    27


Table of Contents

GRAPHIC



CONOR KILROY

Senior Vice President, General Counsel of Ironwood Pharmaceuticals, Inc.

Age: 38

Joined Ironwood 2013

Mr. Kilroy has served as our senior vice president since April 2020 and general counsel since April 2019. Prior to becoming senior vice president and general counsel, Mr. Kilroy served as senior director, assistant general counsel from June 2016 to April 2019, director, senior corporate counsel from June 2014 to June 2016 and as associate director, corporate counsel from June 2013 to June 2014.

Before joining Ironwood, Mr. Kilroy was corporate counsel, securities, at Boston Scientific Corporation from 2012 to 2013 and was an associate at Goodwin Procter LLP from 2007 to 2011.

Mr. Kilroy holds a B.A. from Brandeis University and a J.D. from Boston College Law School.





THOMAS A. McCOURT

President of Ironwood Pharmaceuticals, Inc.

Age: 62

Joined Ironwood 2009

Mr. McCourt has served as our president since April 2019 and, prior to April 2019, had served as our senior vice president of marketing and sales and chief commercial officer since joining Ironwood in 2009.

Prior to joining Ironwood, Mr. McCourt led the U.S. brand team for denosumab at Amgen Inc. from April 2008 to August 2009. Prior to that, Mr. McCourt was with Novartis AG from 2001 to 2008, where he directed the launch and growth of ZELNORM™ for the treatment of patients with IBS-C and CIC and held a number of senior commercial roles, including vice president of strategic marketing and operations.

Mr. McCourt was also part of the founding team at Astra Merck Inc., leading the development of the medical affairs and science liaison group and then serving as brand manager for PRILOSEC® and NEXIUM®.

Mr. McCourt serves on the board of directors, including on the audit and compensation committees, of Acceleron Pharma Inc. and has a degree in pharmacy from the University of Wisconsin.

28    Ironwood


Table of Contents

EXECUTIVE COMPENSATIONGRAPHIC



JASON RICKARD

Senior Vice President, Chief Operating Officer of Ironwood Pharmaceuticals, Inc.

Age: 49

Joined Ironwood 2012

Mr. Rickard has served as our chief operating officer since April 2020. Prior to his appointment as the company's senior vice president, chief operating officer, Mr. Rickard had been the company's senior vice president, operations since July 2018, in which Mr. Rickard most recently led the company's manufacturing, pharmaceutical development, quality, human resources, information technology and facilities functions. Before becoming senior vice president, operations, Mr. Rickard served as the company's vice president global operations and information technology from July 2015 to July 2018; vice president global operations from March 2014 to July 2015; vice president commercial manufacturing supply chain from June 2013 to March 2014; and head of supply chain from January 2012 to June 2013.

Prior to joining Ironwood, Mr. Rickard was with Genentech, Inc. from 2000 to 2012 in roles of increasing responsibility in manufacturing and supply chain. Mr. Rickard began his career as a mechanical engineer at AMOT Controls Corporation.

Mr. Rickard holds an M.S. from California State University—Sacramento and a B.S. from California State University—Chico, both in mechanical engineering.





MICHAEL SHETZLINE, M.D., Ph.D.

Chief Medical Officer, Senior Vice President and Head of Drug Development of Ironwood Pharmaceuticals, Inc.

Age: 61

Joined Ironwood 2019

Dr. Shetzline has served as our chief medical officer, senior vice president and head of drug development since January 2019. Dr. Shetzline is a gastroenterologist and internist, with more than 25 years of experience in the biopharmaceutical industry and academia.

Before joining Ironwood, Dr. Shetzline was vice president and head of gastroenterology clinical sciences at Takeda Pharmaceuticals International Co., or Takeda, where he led global clinical development for all GI assets from January 2015 to January 2019.

Prior to Dr. Shetzline's role at Takeda, Dr. Shetzline served as vice president and global head of gastroenterology at Ferring International Pharmascience Center U.S., Inc., or Ferring, from September 2012 to January 2015, during which he led Ferring's clinical development programs in gastroenterology. Before that, Dr. Shetzline was vice president and global program head crossing multiple therapeutic areas and head of translational medicine GI discovery at Novartis Pharmaceuticals AG from 2002 to 2012.

Dr. Shetzline also served as gastroenterology program director and assistant professor of medicine at Duke University Medical Center from 1997 to 2002. Dr. Shetzline has published over 40 full papers and book chapters and acted as a reviewer for a range of medicine journals.

Dr. Shetzline earned his M.D. and Ph.D. from The Ohio State University in physiology and medicine. Dr. Shetzline completed his internal medicine residency and fellowship in gastroenterology and served on the faculty as a National Institutes of Health supported physician scientist at Duke University Medical Center.

Dr. Shetzline is a Fellow of the American College of Physicians, the American College of Gastroenterology, and the American Gastroenterological Association and certified by the American Board of Internal Medicine.

2020  Proxy Statement    29


Table of Contents

GRAPHIC
Executive Compensation

Dear Ironwood stockholders,

2019 was a transformative year for Ironwood, underscored by the clear execution from the Ironwood team in driving forward our mission to advance treatment of GI diseases and redefine the standard of care for millions of GI patients. Ironwood is undeniably a very different company today than it was a little over a year ago.

In line with the changes in the company's focus, strategy and leadership team marked by the Separation, we took the opportunity in 2019 to refresh a number of the company's significant plans and policies. At our 2019 annual meeting of stockholders, our stockholders approved our 2019 Equity Incentive Plan, which, among other features that we believe will advance the interests of our stockholders, did not continue the "evergreen" feature of our prior equity incentive plan and limited share recycling under the plan. Additionally, in early 2019, we adopted a clawback policy that provides that our board of directors may recover from our current and former executive offers certain incentive compensation under certain conditions upon a financial restatement. We also instituted formal stock ownership guidelines for directors to further align our director compensation program with the long-term performance of the company.

We also made several important changes to Ironwood's executive compensation program. As we discuss further below, we developed a competitive compensation package to recruit Mark Mallon, who became our CEO in connection with the Separation. We adopted a new executive compensation peer group that includes similarly sized commercial biopharmaceuticals peers (based on market capitalization, median revenue, number of employees, as well as other factors) to align to our post-Separation profile. In addition, for our 2020 executive equity compensation program, we decided to replace stock option grants with performance-based stock unit awards that are designed to further align executive pay with our performance, including stock price performance. We believe this important adjustment will motivate our executive team and further tie our executives' compensation to stockholder value.

As always, we are open to your feedback. Thank you for the privilege of serving as your compensation and HR committee chair.

Sincerely,

GRAPHIC

Andrew Dreyfus

Chair, Compensation and HR Committee

30    Ironwood


Table of Contents

GRAPHIC

Compensation Discussion and Analysis

Executive Summary

In 2019 and 2020, our executive compensation program has evolved along with the changes to our business marked by the Separation. Two key highlights, described further below, were: (1) the transition of our chief executive officer in connection with the Separation, and (2) the introduction of performance-based units, or PSUs, into our 2020 equity compensation program for our executive officers in lieu of stock options.

1.
Chief Executive Officer Transition
In January 2019, our board of directors hired Mark Mallon to be our chief executive officer, or CEO, effective upon the Separation. Our previous CEO and founder, Peter Hecht, became the CEO of Cyclerion in connection with the Separation. Compensation for Mr. Mallon in 2019 includes certain one-time cash and equity awards granted to compensate him, in part, for outstanding equity he forfeited by leaving his previous employer and therefore is not representative of our expectations for Mr. Mallon's compensation on a go-forward basis. Additional information on Mr. Mallon's compensation is provided under the caption
2019 CEO Transition Compensation, below.

2.
Introduction of PSUs into 2020 Executive Equity Program
To further tie executive compensation to corporate performance and stockholder value, in 2020, 50% of annual equity-based compensation awarded to our named executive officers was in the form of PSUs, with the remaining 50% of grants in the form of restricted stock units, or RSUs (based on the grant date fair value of equity awards, with PSU awards measured at target). PSUs replaced stock options in our 2020 executive compensation program to further drive accountability to achieve key milestones and deliver stockholder returns. The PSUs awarded in March 2020 to our named executive officers may be earned based on corporate achievement in three categories: (1) completing clinical pipeline new drug application, or NDA, submissions to the U.S. FDA, (2) achieving target cumulative adjusted organic EBITDA, and (3) realizing specified levels of relative stockholder return, or rTSR. Additional information on our PSU program, including the PSU awards granted to our named executive officers in 2020, is provided under the caption
2020 Equity Awards and Shift to 50% Performance-Based Stock Units, below.

Stockholder Engagement and Say-On-Pay Vote Consideration

Feedback from stockholders is an essential part of our executive compensation decision-making processes. Our company engages with many of our largest stockholders on an annual basis. We invite feedback on a wide variety of topics including corporate strategy, capital allocation, governance, and executive compensation. In 2019, senior management met with nearly all of Ironwood's largest 20 stockholders, which represented over 90% of our outstanding shares as of December 31, 2019.

Our stockholders also have the opportunity to cast a non-binding advisory vote on named executive officer compensation, or a "say-on-pay" vote, every year. This allows our stockholders to provide us with regular, timely and direct input on our executive compensation philosophy, policies and practices. We believe this enables us to further align our compensation programs with our stockholders' interests and to enhance our ability to consider stockholder feedback as part of our annual compensation review process. We sought stockholder input on our executive compensation programs through the say-on-pay vote at our 2019 annual meeting of stockholders and approximately 87% of votes cast by our stockholders voted in support of our named executive officer compensation.

2020  Proxy Statement    31


Table of Contents

GRAPHIC

Compensation Decisions for 2019 and 2020

Named Executive Officers for 2019

This section discusses the principles underlying our policies and decisions with respect to the compensation of our executive officers who are named in theSummary Compensation Table, or our named executive officers. Provided below are material factors we believe are relevant to an analysis of these policies and decisions. Our named executive officers for 20182019, which include executives who served the company prior to the Separation, were:

Ironwood executive officers:

    Peter M. Hecht, Ph.D., formerMark Mallon, chief executive officer;

    Gina Consylman, chief financial officer and senior vice president;

    Thomas A. McCourt, president; and

    Halley E. Gilbert, former chief administrative officer and senior vice president, corporate development.

Ironwood executive officers prior to the Separation:

    Peter M. Hecht, Ph.D., former chief executive officer; and

    Mark G. Currie, Ph.D., former senior vice president, chief scientific officer, and president of research and development;development.

Ms. Gilbert resigned from her position with Ironwood effective February 28, 2020. Additional information is provided under the captionPost-Employment Arrangements elsewhere in this proxy statement. Drs. Hecht and Currie each resigned from their respective positions with Ironwood in connection with the Separation in April 2019. Dr. Hecht is no longer an officer or director of Ironwood. Dr. Currie joined our board of directors in April 2019. Additional information is provided under the captionCompensation of Named Executive Officers Who Transitioned to Cyclerion, elsewhere in this proxy statement.

2019 CEO Transition Compensation

Mr. Mallon joined the company as a senior advisor to the board of directors on January 4, 2019 and was named chief executive officer of Ironwood on April 1, 2019 in connection with the completion of the Separation. In order to compensate him, in part, for outstanding equity he forfeited by leaving his previous employer and to align his interests with stockholders, Mr. Mallon's 2019 compensation includes certain one-time cash and equity awards. For this reason, the total compensation that Mr. Mallon received in 2019 is higher than the total compensation that we expect Mr. Mallon will receive on a go-forward basis.

The terms of Mr. Mallon's offer letter provide for the following:

    an initial base salary of $750,000 per year;

    Thomas A. McCourt, president;an annual bonus target of 75% of his base salary, subject to achievement of individual and corporate goals;

    William Huyett, former chief operating officer.a one-time new hire bonus of $880,000, subject to certain clawback provisions if he terminates his employment for any reason or the company terminates his employment for Cause (as defined in his executive severance agreement described below) within two years of his start date;

    an initial equity grant consisting of:

      o
      an option to purchase 171,526 shares of our Class A common stock that vest over four years, with 25% of the options vesting on the first anniversary of his start date and 1/48th of the options vesting each month thereafter for the next 36 months;

      o
      93,036 RSUs that will vest over four years as to 25% of the RSUs on each approximate anniversary of the applicable grant date, and

32    Ironwood


Table of Contents

GRAPHIC
    certain relocation benefits, also subject to certain clawback provisions if Mr. Mallon terminates his employment for any reason or the company terminates his employment for Cause, in each case within 12 months following the payment date of his last relocation reimbursement.

For a description of the impact of the Separation on the number of stock options and RSUs, and the exercise price of stock options, awarded to Mr. Mallon in January 2019 in connection with the commencement of his employment with Ironwood, please seeExecutive SummaryEquity Impact of the Separation and the footnotes to theGrants of Plan-Based Awards table elsewhere in this proxy statement.

2018 was a year of extraordinary change at Ironwood. On May 1, 2018, we announced our intent toseparate our sGC business from our gastrointestinal, or GI, business and create two independent, publicly-traded companies (Ironwood and Cyclerion). OnPer his offer letter, upon becoming CEO on April 1, 2019, we announcedMr. Mallon received an additional option to purchase 423,049 shares of our Class A common stock and an additional grant of 206,873 RSUs. As with his initial equity grant, 25% of the completionoptions vested on the first anniversary of his start date, with 1/48th of the options vesting each month thereafter for the next 36 months, and the RSUs vest as to 25% of the RSUs on the approximate first four anniversaries of the date of grant. This grant was made on April 1, 2019, the effective date of the Separation. In addition, the company has entered into an indemnification agreement and an executive severance agreement with Mr. Mallon, the terms of each of which are consistent with the forms of indemnification agreement and executive severance arrangements described elsewhere in this transaction. Effective uponproxy statement. Additional information on the Separation, Mark Mallon became chief executive officer of Ironwood, succeeding Ironwood's co-founder Peter Hecht. Ironwood is now a GI-focused healthcare company.factors considered in determining Mr. Mallon's initial compensation package is disclosed on page 38. However, thisavailable under the captioncompensation discussionRole of the Compensation and analysisHuman Resources Committee primarily focuseselsewhere in this proxy statement.

The following table presents a summary of the payments made, and value of awards granted, to Mr. Mallon as part of his initial compensation package:

  New Hire Package
(effective January 4, 2019)
  CEO Compensation
(effective April 1, 2019)
 

Base Salary

 $750,000                (1)

Sign-on Bonus

 $880,000   

Restricted Stock Units(2)

 $1,146,204(4)$2,546,607(4)

Stock Options(3)

 $999,516(4)$2,804,815(4)

Total

 $3,775,720 $5,351,422 

(1)  Mr. Mallon's base salary did not change when he became CEO in April 2019 in connection with the Separation.

(2)  Mr. Mallon's RSUs vest over four years as to 25% of the RSUs on each approximate anniversary of the grant date.

(3)  Mr. Mallon's stock options vest as to 25% of the options on the compensationfirst anniversary of the vesting commencement date and 1/48th of the options each month thereafter for the next 36 months.

(4)  Reflects the fair value of time-based RSU and stock option awards on the date of grant calculated in accordance with Financial Accounting Standards Board issued Accounting Standards Codification Topic 718,Compensation—Stock Compensation. For a discussion of the assumptions used in the valuation of awards made in 2019, including these awards to Mr. Mallon, see Note 15 to our named executive officersconsolidated financial statements for the year ended December 31, 2019 included in our Annual Report on Form 10-K that we filed with respectthe SEC on February 13, 2020. All values reported exclude the effects of potential forfeitures.

Mr. Mallon was not eligible to 2018.receive an annual equity award in fiscal year 2019 and instead received initial equity grants in early 2019 as described above.

For information on the cash bonus award paid to Mr. Mallon in 2020 for 2019 performance, as well as Mr. Mallon's base salary increase in 2020 and equity awards granted to Mr. Mallon in 2020, seeNEO Compensation Program, below.

        Our executive officer compensation program remains focused on linkingNEO Compensation Program

As in prior years, the ultimate value of our executive's compensation to our stockholders' returns. With this philosophy,we seek to attract and motivate owner-oriented employees, align their interests with those of our stockholders and create long-term stockholder value. The three primary elements of our executive officer compensation program are base salary, cash bonus and long-term equity incentive compensation. Both annual bonus payments andUnless the value of long-term equity incentive award grants are determined based on the achievement of pre-established performance goals. Long-term equity incentive compensation represents a significant percentage of eachcontext suggests otherwise, "named executive officers" as used in this section refers to our named executive officer's total direct compensation. We believe this emphasis on equity strongly reinforces the concept of "pay for performance," as the single largest component of pay is tied to future increases in the value of our stock. Additionally, in early 2019,officers who remained at Ironwood through 2019.

we adopted a clawback policy that provides that our board of directors may recover from our current and former executive offers certain incentive compensation under certain conditions upon a financial restatement.2020  Proxy Statement    33


        In addition, the pay opportunity in 2018 of our former chief executive officer, Dr. Hecht, demonstrated the strong alignment of our compensation program with our stock's performance. Pay opportunity includes base salary, target bonuses and grant-date fair value of stock options awarded in this time frame. Dr. Hecht has also consistently declined increases in his base salary and, until 2019, the receipt of cash bonuses, and he continued to earn the salary of $100,000 per year that he was first awarded 20 years ago in 1998.


Table of Contents

        Our performance in 2018 included the following achievements:

    Maximize Impact of our Products


    GRAPHIC
    Grew LINZESS® (linaclotide) U.S. net sales, as reported by Ironwood's U.S. collaboration partner Allergan plc, to $761 million for calendar year 2018, an increase of 9% compared to calendar year 2017.

    Initiated a Phase III study with linaclotide designed to evaluate the efficacy and safety of linaclotide 290 mcg on multiple abdominal symptoms including pain, bloating and discomfort.

    Successfully implemented a test market strategy for the lesinurad franchise, ultimately informing the decision to terminate our license agreement with AstraZeneca.

    Our partner Astellas Pharma Inc. received approval for, and then launched LINZESS for adults with chronic constipation in Japan, in addition to the already approved indication for adults with IBS-C.

    Create Value from our Innovative Pipeline

    Initiated a Phase III program with IW-3718, our gastric retentive formulation of a bile acid sequestrant for the potential treatment of persistent gastroesophageal reflux disease (GERD).

    Advanced MD-7246, our delayed release form of linaclotide being evaluated as an oral, intestinal, non-opioid, pain-relieving agent for patients in the U.S. suffering from abdominal pain associated with irritable bowel syndrome with diarrhea (IBS-D).

    Continued enrolling the two lead sGC stimulators, praliciguat and olinciguat, in Phase II trials. Praliciguat is being evaluated in diabetic nephropathy and heart failure with preserved ejection fraction (HFpEF) and olinciguat is being developed in sickle cell disease.

    Exercise Financial Discipline

    Delivered full year revenue growth of 16% at $346.6 million in calendar year 2018 versus calendar year 2017, driven primarily by $264.2 million in our share of the net profits from the sales of LINZESS in the U.S., $69.6 million in sales of linaclotide active pharmaceutical ingredient to Astellas in Japan, and $12.8 million in linaclotide royalties, co-promotion and other revenue.

    Demonstrated strong financial performance, meeting all 2018 financial guidance.

    Completion of a Transformative Transaction(stretch goal)

    Made substantial progress toward the Separation in 2018, ultimately leading to the completion of the transaction on April 1, 2019—less than one year from the initial announcement. The strategic analysis, decision and progress towards the new Ironwood and Cyclerion separation represents a transformative opportunity for shareholders.

        In determining compensation for our named executive officers, our compensation and HR committee emphasizes the achievement of our corporate goals designed to drive and maximize stockholder value. We made strong progress in 2018, including the achievement of certain stretch goals. As a result,our 2018 company performance achievement multiplier, which we used as a key consideration in determining executive compensation for 2018 performance, was 100%, as determined by the compensation and HR committee.


Table of Contents

Compensation Actions in 2019Goals and 2018Accomplishments

    Summary

        The following table summarizes the compensation actions taken by our compensation and HR committee for each of our named executive officers in recognition of the company's and his or her performance in 2018 and to motivate him or her to achieve our 2019 goals.

Name Peter M. Hecht, Ph.D. Gina Consylman Mark G. Currie, Ph.D. Thomas A. McCourt William Huyett 
Title





 Former
Chief Executive
Officer



 Chief
Financial
Officer
and Senior
Vice President

 Former Senior
Vice President,
Chief Scientific
Officer, and
President
of R&D

 President





 Former
Chief
Operating
Officer


 
            

Base salary increase

  (1)$65,000 $15,000 $20,000 $20,000 

2018 base salary

 $100,000 $415,000 $485,000 $465,000 $465,000 

2019 base salary

 $100,000 $480,000 $500,000 $485,000 $485,000 

Cash bonus(2)

 $1,192,500 $207,500 $242,500 $232,500 $232,500 

Annual restricted stock units awarded(3)

    72,500      43,125 

Annual stock options awarded(4)

  1,000,000  145,000  600,000  345,000  258,750 

Additional restricted stock units awarded in connection with the Separation(5)

    12,000  12,000  12,000  12,000 

(1)
Our compensation and HR committee recommended a salary increase for Dr. Hecht, but he declined to accept it.

(2)
Consists of payments made under our annual cash bonus program in 2019 for performance in 2018 for each named executive officer except Dr. Hecht. In January 2019, Dr. Hecht was awarded a discretionary cash bonus of $1,192,500 based primarily on the achievement of 100% of our 2018 corporate goals, including certain stretch goals. While our compensation and HR committee has historically granted Dr. Hecht stock options in lieu of an increase to base salary and cash bonus, and to keep his overall compensation competitive with that of his peers, Dr. Hecht accepted a portion of his compensation in the form of cash, rather than stock options, due to limitations on annual equity grants to individuals under our equity incentive plans.

(3)
These RSUs for shares of our common stock were awarded on January 29, 2019 under our 2010 Plan and vest over four years as to 25% of the award on each approximate anniversary of the grant thereof.

(4)
These options to purchase shares of our common stock were granted under our 2010 Plan with an exercise price of $12.90 per share (the closing price of our common stock on the Nasdaq Global Select Market on the grant date of January 29, 2019) and vest over four years as to 1/48th of the award on each monthly anniversary of January 1, 2019.

(5)
These RSUs for shares of our common stock were granted in recognition of service to Ironwood in connection with work critical to the Separation and will vest in full on May 9, 2019.

Alignment of Pay and Performance for our Chief Executive Officer

    Five-year Pay Opportunity vs. Five-year Realizable Pay

        Because of our stock price performance, Dr. Hecht's realizable pay over the past five years has significantly trailed his disclosed pay opportunities as shown in the chart below. Dr. Hecht's realizable pay is approximately 8.5% of the pay opportunity provided to him from 2014 through 2018, reflecting the heavy emphasis on stock options during this period. The weighted average exercise price of his option grants for 2014 through 2018 is $14.01, as compared to our 2018 fiscal year-end closing stock price of $10.36 on December 31, 2018. Because the vast majority of Dr. Hecht's options were underwater at fiscal year-end, his realizable pay attributable to these awards as of such date totaled $106,800. Combined with his base salary of $100,000 per year and no cash bonus payouts during this


Table of Contents

five-year period other than for 2018, which was paid in 2019, his total five-year realizable value as of our 2018 fiscal year-end was approximately $1.8 million.

GRAPHIC

    Pay opportunity is defined as planned base salary, target bonuses and the grant-date fair value of stock options granted from 2014 through 2018.

    Realizable pay is defined as actual salary received, bonuses paid and the in-the-money value of stock options granted from 2014 through 2018, calculated by determining the difference between the December 31, 2018 closing price of our common stock on the Nasdaq Global Select Market and the exercise price of each stock option.

    Three-year Realizable Pay vs. Three-year Total Stockholder Return

        Further, Dr. Hecht's total realizable pay from 2016 through 2018 shows a strong connection to our total stockholder return, or TSR, relative to our peer group, as shown in the graph below. Data points that are within the shaded area designate peer group companies that exhibit pay-for-performance alignment (meaning less than 25 percentage point difference between CEO realizable pay percentile and company TSR percentile).

GRAPHIC


Table of Contents

    Realizable pay percentile rank was determined using Dr. Hecht's realizable pay for 2016 through 2018 and comparing it to realizable pay for the CEOs of our peer group companies for 2015 through 2017, which is the most recent period for which data was available as of December 31, 2018, in each case as reported by the applicable company in its proxy statement.

    TSR percentile rank was determined using the actual TSR for Ironwood from 2016 through 2018 and for each of the companies in our peer group for the period from 2015 through 2017, which is the most recent period for which data was available as of December 31, 2018.

        This analysis shows that Dr. Hecht's realizable compensation compared to CEOs of our peer companies trailed our relative TSR position for 2016 through 2018. We believe this analysis is appropriate for assessing our pay and performance alignment for the following reasons:

    The analysis is based on the peer group set by the compensation and HR committee and described below;

    It takes into account stock price movement after the grant date (as opposed to grant date fair value reported in the Summary Compensation Table);

    For performance-based equity, the number of shares or units actually vesting is used for time periods where the performance period has been completed; and

    It excludes All Other Compensation, as reported in the Summary Compensation Table, which includes items that are not part of total direct compensation. For Ironwood, All Other Compensation is typically a small portion of Summary Compensation Table pay for Dr. Hecht for the entire year. However, at our peer group companies, items related to executive turnover such as severance payments, vacation payouts to former executives and relocation payments have been reported as All Other Compensation, which can be significant and can skew pay levels.

Elements of Executive Compensation and Determination of Amounts

    Short-and Long-Term Incentive Awards

        For 2018, allocations of cash and equity awards to our named executive officers were, in large part, dependent upon our meeting certain weighted corporate performance goals. We work thoughtfully with our compensation and HR committee and other members of our board of directors to establish what we believe are challenging corporate goals that further the accomplishment of our long-term business plan. In early 2018,2019, our compensation and HR committee approved the corporate performance goals for 2018.

        Dr. Hecht's performance evaluation was based primarily on the achievement of the 2018 corporate goals.2019. Our othernamed executive officers (other than our CEO) were evaluated on the achievement of the 20182019 corporate goals and additional individual goals that contributed toward, and related directly to, the accomplishment of the 20182019 corporate goals. OurThe compensation and HR committee assessed Mr. Mallon's performance based on the full set of corporate goals. Performance measured against the 20182019 corporate and individual goals (as applicable) was used to determinein determining compensation awards and adjustments for our named executive officers in early 2019. These2020.

The 2019 corporate goals, and our actualthe level of achievement ofagainst these goals, in 2018, areas determined by our compensation and HR committee, was as follows:

Corporate Goal
 Target
Percentage (%)
 Actual Level of
Achievement (%)
 

Maximize the impact of our products

  40% 35%

Create value from our innovative pipeline

  25% 22%

Driving value through our partnership choices

  20% 5%

Exercising financial discipline

  10% 10%

Leverage our talent, team and culture

  5% 5%

Totals

  100% 77%
Corporate
Goal
 Stockholder
Impact
 Achievements  Target
Percentage
(%)
  Actual Level of
Achievement
(%)
 
Grow the value of our IBS/constipation franchise Grows the revenue base 

Delivered target U.S. LINZESS net sales with compliance excellence

Obtained top-line Phase III abdominal symptom data and executed a compliant marketing plan to achieve 2019 volume targets

  40% 51%
Create value from our innovative pipeline Advances future business growth and profitability 

Advanced enrollment in Phase III pivotal studies in rGERD, including enrollment of patients with erosive esophagitis

Initiated MD-7246 Phase II study of abdominal pain associated with IBS-D and completed study enrollment well in advance of goals

  30% 22%
Strengthen our financial profile Transitions to cash generation 

Delivered target adjusted EBITDA from continuing operations*

Raised a total of $400 million in convertible notes due 2024 and 2026, and used proceeds to pay for associated capped call transactions, redeem all the outstanding principal balance of our 8.375% notes due 2026, and repurchase $215 million aggregate principal amount of our convertible notes due 2022

  15% 15%
Achieve value-creating corporate milestones Supports potential for long-term growth and profitability 

Successfully executed the Separation

Entered into commercial partnerships in 2019 with Allergan to continue to promote Allergan's VIBERZI® and with Alnylam for Alnylam's GIVLAARI™

  15% 18%
    Totals  100% 106%
  Stretch Goals for Additional Potential Achievement  50% 24%
    TOTALS  150% 130%

* Adjusted EBITDA from continuing operations was calculated by subtracting net interest expense, taxes, depreciation, amortization, fair value of remeasurement of contingent consideration, mark-to-market adjustments on derivatives related to Ironwood's 2.25% convertible notes due 2022, impairment of intangibles, restructuring expenses, separation expenses, and loss on extinguishment of debt from GAAP net income (loss) from continuing operations.

34    Ironwood


Table of Contents

GRAPHIC

In addition to the above corporate goals, the company achieved certain stretch goals in 2019, including higher LINZESS brand profitability compared to target and outperformance relative to adjusted EBITDA from continuing operations expectations. As a result,our compensation and HR committee determined that the progress made towards the Separation, as well as better-than-planned acceleration of our pipeline product candidates. The Separation was a transformative transaction that has the potential to unlock value for shareholders and was a substantial addition to the originally planned corporate activity. Therefore, the Separation and the other stretch goals achieved in connection with the acceleration of our pipeline resulted in a total2019 company performance achievement multiplier, which was used as a key consideration in determining executive compensation awarded for 2019 performance, was 130%.

In support of 100% for 2018, as determined by the compensation and HR committee.

        In addition to the 20182019 corporate goals identified above, for whichour compensation and HR committee assigned ownership of a specific subset of goals to each of our named executive officers, was directly accountable, the following is a summary of the 2018 individual goals for our named executive officers set in early 2018, other than Dr. Hecht:as follows:

NameSummary of Individual Goals
Gina Consylman

Serve as an enterprise leader and strategic partner to the chief executive officer in all parts of our business

Lead and guide the company on all financial decisions, including managing a strong balance sheet to enable the company to meet its objectives and be positioned to achieve its long-term goals

Gina Consylman

Follow a disciplined approach to capital allocation, investing in opportunities to grow the business and create sustainable long-term value

Drive value creation in the evaluation and, when appropriate, pursuit of business development opportunities for the organization through effective cross-functional collaboration and strategic guidance

Represent Ironwood within the investment community

Ensure company compliance with financial regulations and standards, including those related to The Sarbanes-Oxley Act of 2002, as well as SEC reporting

Evolve our culture of ownership, collaboration and innovation to drive incremental value for the company

Create integrated workforce, talent and capability plans that position us to execute our goals and longer-term strategy

Lead and guide the company to execute the Separation and to position the companies for success

Provide the highest quality of advice on all financial and compliance matters that optimize capital structure, strengthen balance sheet, and execute timely and accurate financial filings

Mark G. Currie, Ph.D.

Serve as an enterprise leader and strategic partner to the chief executive officer in all parts of our business

Serve as strategic leader on all research and development decisions and manage investments and expenses to enable the company to meet its objectives and be positioned to achieve its long-term goals

Advance our products and product candidates and further our discovery efforts through pipeline investments in the key value drivers of our business, including with respect to our mid to late stage pipeline

Enhance the clinical profile of LINZESS and drive linaclotide development programs to advance in additional indications, populations and formulations

Leverage internal research and development capability to support the advancement of our uncontrolled gout program

Lead and guide the company to execute the Separation and to position the companies for success

Drive value creation in the evaluation and, when appropriate, pursuit of business development opportunities for the organization through effective cross functional collaboration and strategic guidance

Evolve our culture of ownership, collaboration and innovation to drive incremental value for the company

Create integrated workforce, talent and capability plans that position us to execute our goals and longer-term strategy


Table of Contents

Name
Summary of Individual Goals

Thomas A. McCourt

Serve as an enterprise leader and strategic partner to the chief executive officer in all parts of our business

Serve as strategic leader on all commercial decisions and appropriately manage investments and expenses to enable the company to meet its objectives and be positioned to achieve its long-term goals

Build brand awareness and appropriate growth, while enhancing the global brand for linaclotide through close collaboration with partners and other members of senior management

Drive demand for LINZESS and build the gout franchise through sales of ZURAMPIC and DUZALLO and the emerging products in the pipeline

 

Deliver LINZESS net salestarget adjusted EBITDA from continuing operations

Execute on the Separation, including setting up two independent companies with separate financial systems

Strengthen our balance sheet and commercial contribution while maintainingimprove cost of capital

Improve our financial performance monitoring capabilities

Gain board approval of a culture of compliance excellencerefreshed strategic framework to drive future growth

Halley E. Gilbert 

DriveExecute on the strategic roadmap for DUZALLO,Separation, including the successful completion of the lesinurad test market strategy, while maintainingestablishing transition services and executing development plan

Establish a commercial partnership that increases enterprise value

Maintain our culture of compliance excellence

Provide high quality intellectual property advice, including relating to abbreviated new drug application litigation ongoing in 2019

Thomas A. McCourt 

LeadDeliver target LINZESS net trade sales with compliance excellence

Strengthen LINZESS profile with release of Phase III abdominal symptom data

Refresh LINZESS life cycle management plan in partnership with Allergan

Advance enrollment of the Phase III clinical studies of IW-3718 in rGERD

Initiate MD-7246 Phase II abdominal pain study in IBS-D patients, positioning to deliver top-line data readout in 2020

Strengthen commercial and guide the company to execute the Separation and to position the companies for successdrug development capabilities through completion of a number of targeted program initiatives

Lead the commercial field sales force in successfully commercializing our products, while maintaining a culture of compliant, patient centered care

Drive value creation in the evaluation and, when appropriate, pursuit of business development opportunities for the organization through effective cross functional collaboration and strategic guidance

Evolve our culture of ownership, collaboration and innovation to drive incremental value for the company

Create integrated workforce, talent and capability plans that position us to execute our goals and longer-term strategy

William Huyett

Serve as an enterprise leader and strategic partner to the chief executive officer in all parts of our business

Serve as strategic leader on all operational decisions and appropriately manage investments and expenses to enable the company to meet its objectives and be positioned to achieve its long-term goals while maintaining a culture of compliance

Drive value creation in the evaluation and when appropriate, pursuit of business development opportunities for the organization through effective cross-functional collaboration and strategic guidance

Evolve our culture of ownership, collaboration and innovation to drive incremental value for the company

Create integrated workforce, talent and capability plans that position us to execute our goals and longer-term strategy

Lead and guide the company to execute the Separation and to position the companies for success

Represent Ironwood within the investment community including the value creation of the company product and pipeline products

In early 2019, Dr. Hecht2020, Mr. Mallon evaluated each named executive officer'sthe individual performance in 20182019 of each of the named executive officers listed above and provided feedback and made recommendations to our compensation and HR committee. The committee determined the named executive officers' compensation, taking into account Ironwood's level of achievement of its corporate goals as well as the fact that each named executive officer metexceeded or far exceeded all or substantially allperformance expectations for 2019.

Additional information on the basis for compensation decisions in 2019 relating to our named executive officers is available throughout this section and elsewhere in this proxy statement under the captionsRole of his or her respective individual goals for 2018.the Compensation and Human Resources Committee andRole of the Compensation Consultant: Benchmarking and Peer Group Analysis.

Base salaries are determined at commencement of employment and are generally re-evaluated annually and adjusted, if warranted, to realign salaries with market levels and to reflect the performance of the named executive officer. In determining whether to adjust ana named executive officer's base salary, our compensation and HR committee takes into consideration factors such as our performance


Table of Contents

in prior years, general economic factors and compensation parity among our named executive officers, as well as the abilities, performance and experience of ourthe named executive officers.officer. Our compensation and HR committee also reviews our named executive officers' past compensation at the company and market data.

        Dr. Hecht's salary Please seeRole of $100,000 represents the salary that he has received since he began serving as chief executive officer in 1998,Compensation Consultant: Benchmarking and his compensation was reviewed and approved annually by our compensation and HR committee. In eachPeer Group Analysis for further information.

2020  Proxy Statement    35


Table of January 2019 and January 2018, our compensation and HR committee recommended an increase to Dr. Hecht's base salary to be market competitive with his peers, but Dr. Hecht declined to accept such increase. Our compensation and HR committee recognizes that Dr. Hecht's cash compensation has been well below his market peers but believes that the emphasis on stock ownership significantly aligns his interests with those of our stockholders and the creation of long-term stockholder value.Contents

GRAPHIC

        In January 2018, our compensation and HR committee reviewed and approved the following base salaries for 2018 for our named executive officers other than Dr. Hecht: Dr. Currie received a $15,000 increase in base salary from $470,000 to $485,000 and Mr. McCourt received a $15,000 increase from $450,000 to $465,000. The increase in base salary for each of Dr. Currie and Mr. McCourt was based on our compensation and HR committee's determination that we achieved 84% of our corporate goals in 2017 and in recognition of their each meeting or exceeding all or substantially all of their respective individual and corporate performance goals in 2017. This determination also took into account peer group and other market data from the PM competitive assessment discussed below. Ms. Consylman's base salary, reviewed and approved by the compensation and HR committee in November 2017, remained $415,000 for 2018 due to the substantial completion of calendar year 2017 at the time of her promotion to senior vice president and chief financial officer. Mr. Huyett's initial base salary, reviewed and approved by our compensation and HR committee in December 2017, was $465,000. Mr. Huyett did not receive an increase in base salary due to the short period of time between his joining Ironwood and our compensation and HR committee's 2018 base salary review.

In January 2019, our compensation and HR committee reviewed and approved the following base salaries for 2019 for our named executive officers other(other than Dr. Hecht:Mr. Mallon, whose compensation was set when he commenced service with us, as described above): Ms. Consylman received a $65,000 increase in base salary from $415,000 to $480,000, Dr. Currie received a $15,000 increase in base salary from $485,000 to $500,000, Mr. McCourt received a $20,000 increase from $465,000 to $485,000, and Mr. HuyettMs. Gilbert received a $20,000 increase in base salary from $460,000 to $480,000, and Mr. McCourt received a $20,000 increase from $465,000 to $485,000. The increase in base salary for Ms. Consylman, Ms. Gilbert and Mr. McCourt was based on our compensation and HR committee's determination that we achieved 100% of our corporate goals in 2018 and in recognition that each such named executive officer met or exceeded all or substantially all of his or her respective individual goals for 2018. This determination also took into account peer group and other market data from the Pearl Meyer competitive assessment discussed below. In addition, the increase in base salary for Ms. Consylman in 2019 also includes adjustments to better align her base salary with the external market and her internal peers. In May 2019, Mr. McCourt received a $35,000 increase in base salary from $485,000 to $520,000 in connection with his promotion to president, which increase was effective as of April 1, 2019.

Our cash bonus program is designed to reward the achievement of our annual corporate goals and in the case of our executive officers other than Dr. Hecht, individual goals. The program is also intended to foster and support our performance-driven culture by setting clear, high-value goals, rewarding outstanding performers, and making sure our employees know clearly that we value their contributions. Each cash bonus award is made annually and is based on the extent to which we achieved our corporate goals for the preceding year, as well as the executive's individual performance in that year against his or her individual goals. In 2018, consistent with 2017, each2019, Mr. Mallon's target bonus was 75% of our executive officers had ahis base salary, Mr. McCourt's target bonus was 60% of his base salary, and Mses. Consylman and Gilbert's target ofbonus was 50% of his or hertheir respective base salary.salaries. We believe that these target bonus percentages align the target compensation of our named executive officers with that of our peers, place appropriate emphasis on achievement of our annual performance objectives and facilitate both recruiting, retaining and motivating our executive officers.

Additionally, for each of our named executive officers, other than Dr. Hecht, 70% of each cash bonus award paid in 20192020 for 20182019 performance was based solely on the achievement of our corporate goals and 30% was based on the named executive officer's achievement of his or her individual goals, which, as described above for named executive officers other than Mr. Mallon, included specific accountability for certain of our corporate goalsgoals. In determining Mr. Mallon's cash bonus paid in 2020 for 2019 performance, the compensation and our executive officers'HR committee equated Mr. Mallon's individual performance to the company's 2019 performance achievement multiplier of 130%.


36    Ironwood


Table of Contents

GRAPHIC

goals. Therefore, to calculateThe following summarizes the bonus amount payable, the bonus target was multiplied by the company performance achievement multiplier, and 30%calculation of that figure was further modified by multiplying such amount by theour named executive officers' individual performance achievement multiplier. cash bonus awards paid in 2020 for 2019 performance:

GRAPHIC

This approach was intended to closely align cash bonus awards to the achievement of our corporate goals, while taking into account individual performance and providing structureequity and claritytransparency to the calculation of our executive bonuses. As in 2017, in 2018described above, the company performance achievement multiplier for 2019 was between 0%130%. In February 2020, our compensation and HR committee determined that each of our named executive officers exceeded or far exceeded performance expectations for 2019, resulting in the following individual performance achievement multipliers: Ms. Consylman, 150%; Ms. Gilbert, 130% and theMr. McCourt, 140%. Our compensation and HR committee also determined that Mr. Mallon's individual performance achievement multiplier was between 0% and 200%.130% on the basis that such multiplier was equal to the 130% corporate performance achievement multiplier. The following summarizes the calculation of our executive officers' cash bonus awards paid in 2019 for 2018 performance, other than Dr. Hecht:

50% Bonus Target
×
50% Bonus Target
×
Company Performance
Achievement Multiplier
Company Performance+×=Actual Bonus Payout
Achievement Multiplier
×
Individual Performance
Achievement Multiplier
70% Weighting×
30% Weighting

        In January 2019, our compensation and HR committee reviewed and approved the following bonuses for 20182019 performance for our named executive officers other than Dr. Hecht, each of whom met or exceeded all or substantially all of their respective individual goals for 2018:officers:

Executive Officer
 Annual Cash Bonus for
2018 Performance
 

Gina Consylman

 $207,500 

Mark G. Currie, Ph.D. 

 $242,500 

Thomas A. McCourt

 $232,500 

William Huyett

 $232,500 

Named Executive Officer

  Annual Cash Bonus
for 2019 Performance
 

Mark Mallon

 $797,063 

Gina Consylman

 $358,800 

Halley E. Gilbert

 $340,080 

Thomas A. McCourt

 $454,272 

In January 2019, Dr. Hecht was awarded aaddition to the annual cash bonus for 2019 performance described above, in May 2019, Mses. Consylman and Gilbert each received a special $250,000 cash award in recognition of $1,192,500 based primarily ontheir significant contributions to and performance in connection with the achievement of 100% ofSeparation and, with respect to Ms. Gilbert, for her expanded role overseeing our 2018 corporate goals, including certain stretch goals. While our compensation and HR committee has historically granted Dr. Hecht stock options in lieu of an increase to base salary and cash bonus, and to keep his overall compensation competitive with that of his peers, Dr. Hecht accepted a portion of his compensation in the form of the aforementioned cash payment, rather than stock options, due to limitations on annual equity grants to individuals under our equity incentive plans.development function.

We use equity awards as our incentive vehicle for long-term compensation to attract, reward and motivate our named executive officers in a manner that best alignsis intended to align their interests with those of our stockholders' interests.stockholders. We typically grant equity awards in the first quarter of each year based on our performance in the prior year. Throughout the year, our compensation and HR committee may award additional grants as circumstances warrant. Our compensation and HR committee does not apply a rigid formula in allocating equity awards to our named executive officers as a group or to any particular named executive officer, but sets thean equity pool each year based on achievement of our corporate goals.goals for the prior year, which for 2018 was 100% of our corporate goals, including certain stretch goals, and our expectations for future performance. Individual equity award amounts are then determined based on, among other factors, peer

2020  Proxy Statement    37


Table of Contents

GRAPHIC

group and market data, and our compensation and HR committee adjusts these amounts after considering input from PM, relative company performancecompensation advisors and in the case of our executive officers other than Dr. Hecht, individual performance.

In 2019, our performance in the prior year. Our named executive officers havehad a choice of the composition of their annual equity awards and cancould select from the following choices: 100% stock options; 75% stock options and 25% RSUs; or 50% stock options and 50% RSUs. ThroughoutThe size of executive equity grants was determined based on the year, our compensationfactors described above and HR committee may award additional grants as circumstances warrant.


Table of Contents

        We believe that time-based stock options are inherently performance-based, as they provide value to the recipient only if there is future stock price appreciation and do not provide any value if the stock price declines below the exercise price. This results in a close alignment of our executive officers' compensation, particularly that of Dr. Hecht, with the value of our long-term stockholders' investment in Ironwood. Dr. Hecht has long been a substantial stockholder in the company, currently beneficially owning nearly 3.5% of our total outstanding stock as of April 2, 2019 (as calculated in the beneficial ownership table beginning on page 6).

        In January 2018, our compensation and HR committee determined that we achieved 84% of our 2017 corporate goals. Dr. Hecht was granted an annual stock option award of 390,000 shares based primarily on this achievement of our corporate goals, as well as an additional stock option award of 190,000 shares in lieu of a cash bonus or salary increase. Ms. Consylman, Dr. Currie and Mr. McCourt met or exceeded all or substantially all of their respective individual goals in 2017. Eacheach of our named executive officers, other than Dr. HechtMr. Mallon (who joined Ironwood in January 2019), was awarded the following stock option and RSU awards based on performance during 2017:under our Amended and Restated 2010 Employee, Director and Consultant Equity Incentive Plan, or 2010 Plan, in January 2019:

Executive Officer*
 2018 Annual Stock Option
Grant for 2017
Performance
(# of Shares of
Common Stock
Subject to Stock
Options)
 2018 Annual RSU
Grant for 2017
Performance
(# of Shares of
Common Stock
Subject to RSUs)
 

Gina Consylman

  60,000  30,000 

Mark G. Currie, Ph.D. 

  215,000   

Thomas A. McCourt

  131,250  21,875 

*
Ms. Consylman became chief financial officer

Named Executive Officer

  2019 Annual Stock Option Grant
(# of Shares of Class A common stock
Subject to Stock Options)
  2019 Annual RSU Grant
(# of Shares of Class A common stock
Subject to RSUs)
 

Gina Consylman

 145,000 72,500 

Halley E. Gilbert

  145,000  72,500 

Thomas A. McCourt

 345,000  

On the date of grant, the company in November 2017.

        These stock options and RSUs were granted on February 21, 2018 under our 2010 Plan. The stock options havehad an exercise price of $14.55$12.90 per share (the closing price of our Class A common stock on the Nasdaq Global Select Market on the grant date). Generally subject to the executives' continued employment with the company. The stock options vest monthly over four years as to 1/48th of the options following the date of grant and the RSUs vest as to 25% of the RSUs on each approximate anniversary of the date they were granted. For a description of the impact of the Separation on the number of stock options and RSUs, and the exercise price of stock options, awarded to our named executive officers in January 2019, please seeEquity Impact of the Separation and the footnotes to theGrants of Plan-Based Awards table elsewhere in this proxy statement.

In connection with Ms. Consylman's promotionthe Separation in April 2019, Mr. McCourt was promoted to chief financial officer in November 2017, in January 2018, Ms. Consylmanpresident and was granted an additional 15,00045,704 stock options and 7,50022,852 RSUs, each for shares of our Class A common stock under our 2010 Plan. The stock options have an exercise price of $15.27$11.78 per share (the closing price of our Class A common stock on the Nasdaq Global Select Market on the grant date). Subject to Ms. Consylman'sMr. McCourt's continued employment with the company, (i) the stock options will vest monthly over four years as to 1/48th of the total sharesoptions following the date of Ms. Consylman'sMr. McCourt's promotion, and (ii) the RSUs will vest as to 25% of the shares on each approximate anniversary of the grant thereof.

        Mr. Huyett was not eligible to receive an annual equity award in fiscal year 2018 due to the substantial completion of fiscal year 2017 when he joined Ironwood in December 2017, and instead received an initial grant in early fiscal year 2018. In January 2018, Mr. Huyett was granted 337,500 stock options and 56,250 RSUs. The stock options have an exercise price of $15.27 per share (the closing price of our common stock on the Nasdaq Global Select Market on the grant date). The stock options will vest over four years as to 25% of the shares on the first anniversary of Mr. Huyett's start date and as to 1/48th of the total shares each month thereafter for the next 36 months, and the RSUs will vest as to 25% of the awardRSUs on each approximate anniversary of the grant date.date they were granted.

Equity awards granted to Mr. Mallon in 2019 are described above under the caption2019 CEO Transition Compensation.

In JanuaryDecember 2019, we made special retention awards of RSUs to our named executive officers, other than Mr. Mallon, which vest as to 100% of the RSUs after two years generally subject to the executives' continued employment with the company. Mses. Consylman and Gilbert received 41,150 RSUs and Mr. McCourt received 115,220 RSUs. In establishing the size of these grants, our compensation consultant, Rewards Solutions, Aon (or Aon), presented peer group data and assisted our compensation and HR committee determinedwith approximating the value that we achieved 100%another organization could potentially offer in a sign-on equity grant to recruit our executive talent. In connection with her resignation from the company in February 2020, the 41,150 RSUs granted to Ms. Gilbert in December 2019 terminated in their entirety.

We believe that creating long-term shareholder value requires our executive team to balance their efforts on driving LINZESS growth and advancing our late-stage development programs while at the same time progressing on milestones necessary to expand future product offerings. Accordingly, our 2020 executive equity compensation program is comprised of our 2018 corporate goals, including certain stretch goals. Dr. Hecht was granted50% PSUs and 50% RSUs. In introducing PSUs and providing for an annual stock option awardequal mix of 1,000,000 shares based primarily on the achievement of our 2018 corporate goalsPSUs and to align his total compensation to be market competitive with his peers. In addition, Ms. Consylman,RSUs by grant


38    Ironwood


Table of Contents

Dr. Currie, Mr. McCourt and Mr. Huyett also met or exceeded all or substantially all of their respective individual goals in 2018. Accordingly, in January 2019, each of our named executive officers other than Dr. Hecht was awarded the following stock option and RSU awards under our 2010 Plan based on performance during 2018:

GRAPHIC
Executive Officer
 2019 Annual Stock Option
Grant for 2018
Performance
(# of Shares of
Common Stock
Subject to Stock
Options)
 2019 Annual RSU
Grant for 2018
Performance
(# of Shares of
Common Stock
Subject to RSUs)
 

Gina Consylman

  145,000  72,500 

Mark G. Currie, Ph.D. 

  600,000   

Thomas A. McCourt

  345,000   

William Huyett

  258,750  43,125 

        The stock options have an exercise price of $12.90 per share (the closing price of our common stock ondate fair value (with PSUs measured at target), the Nasdaq Global Select Market on the grant date).

        Ms. Consylman, Dr. Currie, Mr. McCourt, and Mr. Huyett were each granted 12,000 RSUs in July 2018 in recognition of service to the company in connection with work critical to the Separation. Subject to continued service with the company, the RSUs will vest in full on May 9, 2019.

    Executive Severance Agreements

        Our board, through our compensation and HR committee periodically assesses oursought to design a 2020 executive severance arrangementsequity compensation program that provides the appropriate combination of awards to among other things, ensure that such benefits are competitiveincentivize performance, align executive interests with those of our peers. In 2018,stockholders, and encourage executive retention.

As in 2019, long-term equity incentive compensation granted in 2020 is expected to represent a majority of each named executive officer's total compensation for the year (based on the grant date fair value of equity awards, with PSU awards measured at target). We believe this emphasis on equity, and particularly performance-based equity, strongly reinforces the principle of "pay for performance," and closely ties our compensation and HR committee made the determinationexecutives' pay outcomes to amend and restate the severance arrangements with each ofstockholder value creation.

Goals underlying 2020 PSU awards were set to be achieved over a two to three-year performance period based, in part, on our executive officers the terms of which had been in place since 2015.long-range operating plan. Our compensation and HR committee selected the following discussionsperformance goals for our 2020 PSU awards, which we believe drive executive accountability for delivering value to our stockholders:

1)
Gaining the U.S. FDA's acceptance of one or more additional NDAs;

2)
Growing revenue and controlling expenses as measured by cumulative adjusted organic EBITDA; and

3)
Realizing rTSR goals.

The 2020 PSUs use the following metrics, weighting and vesting opportunity:

WeightPerformance
Period
Threshold Goals
(50% attainment)
Target Goals
(100% attainment)
Stretch Goals
(200% attainment)
40%Ending December 2022N/AAcceptance by the U.S. FDA of an NDA for IW- 3718 or other internal or external development programAcceptance by the U.S. FDA of two NDAs, including IW-3718 and/or other internal or external development programs
30%2020 - 2021
Cumulative Target
Threshold cumulative adjusted organic EBITDA through 2021Target cumulative adjusted organic EBITDA through 2021Stretch target cumulative adjusted organic EBITDA through 2021
30%Ending December 2022rTSR at the 25th percentile compared to rTSR peer group through 2022rTSR at the 50th percentile compared to rTSR peer group through 2022rTSR at the 75th percentile compared to rTSR peer group through 2022

Our compensation consultant, Aon, assisted our compensation and HR Committee with PM, believed the existing severance arrangements were not consistent with those inassessing our profile and market characteristics versus several potential benchmarks and then identifying an expanded peer group of commercial biopharmaceutical companies for purposes of the rTSR measurement goal under these PSUs. Our compensation and HR

2020  Proxy Statement    39


Table of Contents

GRAPHIC

committee then approved the following custom, rTSR measurement peer group, which includes all of our current executive compensation peers:

ACADIA Pharmaceuticals, Inc.Ionis Pharmaceuticals, Inc.
Aerie Pharmaceuticals, Inc.Jazz Pharmaceuticals plc
Agios Pharmaceuticals, Inc.Karyopharm Therapeutics Inc.
Akcea Therapeutics, Inc.Ligand Pharmaceuticals Incorporated
Akebia Therapeutics, Inc.Momenta Pharmaceuticals, Inc.
Alkermes plcOPKO Health, Inc.
Amicus Therapeutics, Inc.Pacira BioSciences, Inc.
Amphastar Pharmaceuticals, Inc.Perrigo Company plc
bluebird bio, Inc.Portola Pharmaceuticals, Inc.
Blueprint Medicines CorporationPrestige Consumer Healthcare Inc.
Catalent, Inc.PTC Therapeutics, Inc.
Coherus BioSciences, Inc.Radius Health, Inc.
Corcept Therapeutics IncorporatedSage Therapeutics, Inc.
Eagle Pharmaceuticals, Inc.Sarepta Therapeutics, Inc.
Emergent BioSolutions Inc.Spectrum Pharmaceuticals, Inc.
Endo International plcSupernus Pharmaceuticals, Inc.
Exelixis, Inc.Taro Pharmaceutical Industries Ltd.
Flexion Therapeutics, Inc.Theravance Biopharma, Inc.
GW Pharmaceuticals plcUltragenyx Pharmaceutical Inc.
Halozyme Therapeutics, Inc.United Therapeutics Corporation
Heron Therapeutics, Inc.Vanda Pharmaceuticals Inc.
Horizon Therapeutics Public Limited CompanyVeracyte, Inc.
Insmed IncorporatedVericel Corporation
Intercept Pharmaceuticals, Inc.

40    Ironwood


Table of Contents

GRAPHIC

In February 2020, our named executive officers were granted the following equity awards under our 2019 Equity Incentive Plan, or 2019 Plan:

Named Executive Officer

  2020 Annual PSU Grant
(# of Shares of Class A common stock
Subject to PSUs) (at target)
  2020 Annual RSU Grant
(# of Shares of Class A common stock
Subject to RSUs)
 

Mark Mallon

 221,061 221,061 

Gina Consylman

  68,327  68,327 

Halley E. Gilbert

   

Thomas A. McCourt

  100,482  100,482 

Equity awards granted to Messrs. Mallon and McCourt had target values based approximately on the peer group 50th percentile. Equity awards granted to Ms. Consylman were 13% above the 50th percentile in recognition of her outstanding performance in 2019. The compensation and HR committee did not reflectmake an equity award to Ms. Gilbert because she had provided notice of her intent to resign from the company in February 2020. In addition, to facilitate the transition from stock options that vested monthly to PSUs that are generally subject to two or three year cliff-based vesting, 2020 RSU grants to our compensation structure, which had historically been more heavily weightednamed executive officers vest as to equity over cash. We believeapproximately 33% of the amended and restatedunderlying shares on each approximate anniversary of the grant date.

Executive Severance Agreements

Severance arrangements better alignwe have with our executive severance practices with those of our peers, which is particularly important as we seek to recruit top talent from companies like our peers, to retain our key executives and to foster our performance-driven culture aimed at setting and achieving aggressive, high-value goals.

        Under the amended and restated severance arrangements, ournamed executive officers are eligible to receive certain payments and benefitsdescribed elsewhere in the event of an involuntary termination without "cause" or a "constructive termination" (each as defined belowthis proxy statement under the captionPotential Payments Upon Termination or Change of Control—Named Executive Officer Severance ArrangementsArrangements.), and enhanced payments and benefits in the event of a "change of control termination" (as defined below under the captionPotential Payments Upon Termination or Change of Control—Named Executive Officer Severance Arrangements). These benefits are only payable if the named executive officer has complied with all of our rules and policies, has executed a separation agreement that includes a release of claims and complies with his or her post-employment non-disclosure, non-competitionnondisclosure, noncompetition and non-solicitationnonsolicitation obligations.

We believe that offering these payments and benefits assists us in recruiting, retaining and motivating executive officers, facilitates the operation of our business, allows our named executive officers to better focus their time, attention and capabilities on our business, and provides for a clear and consistent approach to managing involuntary departures with mutually understood separation benefits. A further description of the severance arrangements is set forth belowelsewhere in this proxy statement under the captioncaptionsPost-Employment Arrangements,Named Executive Officer Severance Arrangements andPotential Payments Upon Termination or Change of Control—Named Executive Officer Severance ArrangementsControl.


Table of Contents

    Other Compensation

We maintain broad-based benefits that are provided to all employees, including health insurance, life and disability insurance, dental insurance, fitness and transportation stipends, and a 401(k) plan with a 75% matching company contribution on the first $8,000 of an employee's annual contribution.

We also maintain a relocation program under which we make certain benefits available to newly hired and existing employees, including our named executive officers, who are relocating to accept a new position with Ironwood.the company. Our relocation program covers reasonable expenses associated with the move and certain relocation services, including, as applicable, temporary housing assistance payments and a lump-sum relocation allowance, departure home sale assistance, rental assistance, new home search assistance, home purchase assistance, moving of household goods and vehicles assistance, and reimbursement of final trip expenses to the new area. We also provide tax assistance to our relocating employees to cover the costs associated with certain non-deductible relocation expenses, as we believe that this benefit is important to our ability to attract and motivate employees. Under our relocation program, participants are required to pay back the full amount of all relocation reimbursements in the event that they voluntarily terminate their employment or are terminated for "cause" within 12 months following the payment date of their last relocation reimbursement.

Other than our broad-based benefits, or as otherwise described herein, none of our named executive officers receive perquisites of any nature.

2020  Proxy Statement    41


Table of Contents

GRAPHIC

Post-Employment Arrangements

In February 2019, our compensation and HR committee amended and restated Ms. Gilbert's severance agreement to, among other things, provide Ms. Gilbert the right to resign for any reason by February 2020, and to have that resignation be treated as a "good reason" termination for purposes of her severance and other entitlements under her severance agreement. Ms. Gilbert resigned from the company effective February 28, 2020. For a description of the payments and other benefits Ms. Gilbert received in connection with her resignation, seeNamed Executive Officer Severance Arrangements andPotential Payments Upon Termination or Change of Control elsewhere in this proxy statement.

In February 2020, the company entered into a consulting agreement with Ms. Gilbert under which Ms. Gilbert agreed to advise the company on various corporate development projects and governance matters. The agreement has a term of three months from the effective date, unless earlier terminated pursuant to its terms, and the company will pay Ms. Gilbert $90,000 for her services under the agreement.

Compensation of Named Executive Officers Who Transitioned to Mark MallonCyclerion

        Mr. Mallon, who was recruited to become the chief executive officer of Ironwood following the completion of the Separation, joined the company on January 4, 2019. In order to compensate him, in part, for outstanding equity he forfeited by leaving his previous employer and to align his interests with shareholders, his initial compensation includes certain one-time cash and equity awards. The terms of his offer letter provide for the following:

    an initial base salary of $750,000 per year,

    an annual bonus target of 75% of his base salary, subject to achievement of individual and corporate goals,

    a one-time new hire bonus of $880,000 subject to certain clawback provisions if he terminates his employment for any reason or the company terminates his employment for Cause (as defined in his executive severance agreement described below) within two years of his start date,

    an initial equity grant consisting of:

    an option to purchase 171,526 sharesTwo of our common stock that vest over four years, with 25% of the options vesting on the first anniversary of his start date2019 named executive officers, Peter Hecht and 1/48th of the total shares vesting each month thereafter for the next 36 months and

    93,036 RSUs that will vest over four years as to 25% of the award on each approximate anniversary of the applicable grant date, and

    certain relocation benefits, also subject to certain clawback provisions if Mr. Mallon terminates his employment for any reason or the company terminates his employment for Cause,Mark Currie, became Cyclerion employees in each case within 12 months following the payment date of his last relocation reimbursement.

        Mr. Mallon became chief executive officer of Ironwood on April 1, 2019 in connection with the completionSeparation. Prior to their transition from Ironwood to Cyclerion, the compensation and HR committee made decisions relating to Drs. Hecht and Currie's compensation in line with those made for the other named executive officers, including as described below under the captionCompensation Determination Process and elsewhere in thisCompensation Discussion and Analysis.

In January 2019, our compensation and HR committee reviewed and approved a base salary of $100,000 for Dr. Hecht, which amount was unchanged from his 2018 base salary. Dr. Hecht consistently declined increases in his base salary and he continued to earn the salary of $100,000 per year that he was first awarded in 1998. The compensation and HR committee also reviewed and approved Dr. Currie's base salary and provided him with a $15,000 increase in base salary from $485,000 to $500,000. Because they were only employed by Ironwood through March 2019, actual base salaries paid to Drs. Hecht and Currie for 2019 were $25,000 and $125,000, respectively.

In January 2019, our compensation and HR committee also awarded 1,000,000 stock options to Dr. Hecht and 600,000 stock options to Dr. Currie, which options vested as to 1/48th of the Separation. Perunderlying shares on each monthly anniversary of the vesting commencement date until fully vested. On the date of grant, the stock options had an exercise price of $12.90 per share (the closing price of our Class A common stock on the Nasdaq Global Select Market on the grant date). For a description of the impact of the Separation on the number and the exercise price of stock options awarded to Drs. Hecht and Currie in January 2019, please seeEquity Impact of the Separation and the footnotes to theGrants of Plan-Based Awards table elsewhere in this proxy statement.

For 2019, Dr. Hecht's bonus, with an individual bonus target of 50% of his offer letter, upon becoming CEO hebase salary, was to be determined primarily based on the achievement of our corporate goals. Dr. Currie had an individual bonus target of 50% of his base salary, 70% of which was tied solely to the achievement of our corporate goals for 2019 and 30% of which was tied to the achievement of corporate and individual performance goals (though our compensation and HR committee did not assess Dr. Currie's achievement of his individual goals in 2019 because of Dr. Currie's anticipated transition to Cyclerion). Neither Dr. Hecht nor Dr. Currie received an additional option to purchase 423,049a cash bonus for 2019 performance because they were not employed by Ironwood on the date in 2020 that cash bonuses for 2019 performance were paid. Further, the Separation did not trigger payments under Drs. Hecht and Currie's respective severance agreements with the company.

In connection with the Separation, Dr. Currie joined our board of directors on April 1, 2019. Upon joining our board of directors, Dr. Currie received a restricted stock grant of 2,995 shares of our Class A common stock for his service on our board of directors between April 1, 2019 and an additionalthe 2019 annual meeting of stockholders pursuant to our 2014 Director Compensation Plan. In May 2019, Dr. Currie then received a restricted stock grant of 206,873 RSUs. As with22,706 shares of our Class A common stock pursuant to our 2019 Director Compensation Policy for service on our board of directors from the date of our 2019 annual meeting of stockholders to the date of our 2020 annual meeting of stockholders. Dr. Currie also received a cash retainer of $37,500 for his initial equity grant, 25%service on our board of directors from April 1, 2019 through December 31, 2019. Compensation for Dr. Currie's service on our board of directors in 2019 following the options vest on the first anniversary ofSeparation, as well as his start date, with 1/48th of the total shares vesting each month thereafter for the next 36 months, and the RSUs vest as


42    Ironwood


Table of Contents

GRAPHIC

compensation for services as an Ironwood employee in 2019 prior to 25% of the award per yearSeparation, are included in theSummary Compensation Table, below.

Additional information on the first four anniversaries of the date of grant. This grant was made on April 1,basis for compensation decisions in 2019 the effective date of the Separation.

        In addition, the company has entered into an indemnification agreementrelating to Drs. Hecht and an executive severance agreement with Mr. Mallon, the terms of each of which are consistent with the forms of indemnification agreement and executive severance arrangements describedCurrie is available elsewhere in this proxy statement. Mr. Mallon's compensation willstatement under the captionsRole of the Compensation and Human Resources Committee andRole of the Compensation Consultant: Benchmarking and Peer Group Analysis.

Equity Impact of the Separation

The employee matters agreement executed in connection with the Separation provided that outstanding Ironwood equity awards held by Ironwood and Cyclerion employees, including equity grants made in 2019 prior to the Separation to our 2019 named executive officers, were adjusted in accordance with the following principles:

    For each award, the intent was to maintain, immediately following the distribution date, the economic value of the award immediately before the distribution date.

    For both Cyclerion and Ironwood employees, except as noted below, vested Ironwood equity awards were converted into equity awards of both Ironwood and Cyclerion using the "basket approach" (as described below).

    For Cyclerion employees, except as noted below, unvested Ironwood equity awards were converted into Cyclerion equity awards using the "concentration approach" (as described below).

    For Ironwood employees, unvested Ironwood equity awards remained as Ironwood equity awards using the "concentration approach."

    For non-employee directors of Cyclerion who had been non-employee directors of Ironwood, unvested Ironwood restricted stock were converted into unvested Cyclerion restricted stock using the "concentration approach."

    For non-employee directors of Ironwood who remained non-employee directors of Ironwood, unvested Ironwood restricted stock continued as unvested Ironwood restricted stock, adjusted using the "concentration approach."

    To the extent any adjustments to outstanding equity awards resulted in fractional interests in shares, the fractional interests were rounded down to the nearest whole share and Ironwood or Cyclerion, as the case may be, includedmade cash payments to its respective employees in lieu of such fractional interests.

Basket Approach

Following the distribution, the number of shares underlying converted Cyclerion equity awards (whether held by Ironwood or Cyclerion employees) was determined according to a fixed ratio of one share of Cyclerion common stock for every 10 shares of Ironwood Class A common stock. The exercise price associated with converted Cyclerion equity awards (whether held by Ironwood or Cyclerion employees) was determined according to formulas based on the 10 day volume weighted average trading price of Ironwood Class A common stock for the 10 days immediately preceding the distribution and the purchase price of $175.0 million for Cyclerion common stock paid in a private placement Cyclerion executed in connection with the distribution.

Concentration Approach

Following the distribution, the number of shares underlying converted Cyclerion equity awards and any associated exercise prices was determined according to formulas based on the 10 day volume weighted average trading price of Ironwood Class A common stock for the 10 days immediately preceding the distribution and the purchase price of Cyclerion common stock paid in the Summary Compensation private placement referenced above.

2020  Proxy Statement    43


Table next yearof Contents

GRAPHIC

The following table contains a summary of the treatment of each type of Ironwood equity award in the 2020 proxy statement.Separation:

Type of Ironwood AwardCyclerion EmployeesIronwood Employees
Vested Stock Options (other than Vested Incentive Stock Options granted under the Ironwood 2010 Incentive Plan)Continued to hold vested Ironwood stock options and received a pro rata portion of vested stock options of Cyclerion, each as equitably adjusted to reflect the distributionContinued to hold vested Ironwood stock options and received a pro rata portion of vested stock options of Cyclerion, each as equitably adjusted to reflect the distribution
Vested Incentive Stock Options granted under the Ironwood 2010 Incentive PlanSubstituted with vested Cyclerion incentive stock options, unless employee elected to convert to non-qualified stock options of both Ironwood and Cyclerion, each as equitably adjusted to reflect the distributionContinued to hold vested Ironwood incentive stock options, unless employee elected to convert to non-qualified stock options of both Ironwood and Cyclerion, each as equitably adjusted to reflect the distribution
Unvested Stock OptionsSubstitute with unvested Cyclerion stock options of comparable valueContinue to hold unvested Ironwood stock options, as equitably adjusted to reflect the distribution
Restricted Stock Units (other than July 2018 Recognition Restricted Stock Units)Substituted with Cyclerion restricted stock units of comparable valueContinued to hold Ironwood restricted stock units, as equitably adjusted to reflect the distribution
July 2018 Recognition Restricted Stock UnitsContinued to hold Ironwood restricted stock units, as equitably adjusted to reflect the distributionContinued to hold Ironwood restricted stock units, as equitably adjusted to reflect the distribution

Shareholder EngagementEach Ironwood equity award that was converted into a Cyclerion equity award is subject to substantially the same terms and Say-on-Pay Vote Considerationvesting conditions as were applicable to the Ironwood equity awards prior to the distribution. Please seeOutstanding Equity Awards at Fiscal Year-End—Ironwood Equity Awards at Fiscal Year-End

Our stockholders haveandOutstanding Equity Awards at Fiscal Year-End—Cyclerion Equity Awards at Fiscal Year-End for detailed information on the opportunity to cast an advisory (non-binding) voteimpact of the Separation on the equity awards held by our 2019 named executive officer compensation, or a "say-on-pay" vote, every year. This allows our stockholders to provide us with regular, timely and direct input on executive compensation philosophy, policies and practices. We believe this enables us to further align our compensation programs with our stockholders' interests and to enhance our ability to consider stockholder feedback as part of our annual compensation review process. We sought stockholder input with last year's say-on-pay vote at our 2018 annual meeting of stockholders, andover 95% of votes cast by our stockholders votedofficers, including equity grants made in support of our named executive officer compensation.

        In addition2019 prior to the formal say-on-pay vote, our senior management frequently meets with stockholders informally through regular investor relations channels to discuss topics important to our business, including Ironwood's corporate strategy, capital allocation, governanceSeparation.

Basis for Our Compensation Policies and Decisions

Our Values and executive compensation. In 2018, senior management met with nearly all of Ironwood's largest 20 stockholders, representing approximately 90% of our outstanding shares. We believe that these discussions are essential to understanding the topics that are most important to our stockholders and play a critical role in developing and executing our strategy.Goals

Basis for Our Compensation Policies and Decisions

    Compensation Philosophy

The objective of our compensation policies is to provide compensation and incentives that align employee actions and motivations with the interests of our stockholders; attract, retain, motivate and reward outstanding talent across Ironwood through well-communicated programs that are aligned with our core valuesvision and business mission; and support a positive company culture.

        Our core values are:

    Ownership:  drive outstanding long-term value.

    Collaboration:  achieve more together.

    Innovation:  make a difference for patients.

    Excellence:  foster greatness in each other.

    Humanity:  act with honesty, integrity and respect.

    Have fun.

        In addition, we have incorporated the concept of "critical success factors" into our performance management and compensation philosophy that we believe provide a useful framework for being a productive and successful member of our team. Among other uses, these success factors enable managers to use a common language of expected behaviors upon which individual performance can be managed and evaluated.


Table of Contents

We are guided by the following principles with respect to our compensation determinations:

    design compensation and incentive programs that align employee actions and motivations with the interests of our stockholders, support our business objectives and hold employees accountable for the achievement of key goals and milestones;

    foster and support our performance-driven culture by setting clear, aggressive, high-valuehigh value goals, rewarding outstanding performers to the extent these goals are achieved, and making sure our best performers know clearly that we value their contributions;

    as with all spending, serve as careful stewards of our stockholders' assets when making compensation decisions;



44    Ironwood


Table of Contents

GRAPHIC
    maximize our employees' sense of ownership so that they have a long-term owner's perspective, can see the impact of their efforts on our success, and can share in the benefits of that success through the opportunity to become stockholders of Ironwood via stock options, RSUs and other equitythrough equity-based awards;

    recognize that compensation is one of a number of tools to stimulate and reward productivity, great drug making,development, and successful commercialization, together with recognizing individual growth potential, providing a great workplace culture, and sharing in our success;

    foster a strong team culture, focused on our principles of great drug makingdevelopment and commercializing those drugs that we discover or in-license and develop,commercialization, which is reinforced through our compensation and incentive programs;

    design compensation and incentive programs that are fair, equitable and competitive; and

    design compensation and incentive programs that are simple and understandable.

Executive Compensation Governance

Highlighted procedures and tools that we use to ensure effective governance of compensation plans and decisions include:

    our compensation and HR committee has the authority to hire independent counsel and other advisors;

    our compensation and HR committee conducts a regular review and assessment of risk as it relates to our compensation policies and practices;

    as part of our insider trading prevention policy, our executive officers and directors are prohibited from engaging in any hedging or monetization transactions of our Class A common stock, including through the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds;

    we have no perquisites other than broad-based benefits, including health and welfare benefits, transportation and fitness stipends, a 401(k) plan and a relocation program that we make available to all of our employees; under our relocation program, participants are required to pay back the full amount of all relocation benefits in connection with their departure from Ironwood in certain circumstances;

    our amended and restated executive severance agreements (i) do not provide for tax gross-ups and (ii) contain double-trigger requirements for equity acceleration and other benefits in the event of a change of control;

    seven of our nine directors are independent, including all members of our compensation and HR committee, and subjectwe have instituted stock ownership guidelines that will require directors to certain limited exceptions, no director may transfer any sharesaccumulate and continuously hold a specified amount of restrictedour Class A common stock while such person is a director of Ironwood;(seeDirector Stock Ownership Guidelines elsewhere in this proxy statement for additional information); and


Table of Contents

    in early 2019, we adopted a clawback policy that provides our board of directors, in the event of a financial restatement due to material noncompliance with financial reporting requirements and where an executive engaged in intentional misconduct that caused or partially caused the need for the restatement, with the discretionary right to recover from our current and former executive officers that portion of the bonus or other incentive compensation that was received by the covered executives or effect the cancellation of unvested and vested equity awards previously granted to the covered executives based on our financial performance results and that would not have been awarded based on the restated results. The board of directors' recovery rights under this policy will be without prejudice to other remedies the company may have for the recovery or adjustment of incentive compensation. Additionally, if we are required to restate our financial results due to our material noncompliance with any financial reporting requirements under the federal securities laws as a result of misconduct, our chief executive officer and chief financial officer may be legally required to reimburse us for any bonus or other incentive-based or equity-based compensation they receive in accordance with the provisions of section 304 of the Sarbanes-Oxley Act of 2002.

    2020  Proxy Statement    45


    Table of Contents

    GRAPHIC

    Compensation Determination Process

Our compensation policies and individual compensation determinations are evaluated annually, and we takeour compensation and HR committee takes into consideration our results of operations, our long-long and short-term goals, individual goals, market data, the competitive market for our executive officers and general economic factors.factors when making individual compensation determinations with respect to our named executive officers. As set forth in our compensation and HR committee's written charter, our compensation and HR committee has the responsibility of reviewing and approving the compensation of our executive officers; annually reviewing and determining our chief executive officer's compensation based on the committee's evaluation of his performance; recommending to the full board of directors the adoption of new compensation plans; administering our existing plans; reviewing and recommending director and committee compensation to the full board; andboard of directors; overseeing succession planning for our senior management.management; and reviewing risks associated with our compensation policies and practices. In addition, our compensation and HR committee is responsible for ensuring that our compensation policies are aligned with our compensation philosophy and guiding principles.

        In 2018,Early each year, our compensation and HR committee made all of the compensation determinations with respect to each of our executive officers. In making its determinations with respect to Dr. Hecht, our compensation and HR committee took into account the feedback from the other members of our board, as well as the feedback from each of our other executive officers, and a number of other members of our management team. In making its determinations with respect to each of our executive officers other than Dr. Hecht, our compensation and HR committee took into account the feedback and recommendations from Dr. Hecht, the executive officer's direct reports and other members of our management team.

        The components of each of our executive officer's initial compensation package was based on numerous factors, including:

    the individual's particular background and circumstances, including prior relevant work experience and compensation paid prior to joining us;

    the individual's role with us and the compensation paid to similar persons in the companies represented in the compensation data that we reviewed;

    the demand for people with the individual's specific expertise and experience at the time of hire;

    performance goals and other expectations for the position;

    comparison to other executive officers within Ironwood having similar levels of expertise and experience; and

Table of Contents

    uniqueness of industry skills.

        Our compensation and HR committee has the authority to select and retain independent advisors and consultants to assist it with carrying out its responsibilities, and we are required to pay any related expenses approved by the committee. For 2018, our compensation and HR committee exercised its authority to engage Pearl Meyer & Partners, LLC, or PM, as a compensation consultant. PM reported directly to our compensation and HR committee and did not provide us with any services other than those requested by our compensation and HR committee and the review of thisCompensation Discussion and Analysis for conformance with best practices. Based on the scope of our compensation and HR committee's engagements with PM, it was determined that PM does not have a conflict of interest in its role as compensation consultant under applicable rules.

        In order to assist our compensation and HR committee in setting 2018 compensation, PM conducted a competitive assessment of 2017 compensation for our executive officers, which reflected that Dr. Hecht's target total cash compensation was well below the median for our peer group companies. His equity-based compensation bridged this gap, placing his target total direct compensation within a competitive range of the peer group median. The assessment also reflected that target total direct compensation for our other executive officers was below the peer group median in aggregate, but still within a competitive range. PM's assessment analyzed:

    base salary;

    target total cash compensation (which is base salary plus the target bonus);

    long-term equity incentives (which are valued based on grant date fair value); and

    target total direct compensation (which is target total cash compensation plus the value of the most recent long-term incentive grant).

        The table below reflects our 2017 target compensation in comparison to the competitive assessment data.

 
 2017 Target Compensation vs.
Peer Group (pay as percent of
median)
 
 
 Chief Executive
Officer
 Average for Other
Executive Officers
 

Base Salary

  12% 89%

Target Total Cash Compensation

  9% 87%

Equity

  129% 92%

Target Total Direct Compensation

  107% 93%

        Our peer group is comprised of publicly traded companies in the pharmaceutical, biotechnology and life sciences industries that represent the most likely competitors for our executive talent. In recognition that our peer group companies tend to be larger than us (including with respect to revenues), PM also presented two alternative market perspectives to our compensation and HR committee:

    1.
    the Radford Global Life Sciences Survey, comprised of companies that represent a broader market perspective and similar employee population to us, but may not share our growth prospects, and

    2.
    a Market Composite, which combines the peer group data and Radford Global Life Sciences Survey data by weighting each source equally.

        Our compensation and HR committee reviewed the 25th, 50th and 75th percentiles for each of these three market perspectives to better understand how competitive pay varied with company size and other factors. PM also prepared an analysis of incentive program market trends, including analyses


Table of Contents

of the short- and long-term elements of compensation as compared to those in our peer group, and a detailed equity usage and dilution analysis of Ironwood as compared with the companies in our peer group.

        Our compensation and HR committee considered the results of PM's competitive assessment in evaluating compensation for 2018, and determined that no significant changes to the design of our executive officers' compensation were warranted. The results of PM's assessment have been, and will continue to be, taken into consideration when making compensation decisions, but will not be used to mandate any specific actions.

        Our peer group, which was compiled by PM with input from our management team, our board, and our compensation and HR committee, is reviewed annually by our compensation and HR committee for composition and appropriateness. We take a rules-based approach in reviewing and setting our peer group and apply a qualitative lens to the result to help focus the group on the companies with which we are competing for talent. We first identify a potential pool of peer companies from a number of sources, including the companies listing Ironwood in their peer groups and the other companies listed in such peer companies' peer groups, as well as companies included in third-party peer group assessments. We then consider certain size filters including revenue, number of employees and research and development expense, as well as certain business model filters including product focus, market capitalization and growth.

        Our peer group is composed of the following 15 companies, which at the time of our review had a median market capitalization of approximately $3.8 billion, a median of approximately 545 employees, and a commercial drug or drug candidate in later stage development:

Acorda Therapeutics, Inc.Incyte Corporation
Agios Pharmaceuticals, Inc.Intercept Pharmaceuticals, Inc.
Alkermes plcMomenta Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.Nektar Therapeutics
AMAG Pharmaceuticals, Inc.Seattle Genetics, Inc.
Assertio Therapeutics, Inc. (formerly Depomed, Inc.)Tesaro, Inc.
Horizon Pharma plcUnited Therapeutics Corporation
Vertex Pharmaceuticals Incorporated

Process for Determining Individual Compensation and Role of Executive Officers

        Each January, our compensation and HR committee, in conjunction with our senior management, finalizes its assessment of our corporate performance for the prior year. Upon completion of oursuch goal assessment, our bonus and equity pools are calibrated for corporate performance and approved by our compensation and HR committee. Our compensation and HR committee assigns a portion of each of these pools to all of our employees other than our executive officers, and delegates the allocation of these portions to our chief executive officer and our chief financial officer. Our compensation and HR committee also approves any salary increase, cash bonus and equity awards for our chief executive officer and, in consultation with our chief executive officer, for each of our other executive officers. In making these compensation-related decisions for 2018,2019 performance, our compensation and HR committee and senior management considered the competitive assessment prepared by PMPearl Meyer, and described in more detail above,below, as well as the other factors described in thisCompensation Discussion and Analysis.

Additionally, our compensation and HR committee may decide, as appropriate, to modify the mix or amount of base salary, bonus, and long-term incentives to best fit an executive officer's specific circumstances or, if required by competitive market conditions, to attract, retain and motivate skilled personnel. For example, our compensation and HR committee may decide to grant additional equity awards to an executive officer if that officer receives a base salary or cash bonus award significantly below that of his or her counterparts in our peer group, or other market data reviewed by our compensation and HR committee, despite successful attainment of our corporate or his or her individual goals. We believe that this discretion and flexibility allows our compensation and HR committee to better achieve our compensation objectives.


Role of the Compensation and Human Resources Committee

In 2019, our compensation and HR committee made all of the compensation determinations with respect to each of our 2019 named executive officers. In making its determinations with respect to Dr. Hecht, our compensation and HR committee took into account the feedback from members of our board of directors, as well as the feedback from each of our other executive officers, and a number of other members of our management team. In developing Mr. Mallon's initial compensation package, our compensation and HR committee endeavored to compensate Mr. Mallon, in part, for the outstanding equity that he forfeited by leaving his previous employer. The compensation and HR committee also took into account the factors listed in the following paragraph in determining Mr. Mallon's initial compensation package. In making its determinations with respect to each of our named executive officers other than Dr. Hecht and Mr. Mallon, our compensation and HR committee took into account the feedback and recommendations from Dr. Hecht in the first quarter of 2019 and from Mr. Mallon for the remainder of 2019, as well as from the named executive officer's direct reports and other members of our management team.

The components of each of our named executive officer's, including Mr. Mallon's, initial compensation package was based on numerous factors, including:

    the individual's particular background and circumstances, including prior relevant work experience and compensation paid prior to joining us;

    the individual's role with us and the compensation paid to similar persons in the companies represented in the compensation data that our compensation and HR committee reviewed;

46    Ironwood


Table of Contents

GRAPHIC
    the demand for people with the individual's specific expertise and experience at the time of hire;

    performance goals and other expectations for the position;

    comparison to other executive officers within Ironwood having similar levels of expertise and experience; and

    uniqueness of industry skills.

Role of the Compensation Consultant: Benchmarking and Peer Group Analysis

Our compensation and HR committee has the authority to select and retain independent advisors and consultants to assist it with carrying out its responsibilities, and we are required to pay any related expenses approved by the committee. In 2019, our compensation and HR committee exercised its authority to engage Pearl Meyer as a compensation consultant from January through July and Aon from August through December. Each of Pearl Meyer and Aon reported directly to our compensation and HR committee during the period of its engagement. Pearl Meyer did not provide us with any services in 2019 other than those requested by our compensation and HR committee. Prior to its engagement as compensation consultant beginning in August 2019, Aon provided us with certain services in 2019 related to the equity impact of the Separation. In addition, following its engagement as compensation consultant, we purchased certain benefits surveys and employee compensation benchmarking data from Aon. Aon also reviewed thisCompensation Discussion and Analysis for conformance with best practices. Based on the scope of our compensation and HR committee's engagements with Pearl Meyer and Aon, it was determined that neither Pearl Meyer nor Aon had a conflict of interest in their respective roles as compensation consultant under applicable rules for the period of their engagements.

In order to assist our compensation and HR committee in setting 2019 compensation, Pearl Meyer conducted a competitive assessment of 2018 target compensation for our named executive officers, with a focus on the following components of our named executive officer compensation:

    base salary;

    target total cash compensation (which is base salary plus the target bonus);

    long-term equity incentives (which are valued based on grant date fair value); and

    target total direct compensation (which is target total cash compensation plus the value of the most recent long-term incentive grant).

In conducting this assessment, Pearl Meyer analyzed the components of our named executive officer compensation listed above, in each case measured against our peer group at the time, recognizing that such peer group companies tended to be larger than us (including with respect to revenues). The peer group that was in place for this assessment was composed of the following 15 companies, which at the time of our review had a median market capitalization of approximately $3.0 billion, a median of approximately 540 employees, and a commercial drug or drug candidate in later stage development:

Acorda Therapeutics, Inc.Intercept Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.Ionis Pharmaceuticals
Alkermes plcNektar Therapeutics
Alnylam Pharmaceuticals, Inc.Pacira Pharmaceuticals
AMAG Pharmaceuticals, Inc.Serepta Therapeutics
Corcept TherapeuticsTesaro, Inc.
Horizon Pharma plcUnited Therapeutics Corporation
ImmunoGen

2020  Proxy Statement    47


Table of Contents

GRAPHIC

In assisting our compensation and HR committee in setting 2019 compensation, Pearl Meyer also presented proxy data from the Radford Global Life Sciences Survey, which was comprised of companies that represent a broader market perspective and similar employee population to us, and a Market Composite, which combined the peer group data and Radford Global Life Sciences Survey data by weighting each source equally. Although this competitive assessment was not used to mandate any specific compensation decisions, our compensation and HR committee considered the results of this assessment when making base salary, cash bonus and long-term equity incentive award determinations with respect to our named executive officers in early 2019.

Our peer group is reviewed at least annually by our compensation and HR committee. In setting our peer group, our compensation and HR committee applies a qualitative lens to help focus the group on the companies with which we are competing for talent. Our compensation and HR committee first identifies a potential pool of peer companies from a number of sources, including the companies listing Ironwood in their peer groups and the other companies listed in such peer companies' peer groups, as well as companies included in third-party peer group assessments. Our compensation and HR committee then considers certain size filters including market capitalization, revenue, and number of employees, as well as certain business model filters including commercial focus, and growth.

In July 2019, our compensation and HR committee approved a new peer group, which peer group Aon used as a reference point in advising our compensation and HR committee regarding compensation decisions made beginning in the fourth quarter of 2019. This updated peer group is composed of the following 17 companies, which at the time of our review had a median market capitalization of approximately $2.7 billion, median revenue of approximately $249 million, a median of 482 employees, and a commercial drug or drug candidate in later stage development:

ACADIA Pharmaceuticals, Inc.Halozyme Therapeutics, Inc.
Agios Pharmaceuticals, Inc.Horizon Therapeutics plc
Akcea Therapeutics, Inc.Intercept Pharmaceuticals, Inc.
Alkermes plcPacira BioSciences, Inc.
Amicus Therapeutics, Inc.PTC Therapeutics, Inc.
bluebird bio, Inc.Radius Health, Inc.
Blueprint Medicines CorporationSupernus Pharmaceuticals, Inc.
Coherus BioSciences, Inc.United Therapeutics Corporation
Corcept Therapeutics Incorporated

Tax and Accounting Considerations

While our compensation and HR committee generally considers the tax and accounting implications of its executive compensation decisions, neither element was a material consideration in the compensation awarded to our named executive officers in 2018.2019.

Executive Compensation Practices and Risk Assessment

Our compensation and HR committee has reviewed our 2019 compensation policies as generally applicable to our employees and believes that our policies dodid not encourage excessive and unnecessary risk-taking, and that the level of risk that they dodid encourage iswas not reasonably likely to have a material adverse effect on Ironwood. Our compensation and HR committee considered the following, among other factors, in reviewing our compensation policies:policies related to 2019 compensation:

    our use of different types of compensation vehicles providesprovided a balance of long-long and short-term incentives with fixed and variable components;



48    Ironwood


Table of Contents

GRAPHIC
    we grantgranted equity-based awards with time-based vesting, and milestone-based vesting, both of which encourageencouraged participants to look to long-term appreciation in equity values;

    our annual bonus determinations for each employee arewere dependent on achievement of companya diverse set of company-level goals, which we believe promotepromoted long-term value; and

    our system of internal control over financial reporting and code of business conduct and ethics, among other things, reducereduced the likelihood of manipulation of our financial performance to enhance payments under any of our incentive plans.

2020  Proxy Statement    49


Table of Contents

GRAPHIC

Compensation Tables

Summary Compensation Table

The following table sets forth information regarding the compensation paid or accrued to, or earned by, each of our named executive officers during the years ended December 31, 2019, 2018 2017 and 2016.2017.

Name and Principal Position
 Year Salary
($)
 Bonus
($)
 Stock
Awards
($)(1)
 Option
Awards
($)(1)
 Non-Equity
Incentive Plan
Compensation
($)(2)
 All Other
Compensation
($)(3)
 Total
($)
 
Peter M. Hecht, Ph.D.   2018  100,000  1,192,500(4)   3,842,268    25,348  5,160,116 

Former Chief Executive

  2017  100,000      5,887,416    8,040  5,995,456 

Officer

  2016  100,000      4,135,830    8,065  4,243,895 

Gina Consylman

 

 

2018

 

 

415,000

 

 


 

 

782,385

(5)

 

501,764

(6)

 

207,500

 

 

8,040

 

 

1,914,689

 

Chief Financial Officer and

  2017  334,263    440,213    185,000  8,040  967,516 

Senior Vice President

  2016               

Mark G. Currie, Ph.D. 

 

 

2018

 

 

485,000

 

 


 

 

231,360

 

 

1,424,289

 

 

242,500

 

 

62,271

 

 

2,445,420

 

Former Senior Vice President,

  2017  470,000      1,936,650  210,000  8,040  2,624,690 

Chief Scientific Officer and

  2016  454,000      1,092,045  301,000  8,040  1,855,085 

President of R&D

                         

Thomas A. McCourt

 

 

2018

 

 

465,000

 

 


 

 

549,641

 

 

869,479

 

 

232,500

 

 

34,002

 

 

2,150,622

 

President

  2017  450,000    440,212  1,220,089  191,000  8,040  2,309,341 

  2016  435,000      813,225  288,000  8,040  1,544,265 

William Huyett*

 

 

2018

 

 

465,000

 

 


 

 

1,090,298

(7)

 

2,346,469

(8)

 

232,500

 

 

8,040

 

 

4,142,307

 

Former Chief Operating

  2017               

Officer

  2016               

Name and Principal Position*

  Year  Salary
($)
  Bonus
($)
  Stock
Awards
($)(1)
  Option
Awards
($)(1)(2)
  Non-Equity
Incentive Plan
Compensation
($)(3)
  All Other
Compensation
($)(4)
  Total
($)
 

Mark Mallon

 2019 750,000 880,000(5)3,692,810(6)3,804,331(7)797,063 144,596 10,068,800 

Chief Executive Officer

 2018        

 2017        

Gina Consylman

  2019  480,000  250,000(8) 1,467,731(9) 888,546  358,800  8,502  3,453,579 

Chief Financial Officer and

  2018  415,000    782,385  501,764  207,500  8,040  1,914,688 

Senior Vice President

  2017  334,263    440,213    185,000  8,040  967,516 

Halley E. Gilbert

 2019 480,000 250,000(8)1,467,731(9)888,546 340,080 8,502 3,434,859 

Former Chief Administrative Officer and

 2018 460,000  740,610 463,722 230,000 33,425 1,927,757 

Senior Vice President, Corporate Development

 2017 440,000  670,800 619,728 195,000 8,040 1,933,568 

Thomas A. McCourt

  2019  511,250(10)   1,760,143(11) 2,370,159  454,272  8,502  5,104,326 

President

  2018  465,000    549,641  869,479  232,500  34,002  2,150,622 

  2017  450,000    440,212  1,220,089  191,000  8,040  2,309,341 

Peter M. Hecht, Ph.D.

 2019 25,000(12)  6,127,900  6,589 6,159,489 

Former Chief Executive Officer

 2018 100,000 1,192,500  3,842,268  25,348 5,160,116 

 2017 100,000   5,887,416  8,040 5,995,456 

Mark G. Currie, Ph.D.

  2019  125,000(13)   286,306(14) 3,676,740    44,088  4,132,134 

Former Senior Vice President,

  2018  485,000    231,360  1,424,289  242,500  62,271  2,445,420 

Chief Scientific Officer and President of R&D

  2017  470,000      1,936,650  210,000  8,040  2,624,690 

*

Mr. HuyettMallon joined the company in December2019. Ms. Gilbert was a named executive officer in 2017 andbut was not a named executive officer in 2017 or 2016.

2018. Ms. Gilbert resigned from the company effective in February 2020. Drs. Hecht and Currie transitioned to Cyclerion in April 2019 in connection with the Separation. Also in connection with the Separation in April 2019, Dr. Currie joined our board of directors.

(1)

For 2018,2019, reflects the fair value of time-based RSU, RSAs, and stock option awards on the date of grant calculated in accordance with Financial Accounting Standards Board issuedAccounting Standards Codification Topic 718, Compensation—Stock Compensation, or ASC 718. For a discussion of the assumptions used in the valuation of awards made in 2018,2019, see Note 14

Table of Contents

    15 to our consolidated financial statements for the year ended December 31, 20182019 included in our Annual Report on Form 10-K that we filed with the SEC on February 25, 2019, or our 2018 Form 10-K, and that accompanies this proxy statement.13, 2020. All values reported exclude the effects of potential forfeitures. Unless otherwise noted, reflects the fair value of RSUs awarded in January 2019 in connection with annual equity awards.

(2)

  Unless otherwise noted, reflects the fair value of stock options awarded in January 2019 in connection with annual equity awards.

(3)  Consists of payments made under our annual cash bonus program in the following year2020 for performance in the identified year,2019, as described aboveelsewhere in this proxy statement under the captionElements of Executive Compensation and Determination of Amounts—Cash Bonus.

(3)

(4)  For each executive officer, $6,000 of such amount consists of matching contributions made under our 401(k) plan, as well as an amount attributable to a transportation stipend and a fitness stipend. Additionally, for Drs. Hecht and Currie andFor Mr. McCourt,Mallon, such amount includes $99,036 that he received for relocation expenses pursuant to his new hire arrangement and intended to facilitate his transition to the Boston, Massachusetts area, as well as $37,137 that he received during the year for reimbursement of taxes owed on this relocation allowance. For Dr. Currie, such amount includes $37,500 for his service on our board of directors from April 1, 2019 through December 31, 2019.

(5)  Reflects the sign-on bonus paid to Mr. Mallon in 2018 includes $17,308, $54,231, and $25,962, respectively, representing the payout of previously earned but unused sabbatical leaveJanuary 2019 in connection with the termination of that broad-based program.

(4)
Consists of a one-time discretionary bonus approved by our compensation and HR committee in fiscal year 2019 for fiscal year 2018 performance based primarily on the achievement of 100% of our 2018 corporate goals, including certain stretch goals. While our compensation and HR committee has historically granted Dr. Hecht stock options in lieu of an increase to base salary and the receipt of a cash bonus, and to keep his overall compensation competitive with thatcommencement of his peers, Dr. Hecht accepted a portion of his 2018 compensationemployment in the form of cash, rather than stock options, due to limitations on annual equity grants to individuals under our equity incentive plans.

(5)
January 2019.

(6)  Includes the fair value of 7,500(a) 93,036 RSUs awarded to Ms. ConsylmanMr. Mallon in January 2018,2019 in connection with herthe commencement of his employment in January 2019 and (b) 206,873 RSUs awarded to Mr. Mallon in April 2019 in connection with his promotion to chief financialexecutive officer in November 2017.

(6)
upon completion of the Separation.

(7)  Includes the fair value of (a) 171,526 stock options awarded to purchase 15,000 sharesMr. Mallon in January 2019 in connection with the commencement of his employment in January 2019 and (b) 423,049 stock options awarded to Mr. Mallon in April 2019 in connection with his promotion to chief executive officer upon completion of the Separation.

50    Ironwood


Table of Contents

GRAPHIC

(8)  Reflects a special bonus awarded to Ms. Consylman and Ms. Gilbert in January 2018,May 2019 in recognition of their significant contributions to and performance in connection with the Separation, and with respect to Ms. Gilbert, her promotion to chief financial officer in November 2017.

(7)
expanded role overseeing our corporate development function.

(9)  Includes the fair value of 56,250(a) 72,500 RSUs awarded to Mr. Huyetteach of Ms. Consylman and Ms. Gilbert in January 2018,2019 in connection with his appointment as chief operating officerannual equity awards and (b) 41,150 RSUs awarded to each of Ms. Consylman and Ms. Gilbert in December 2017.

(8)
2019 as a special retention award.

(10)  Reflects Mr. McCourt's pro-rated salary of $485,000 for the period January 1, 2019 through March 31, 2019 during which time he served as our senior vice president, marketing and sales, and chief commercial officer, and his pro-rated salary of $520,000 for the period April 1, 2019 through December 31, 2019 during which time he served as our president.

(11)  Includes the fair value of stock options to purchase 337,500 shares(a) 22,852 RSUs awarded to Mr. HuyettMcCourt in January 2018,May 2019 in connection with his appointment as chief operating officerpromotion to president and (b) 115,220 RSUs awarded to Mr. McCourt in December 2017.

2019 as a special retention award.

(12)  Reflects the pro-rated portion of Dr. Hecht's $100,000 annual salary, which was paid for the period January 1, 2019 through March 31, 2019, during which he served as our chief executive officer.

(13)  Reflects the pro-rated portion of Dr. Currie's $500,000 annual salary, which was paid for the period January 1, 2019 through March 31, 2019, during which he served as our senior vice president, chief scientific officer and president of R&D.

(14)  Includes the fair value of (a) 2,995 RSAs awarded to Dr. Currie in April 2019 in connection with his service on our board of directors between April 1, 2019 and the 2019 annual meeting of stockholders and (b) 22,706 RSAs awarded to Dr. Currie in May 2019 in connection with his service on our board of directors from the date of our 2019 annual meeting of stockholders to the date of our 2020 annual meeting of stockholders.

Grants of Plan-Based Awards

The following table sets forth information regarding non-equity and equity awards granted to each of our named executive officers during the year ended December 31, 2018.2019. All non-equity incentive plan awards were made pursuant to our cash bonus program described in more detail aboveelsewhere in this proxy statement under the captionElements of Executive Compensation and Determination of Amounts—Cash Bonus.

We granted RSUs and stock option awards to our named executive officers, other than Mr. Mallon, in 2018January 2019 in recognition of performance in 2017; in2018. In addition, each named executive officer, other than Dr. Hecht, waswe granted 12,000 RSUs in July 2018 in recognition of service to IronwoodMr. Mallon RSU and stock option awards in connection with work criticalthe commencement of his employment with the company in January 2019 and in connection with his becoming chief executive officer upon the completion of the Separation in April 2019. We also granted Mr. McCourt a stock option award in connection with his promotion to president upon the completion of the Separation in April 2019. In addition, Mses. Consylman and Gilbert and Mr. McCourt were granted special RSU retention awards in December 2019. We granted Dr. Currie RSAs in connection with his joining our board of directors upon completion of the Separation in April 2019 and for his service on our board of directors from the date of our 2019 annual meeting of stockholders to the Separation. date of our 2020 annual meeting of stockholders.

All RSUs granted in 2018 represented2019 represent the right to receive shares of our Class A common stock, all RSAs granted in 2019 are awards of our Class A common stock that are subject to restrictions, and all stock options granted in 2018 consisted2019 consist of options to purchase shares of our Class A common stock with an exercise price equal to the fair market value of our Class A common stock on the date of grant. All such equityEquity awards granted in 2019 before our 2019 annual meeting of stockholders were granted under our 2010 Plan and equity awards granted in 2019 after our 2019 annual meeting of stockholders were granted under our 2019 Plan. The vesting schedule of each RSA, RSU and eachstock option included in the following table is described in the footnotes to theIronwood Outstanding Equity Awards at Fiscal Year-End table.


Information presented in this table relating to grants made prior to the date of the Separation has not been adjusted for the impact of the Separation. For information on the impact of the Separation on grants made prior to the date of the Separation, please refer to the footnotes that follow this table. For additional information on adjustments made to

2020  Proxy Statement    51


Table of Contents

GRAPHIC

The following table reflectsoutstanding equity awards in connection with the conversionSeparation, please seeCompensation Discussion and Analysis—Equity Impact of our Class B common stock to Class A common stock, which was effective December 31, 2018.the Separation, elsewhere in this proxy statement.

 
  
  
 Estimated
Future
Payouts
Under
Non-Equity
Incentive
Plan
Awards(1)
  
  
  
  
 
 
  
 Compensation
and HR
Committee
Approval
Date (if
different
than
Grant Date)
  
 All Other
Option
Awards:
Number of
Securities
Underlying
Options
(#)
  
  
 
 
  
 All Other
Stock
Awards:
Number of
Shares of
Stock or
Units (#)
 Exercise
or Base
Price of
Option
Awards
($/Sh)
 Grant Date
Fair Value
of Stock
and Option
Awards
($)(2)
 
 
 Grant
Date
 
Name
 Target ($) 

Peter M. Hecht, Ph.D. 

  2/21/2018  1/25/2018      580,000  14.55  3,842,268 

      50,000         

Gina Consylman

  
1/2/2018

(3)
 
11/22/2017
  
  
  
15,000
  
15.27
  
104,288
 

  2/21/2018  2/12/2018      60,000  14.55  397,476 

  1/2/2018(3) 11/22/2017    7,500      114,525 

  2/21/2018  2/12/2018    30,000      436,500 

  7/31/2018(4) 7/27/2018    12,000      231,360 

      207,500         

Mark G. Currie, Ph.D. 

  
2/21/2018
  
2/12/2018
  
  
  
215,000
  
14.55
  
1,424,289
 

  7/31/2018(4) 7/27/2018     12,000      231,360 

      242,500         

Thomas A. McCourt

  
2/21/2018
  
2/12/2018
  
  
  
131,250
  
14.55
  
869,479
 

  2/21/2018  2/12/2018    21,875      318,281 

  7/31/2018(4) 7/27/2018    12,000      231,360 

      232,500         

William Huyett

  
1/2/2018

(5)
 
11/22/2017
  
  
  
337,500
  
15.27
  
2,346,469
 

  1/2/2018(5) 11/22/2017    56,250      858,938 

  7/31/2018(4) 7/27/2018    12,000      231,360 

      232,500         

Name

  Grant Date  Compensation
and HR
Committee
Approval Date
(if different than
Grant Date)
  Estimated
Future Payouts
Under Non-
Equity Incentive
Plan Awards(1)
Target ($)
  All Other
Stock Awards:
Number of
Shares of
Stock or
Units (#)*
  All Other
Option Awards:
Number of
Securities
Underlying
Options (#)
  Exercise or
Base Price
of Option
Awards
($/Sh)
  Grant Date Fair
Value of Stock
and Option
Awards ($)(2)
 

Mark Mallon

 1/9/2019(3)1/3/2019  93,036(4)  1,146,204 

 1/9/2019(3)1/3/2019   171,526(5)12.32 999,516 

 4/1/2019(6)3/29/2019  206,873   2,546,607 

 4/1/2019(6)3/29/2019   423,049 14.02 2,804,815 

   562,500     

Gina Consylman

  1/29/2019  1/22/2019    72,500(7)     935,250 

  1/29/2019  1/22/2019      145,000(8) 12.90  888,546 

  12/16/2019(9) 12/16/2019    41,150      532,481 

      240,000         

Halley E. Gilbert

 1/29/2019 1/22/2019  72,500(7)  935,250 

 1/29/2019 1/22/2019   145,000(8)12.90 888,546 

 12/16/2019(9)12/16/2019  41,150   532,481 

   240,000     

Thomas A. McCourt

  1/29/2019  1/22/2019      345,000(10) 12.90  2,114,126 

  5/1/2019(11)     22,852      269,197 

  5/1/2019(11)       45,704  11.78  256,034 

  12/16/2019(9) 12/16/2019    115,220      1,490,947 

      312,000         

Peter M. Hecht, Ph.D

 1/29/2019 1/22/2019   1,000,000(12)12.90 6,127,900 

   50,000     

Mark G. Currie, Ph.D

  1/29/2019  1/22/2019      600,000(13) 12.90  3,676,740 

  4/1/2019      2,995(14)     41,990 

  5/29/2019      22,706(14)     244,317 

      250,000         

* Unless otherwise noted, all stock awards listed in the "All Other Stock Awards: Number of Shares of Stock or Units (#)" column are RSUs.

(1)

Consists of the target cash bonus payment for 20182019 performance under our cash bonus program. As described in more detail aboveelsewhere in this proxy statement under the captionElements of Executive Compensation and Determination of Amounts—Cash Bonus, in 2018 each of our named executive officers, other than Dr. Hecht,2019, Mr. Mallon had an individual bonus target of 50%75% of his or her base salary, 70% of which was tied solely to the achievement of our corporate goals for 20182019 (which was not determined as of December 31, 2018)2019) and 30% of which was tied to the achievement of corporate and individual performance goals (the range of which was not determined as of December 31, 2018)2019). In determining Mr. Mallon's cash bonus for 2019, the compensation and HR committee equated Mr. Mallon's individual performance with that of the company overall. Mses. Consylman and Gilbert had an individual bonus target of 50% of their respective base salaries, 70% of which was tied solely to the achievement of our corporate goals for 2019 (which was not determined as of December 31, 2019) and 30% of which was tied to the achievement of corporate and individual performance goals (the range of which was not determined as of December 31, 2019). Mr. McCourt had an individual bonus target of 60% of his base salary (which percentage was increased from 50% in connection with his promotion to president in May 2019), 70% of which was tied solely to the achievement of our corporate goals for 2019 (which was not determined as of December 31, 2019) and 30% of which was tied to the achievement of corporate and individual performance goals (the range of which was not determined as of December 31, 2019). Actual bonus payments for 2019 performance are set forth in theSummary Compensation Table elsewhere in this proxy statement.

Dr. Hecht's bonus, with an individual bonus target of 50% of his base salary, was to be determined primarily based on the achievement of our corporate goals. ActualDr. Currie had an individual bonus target of 50% of his base salary, 70% of which was tied solely to the achievement of our corporate goals for 2019 (which was not determined as of December 31, 2019) and 30% of which was tied to the achievement of corporate and individual performance goals (the range of which was not determined as of December 31, 2019). Neither Dr. Hecht nor Dr. Currie received a bonus payment for 2019 performance because they transitioned to Cyclerion in connection with the Separation and, as a result, were not employed by Ironwood on the date in 2020 on which bonus payments for 20182019 performance are set forth in the Summary Compensation Table above.

were made.

(2)

Reflects the fair value of time-based RSU, RSA and stock option awards on the date of grant calculated in accordance with ASC 718.

718, excluding the effects of potential forfeitures. For a discussion of the assumptions used in the valuation of the time-based RSU, awardsRSA and stock option awards granted to our named executive officers in 2018,2019, see footnote 1 to theSummary Compensation Table above.elsewhere in this proxy statement.

(3)
Awarded to Ms. Consylman in connection with her promotion to chief financial officer in November 2017.

(4)
Awarded in recognition

52    Ironwood


Table of service to the company in connection with work critical to the Separation.

(5)
Contents

GRAPHIC

(3)  Awarded to Mr. HuyettMallon in connection with his appointmentjoining the company in January 2019.

(4)  As of the date of the Separation, 93,036 RSUs were unvested. Unvested RSUs held as of the date of the Separation were converted into 104,536 unvested Ironwood RSUs.

(5)  As of the date of the Separation, no stock options were vested and 171,526 stock options were unvested. Unvested stock options held as of the date of the Separation were converted into 192,729 unvested Ironwood stock options with an exercise price of $10.97.

(6)  Awarded to Mr. Mallon in connection with his becoming chief operatingexecutive officer in connection with the Separation in April 2019.

(7)  As of the date of the Separation, 72,500 RSUs were unvested. Unvested RSUs held as of the date of the Separation were converted into 81,462 unvested Ironwood RSUs.

(8)  As of the date of the Separation, 9,062 stock options were vested and 135,938 stock options were unvested. Vested stock options held as of the date of the Separation were converted into 9,062 vested Ironwood stock options with an exercise price of $11.49 and 906 vested Cyclerion stock options with an exercise price of $14.21. Unvested stock options held as of the date of the Separation were converted into 152,742 unvested Ironwood stock options with an exercise price of $11.49.

(9)  Awarded as a special RSU retention award in December 2017.

2019.

(10)  As of the date of the Separation, 21,562 stock options were vested and 323,438 stock options were unvested. Vested stock options held as of the date of the Separation were converted into 21,562 vested Ironwood stock options with an exercise price of $11.49 and 2,156 vested Cyclerion stock options with an exercise price of $14.21. Unvested stock options held as of the date of the Separation were converted into 363,420 unvested Ironwood stock options with an exercise price of $11.49.

(11)  Awarded to Mr. McCourt in connection with his promotion to president in April 2019.

(12)  As of the date of the Separation, 62,500 stock options were vested and 937,500 stock options were unvested. Vested stock options held as of the date of the Separation were converted into 62,500 vested Ironwood stock options with an exercise price of $11.49 and 6,250 vested Cyclerion stock options with an exercise price of $14.21. Unvested stock options held as of the date of the Separation were converted into 851,580 unvested Cyclerion stock options with an exercise price of $14.21.

(13)  As of the date of the Separation, 37,500 stock options were vested and 562,500 stock options were unvested. Vested stock options held as of the date of the Separation were converted into 37,500 Ironwood stock options with an exercise price of $11.49 and 3,750 Cyclerion stock options with an exercise price of $14.21. Unvested stock options held as of the date of the Separation were converted into 510,948 unvested Cyclerion stock options with an exercise price of $14.21.

(14)  Reflects RSAs received as compensation for service on our board of directors.


2020  Proxy Statement    53


Table of Contents

GRAPHIC

Outstanding Equity Awards at Fiscal Year-End

As described elsewhere in this proxy statement under the captionCompensation Discussion and Analysis—Equity Impact of the Separation, portions of certain Ironwood equity awards were converted into Cyclerion equity awards in connection with the Separation. The following table setstables set forth information regarding outstanding Ironwood and Cyclerion equity awards held by each of our named executive officers on December 31, 2018,2019, the last day of our last fiscal year. The following table reflectsInformation presented has been adjusted, as necessary, to reflect the conversionimpact of our Class B common stock to Class A common stock, which was effective December 31, 2018.the Separation.

Ironwood Equity Awards at Fiscal Year-End

 
 Option Awards Stock Awards 
Name
 Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable
 Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable
 Equity Incentive
Plan Awards:
Number of
Securities
Underlying
Unexercised
Unearned
Options (#)
 Option
Exercise
Price ($)
 Option
Expiration
Date
 Number of
Shares or
Units of
Stock That
Have Not
Vested (#)(1)
 Market
Value of
Shares or
Units of
Stock That
Have Not
Vested
($)(2)
 

Peter M. Hecht, Ph.D. 

  110,000      4.89  2/11/2019(3)    

  20,000    20,000  5.48  7/28/2019(4)    

  125,000      11.25  2/2/2020(3)    

  175,000      11.11  2/1/2021(3)    

  300,000      14.72  2/1/2022(3)    

  375,000      13.08  2/1/2023(3)    

  325,000      14.11  3/3/2024(5)    

  553,229  11,771    15.62  3/16/2025(5)    

  648,958  241,042    10.24  3/1/2026(5)    

  364,166  395,834    16.77  2/27/2027(5)    

  132,916  447,084    14.55  2/21/2028(5)    

Gina Consylman

  
40,000
  
  
  
15.48
  
7/1/2024

(6)
 
  
 

  8,322  178    15.62  3/16/2025(5)    

  4,062  938    11.45  9/16/2025(5)    

  21,875  8,125    10.24  3/1/2026(5)    

  4,062  10,938    15.27  1/2/2028(5)    

  13,750  46,250    14.55  2/21/2028(5)    

            81,749  846,920 

Mark G. Currie, Ph.D. 

  
  
  
20,000
  
5.48
  
7/28/2019

(4)
 
  
 

  8,888      11.25  2/2/2020(3)    

  41,041       11.11  2/1/2021(3)      

  110,000      14.72  2/1/2022(3)    

  200,000      13.08  2/1/2023(3)    

  85,000      14.11  3/3/2024(5)    

  25,000    25,000  15.62  3/16/2025(7)      

  128,515  2,735    15.62  3/16/2025(5)    

  88,124  63,646    10.24  3/1/2026(5)    

  119,791  130,209    16.77  2/27/2027(5)    

  49,270  165,730    14.55  2/21/2028(5)    

            17,468  180,686 

Thomas A. McCourt

  
90,000
  
  
40,000
  
5.48
  
9/7/2019

(8)
 
  
 

  130,000      5.48  9/7/2019(6)    

  20,000      11.25  2/2/2020(3)    

  95,000      11.11  2/1/2021(3)    

  95,000      14.72  2/1/2022(3)      

  110,000      13.08  2/1/2023(3)    

  80,000      14.11  3/3/2024(5)    

  95,468  2,032    15.62  3/16/2025(5)    

  127,604  47,396    10.24  3/1/2026(5)    

  75,468  82,032    16.77  2/27/2027(5)    

  30,077  101,173    14.55  2/21/2028(5)      

            57,624  596,985 

William Huyett

  
84,375
  
253,125
  
  
15.27
  
1/2/2028

(6)
 
  
 

            54,187  561,377 


 Option Awards  Stock Awards  

Name

  Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable
  Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable
  Option
Exercise
Price ($)
  Option
Expiration
Date
  Number of
Shares of
Units of
Stock That
Have Not
Vested (#)(1)
  Market Value of
Shares or Units of
Stock That Have
Not Vested ($)(2)
 

Mark Mallon

  192,729 10.97 1/9/2029(3)  

  423,049 14.02 4/1/2029(3)  

     311,409 4,144,854 

Gina Consylman

  43,563    13.78  7/1/2024(3)      

  8,500    13.91  3/16/2025(4)      

  5,077    10.20  9/16/2025(4)      

  29,993  702  9.12  3/1/2026(4)      

  8,161  8,075  13.60  1/2/2028(4)      

  29,986  35,113  12.95  2/21/2028(4)      

  36,216  125,588  11.49  1/29/2029(4)      

          174,014(6) 2,316,126 

Halley E. Gilbert

 60,000  10.02 2/2/2020(5)  

 60,000  9.89 2/1/2021(5)  

 30,000  10.53 12/12/2021(5)  

 45,000  13.11 2/1/2022(5)  

 30,000  11.65 2/1/2023(5)  

 25,000  10.25 12/2/2023(5)  

 65,000  12.56 3/3/2024(4)  

 57,500  13.91 3/16/2025(4)  

 64,984 1,522 9.12 3/1/2026(4)  

 59,982 24,344 14.93 2/27/2027(4)  

 34,986 40,963 12.95 2/21/2028(4)  

 36,216 125,588 11.49 1/29/2029(4)  

     183,707(7)2,445,140 

Thomas A. McCourt

  20,000    10.02  2/2/2020(5)      

  99,988    9.89  2/1/2021(5)      

  95,971    13.11  2/1/2022(5)      

  110,962    11.65  2/1/2023(5)      

  80,504    12.56  3/3/2024(4)      

  97,500    13.91  3/16/2025(4)      

  174,959  4,097  9.12  3/1/2026(4)      

  118,089  47,929  14.93  2/27/2027(4)      

  65,595  76,809  12.95  2/21/2028(4)      

  86,170  298,812  11.49  1/29/2029(4)      

  6,665  39,039  11.78  5/1/2029(4)      

          171,252(8) 2,279,364 

54    Ironwood


Table of Contents

GRAPHIC

 Option Awards  Stock Awards  

Name

  Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable
  Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable
  Option
Exercise
Price ($)
  Option
Expiration
Date
  Number of
Shares of
Units of
Stock That
Have Not
Vested (#)(1)
  Market Value of
Shares or Units of
Stock That Have
Not Vested ($)(2)
 

Peter M. Hecht, Ph.D.

 125,000  10.02 2/2/2020(5)  

 130,980  9.89 2/1/2021(5)  

 292,467  13.11 2/1/2022(5)  

 367,355  11.65 2/1/2023(5)  

 318,229  12.56 3/3/2024(4)  

 565,000  13.91 3/16/2025(4)  

 723,125  9.12 3/1/2026(4)  

 427,500  14.93 2/27/2027(4)  

 181,250  12.95 2/21/2028(4)  

 62,500  11.49 1/29/2029(5)  

       

Mark G. Currie, Ph.D.

  8,888    10.02  2/2/2020(5)      

  101,971    13.11  2/1/2022(5)      

  190,383    11.65  2/1/2023(5)      

  83,229    12.56  3/3/2024(4)      

  131,250    13.91  3/16/2025(4)      

  25,000    13.91  3/16/2025(9)      

  107,707    9.12  3/1/2026(4)      

  140,625    14.93  2/27/2027(4)      

  67,187    12.95  2/21/2028(4)      

  37,500    11.49  1/29/2029(4)      

          22,706(10) 302,217 

(1)

The  Unless otherwise indicated, awards in this column reflect RSUs that vest over four years as to 25% of the award on each approximate anniversary of the grant thereof, with the exception of the 12,000 RSUs held by each named executive officer (other than Dr. Hecht), which vest in full on May 9, 2019.

thereof.

(2)

Market value is calculated by multiplying the number of RSUs or RSAs that have not vested by the closing price of our Class A common stock on the Nasdaq Global Select Market on December 31, 2018,2019, which was $10.36.

$13.31.

(3)

  The options vest as to 25% of the shares on the first anniversary of the vesting commencement date and 1/48th of the shares each month thereafter for the next 36 months, generally subject to the executive's continued employment with the company on the applicable vesting date.

(4)  The options vest as to 1/48th of the shares on each monthly anniversary of the vesting commencement date, generally subject to the executive's continued employment with the company on the applicable vesting date, until fully vested.

(5)  The options vest as to 1.25% on each monthly anniversary of the vesting commencement date for the first 36 months, and as to 4.5833% of the award on each monthly anniversary thereafter until fully vested.

(4)
The options vest asvested, generally subject to (a) 50% of the shares uponexecutive's continued employment with the achievement of $1 billion in annual (calendar year) net global pharmaceutical product sales (including partnered or licensed product revenue) and (b) 50% of the shares upon acceptance by the FDA of a second NDA for a product from an internal or external development program (excluding supplemental NDAs for linaclotide, but including NDAs for linaclotide combination products). External development programs shall be pre-qualified for milestone vesting eligibility by our compensation and HR committee as of the time of program initiation at Ironwood.

Table of Contents

(5)
The options vest as to 1/48th of the shares on each monthly anniversary of the vesting commencement date until fully vested.

(6)
The options vest as to 25% of the sharescompany on the first anniversary of theapplicable vesting commencement date and 1/48th of the shares each month thereafter for the next 36 months.

(7)
The optionsdate.

(6)  Includes 41,150 RSUs held by Ms. Consylman, which vest in two equal installments of 25,000 options each.full on November 18, 2021, subject to continued employment with the company on the applicable vesting date.

(7)  Includes 41,150 RSUs that were awarded to Ms. Gilbert, which were to vest in full on November 18, 2021, but were terminated in their entirety in connection with Ms. Gilbert's resignation from the company effective February 2020.

(8)  Includes 115,220 RSUs held by Mr. McCourt, which vest in full on November 18, 2021, subject to continued employment with the company on the applicable vesting date.

(9)  The option vested as to 25,000 shares upon the first-dosing in the first clinical study of the next phase following achievement of proof of concept for the first internally derived or externally accessed product (other than linaclotide) qualified by our compensation and HR committee as targeting a new indication, category or market.

(10)  The option vestsRSAs vest as to the remaining 25,000 shares upon the first-dosing in the first clinical study of the next phase following achievement of proof of concept for the second internally derived or externally accessed product (other than linaclotide) qualified by our compensation and HR committee as targeting a new indication, category or market.

(8)
The option vested as to (a) 25%100% of the shares on the date immediately uponpreceding the first acceptance by2020 annual meeting of stockholders, subject to continued service as a director on the FDA of an NDA filed by us; (b) 25% of the shares upon the first commercial sale of linaclotide; and (c) 25% of the shares upon acceptance by the FDA of a second NDA for a product from an internal or external development program (excluding supplemental NDAs for linaclotide, but including NDAs for linaclotide combination products). The remaining portion of the vests as to 25% of the shares upon the achievement of $1 billion in annual (calendar year) net global pharmaceutical product sales (including partnered or licensed product revenue). External development programs shall be pre-qualified for milestone vesting eligibility by our compensation and HR committee as of the time of program initiation at Ironwood.
date.

Options ExercisedCyclerion Equity Awards at Fiscal Year-End

The Cyclerion equity awards reflected in the following table were granted in connection with the Separation. Each Ironwood equity award that was converted into a Cyclerion equity award is subject to substantially the same terms and vesting conditions as were applicable to the Ironwood equity awards prior to the distribution. The following table does

2020  Proxy Statement    55


Table of Contents

GRAPHIC

not include any Cyclerion equity awards that may have been granted by Cyclerion to Drs. Hecht and Currie following the Separation.

Name

  Number of Securities
Underlying Unexercised
Options (#) Exercisable
  Number of Securities
Underlying Unexercised
Options (#) Unexercisable
  Option
Exercise
Price ($)
  Option
Expiration
Date
 

Mark Mallon

     

Gina Consylman

  1,117    17.05  7/1/2024 

  850    17.20  3/16/2025 

  437    12.61  9/16/2025 

  2,437    11.28  3/1/2026 

  500    16.82  1/2/2028 

  1,875    16.02  2/21/2028 

  906    14.21  1/29/2029 

Halley E. Gilbert

 5,999  12.39 2/2/2020 

 6,000  12.24 2/1/2021 

 2,999  13.03 12/12/2021 

 4,499  16.21 2/1/2022 

 2,999  14.40 2/1/2023 

 2,499  12.68 12/2/2023 

 6,499  15.54 3/3/2024 

 5,750  17.20 3/16/2025 

 5,281  11.28 3/1/2026 

 4,500  18.47 2/27/2027 

 2,187  16.02 2/21/2028 

 906  14.21 1/29/2029 

Thomas A. McCourt

  1,999    12.39  2/2/2020 

  5,464    12.24  2/1/2021 

  8,713    16.21  2/1/2022 

  10,221    14.40  2/1/2023 

  7,591    15.54  3/3/2024 

  9,750    17.20  3/16/2025 

  14,218    11.28  3/1/2026 

  8,859    18.47  2/27/2027 

  4,101    16.02  2/21/2028 

  2,156    14.21  1/29/2029 

Peter M. Hecht, Ph.D.

 12,499  12.39 2/2/2020 

 53,083  12.24 2/1/2021 

 36,088  16.21 2/1/2022 

 43,679  14.40 2/1/2023 

 37,972  15.54 3/3/2024 

 56,500  17.20 3/16/2025 

 207,051 16,842 11.28 3/1/2026 

 157,809 186,968 18.47 2/27/2027 

 105,933 274,397 16.02 2/21/2028 

 157,642 700,188 14.21 1/29/2029 

Mark G. Currie, Ph.D.

  888    12.39  2/2/2020 

  37,279    12.24  2/1/2021 

  17,490    16.21  2/1/2022 

  27,772    14.40  2/1/2023 

  9,930    15.54  3/3/2024 

  15,625  22,708  17.20  3/16/2025 

  46,347  4,447  11.28  3/1/2026 

  51,910  61,503  18.47  2/27/2027 

  39,268  101,716  16.02  2/21/2028 

  94,588  420,110  14.21  1/29/2029 

56    Ironwood


Table of Contents

GRAPHIC

Option Exercises and Stock Vested Table

The following table sets forth certain information regarding the exercise of options to purchase our Class A common stock and the vesting of RSUs and RSAs that were held by our named executive officers during the year ended December 31, 2018. The following table reflects the conversion of our Class B common stock to Class A common stock, which was effective December 31, 2018.2019.

 
 Option Awards Stock Awards 
Name
 Number of Shares
Acquired on
Exercise
(#)
 Value Realized
on Exercise
($)(1)
 Number of Shares
Acquired on
Vesting
(#)
 Value Realized
on Vesting
($)(2)
 

Peter M. Hecht, Ph.D. 

         

Gina Consylman

      16,500  234,578 

Mark G. Currie, Ph.D. 

  488,301(3) 4,953,961  5,469  81,160 

Thomas A. McCourt

  30,000(4) 435,600  10,625  157,675 

William Huyett

      14,063  169,881 


  Option Awards  Stock Awards
 

Name

  Number of Shares
Acquired on Exercise
(#)
  Value Realized on
Exercise
($)(1)
  Number of Shares
Acquired on Vesting
(#)
  Value Realized on
Vesting
($)(2)
 

Mark Mallon

     

Gina Consylman

      38,116  482,063 

Halley E. Gilbert

 40,449(3)274,365 47,545 642,588 

Thomas A. McCourt

  220,000(4) 959,452  29,577  380,076 

Peter M. Hecht, Ph.D.

 130,000(5)958,114   

Mark G. Currie, Ph.D.

      21,946(6) 266,820(7)

(1)

Computed by determining the difference between the market price of our Class A common stock upon exercise and the exercise price of the exercised stock option, in each case on the date of exercise, multiplied by the number of shares acquired upon exercise of the option.

(2)

Computed by multiplying the number of shares of Class A common stock underlying the vested RSUs or RSAs by the market price of our Class A common stock on the vesting date. This amount represents the total number

(3)  Includes 20,449 shares of shares that vested; however, a portion of such shares were sold to satisfy tax withholding obligations.

(3)
Includes 235,000 shares ofClass A common stock that Dr. CurrieMs. Gilbert acquired through an option exercises and then sold on the open market,exercise, as such stock options were expiring.expiring, and then held, thereby increasing her ownership of our Class A common stock by such amount. Also includes 253,30120,000 shares of our Class A common stock that Dr. CurrieMs. Gilbert acquired through option exercises as such stock options were expiring, and then sold on the open market.

(4)

Represents 30,000220,000 shares of our Class A common stock that Mr. McCourt acquired through option exercises as such stock options were expiring, and then sold on the open market.

(5)  Includes 20,449 shares of Class A common stock that Dr. Hecht acquired through an option exercise, as such stock options were expiring, and then held, thereby increasing his ownership of our Class A common stock by such amount. Also includes 109,551 shares of our Class A common stock that Dr. Hecht acquired through option exercises as such stock options were expiring, and then sold on the open market to satisfy tax withholding obligations.

(6)  Includes (a) 18,951 shares of Class A common stock that Dr. Currie acquired through the vesting of RSUs granted in connection with Dr. Currie's employment with the company and (b) 2,995 shares of our Class A common stock that Dr. Currie acquired through the vesting of RSAs granted in April 2019 in connection with his joining our board of directors.

(7)  Includes (a) $224,830 attributable to the vesting of RSUs, which were granted in connection with Dr. Currie's employment with the company, and (b) $41,990 attributable to the vesting of RSAs, which were granted in connection with Dr. Currie's joining our board of directors in April 2019.

Potential Payments Upon Termination or Change of Control

        Except as described below, there are currently no other agreements or arrangements pursuant to which our named executive officers would receive severance benefits in the event of a separation from Ironwood.


Table of Contents

    Named Executive Officer Severance Arrangements

We have entered into severance arrangements with each of our named executive officers. Under the severance arrangements, our named executive officers are eligible to receive certain payments and benefits in the event of an involuntary termination without "cause" or a "constructive termination,termination." andEach of our executives also are eligible to receive enhanced payments and benefits in the event of a change of control plus actual or constructive involuntary termination of employment ("double trigger"). For additional information, please see the definition of "change of control termination" (as defined below).termination," below. Unless the context suggested otherwise, "named executive officers" as used in this section refers to our named executive officers who remained at the company following the Separation.

    2020  Proxy Statement    57


    Table of Contents

    GRAPHIC

    Severance Benefits not in Connection with a Change of Control

In the event of a termination without cause or a constructive termination not qualifying as a change of control termination, each of our named executive officers would be entitled to receive (i) a lump-sum payment equal to 12 months of his or her base salary for the year of termination, plus an amount equal to a maximum of six months of his or her base salary for any period beginning as of the first anniversary of his or her termination date, provided he or she has not secured new, reasonably similar full-time employment (for Dr. Hecht,Mr. Mallon, a lump-sum payment equal to 18 months of his base salary for the year of termination); (ii) a lump-sum payment equal to his or her target cash bonus for the year of termination, pro-rated based on the percentage of the year worked prior to the triggering event; (iii) a lump-sum payment equal to his or her actual bonus for the prior year if not yet paid as of the termination date; (iv) a lump-sum payment equal to his or her full target cash bonus for the year of termination (for Dr. Hecht,Mr. Mallon, multiplied by 1.5); (v) 12 months of subsidized COBRA benefits, plus up to an additional six months of subsidized COBRA benefits for any period beginning as of the first anniversary of his or her termination date, provided he or she has not been eligible to participate in the group medical plan of another employer (for Dr. Hecht,Mr. Mallon, 18 months of subsidized COBRA benefits); and (vi) outplacement assistance benefits. The non-equity based severance benefits described in items (i) through (vi) of this paragraph, collectively, are referred to as the "Non-Equity Severance Benefits."

In addition, each executive severance agreement provides that any outstanding equity awards subject solely to time-based vesting would vest as to (1) the portion of the equity award that would have vested if the named executive officer had remained employed for 18 months (for Dr. Hecht,Mr. Mallon, 24 months) following the termination date and (2) an additional portion of the equity award that would have vested on the next regular vesting date after such 18-month period (for Dr. Hecht,Mr. Mallon, such 24-month period) as if the equity award vested on a daily basis from the last regular award vesting date occurring prior to the end of the 18-month period (for Dr. Hecht,Mr. Mallon, the 24-month period) through such next regular vesting date. Any equity awards that do not vest pursuant to the preceding sentence would remain outstanding and eligible to vest upon the occurrence of a change of control termination (as defined below) in the time periods described below for such a termination.termination (for Ms. Gilbert, such shares that otherwise would be cancelled shall remain outstanding for 24 months and vest if, within that time period, the company enters into a definitive agreement that, if consummated, would result in a change of control). Further, the exercisability of any outstanding vested stock options held by the named executive officer as of the termination date (including, other than for Ms. Gilbert, any vested options to purchase Cyclerion common stock granted in connection with the Separation in substitution for or replacement of vested options to purchase Ironwood Class A common stock) would be extended through the earlier of 24 months (for Dr. Hecht,Mr. Mallon, 36 months) following the termination date (or, in the event that Ironwood publicly announced it was conducting negotiations leading to a change of control or entered into a definitive agreement that would have resulted in a change of control during such 24-month period (for Dr. Hecht,Mr. Mallon, such 36-month period), the later of (i)(A) the expiration of the 24-month period (for Dr. Hecht,Mr. Mallon, the 36-month period) or (ii)(B) the first to occur of the date that is three months following the change of control and 30 days following the date on which Ironwood announced that such definitive agreement had been terminated or that Ironwood's efforts to consummate the change of control contemplated by the previously-announced negotiations or by a previously executed definitive agreement had been abandoned) or the stock option's final expiration date. The equity-based severance benefits described in this paragraph are referred to as the "Equity Severance Benefits."


Table of Contents

    Change of Control Severance Benefits

In the event of a change of control termination, each of our named executive officers would be entitled to receive the following benefits under his or her executive severance agreement: (i)(1) a lump-sum payment in an amount equal to 18 months (for Dr. Hecht,Mr. Mallon, 24 months) of his or her base salary as of the time of termination; (ii)(2) a lump-sum payment of his or her target cash bonus for the year of termination, pro-rated based on the percentage of the year worked prior to the triggering event; (iii)(3) a lump-sum payment equal to his or her actual bonus for the prior year if not yet paid as of the termination date; (iv)(4) a lump-sum payment equal to his or her full target cash bonus for the year of termination,

58    Ironwood


Table of Contents

GRAPHIC

multiplied by 1.5 (for Dr. Hecht,Mr. Mallon, multiplied by 2.0); (v)(5) 18 months (for Dr. Hecht,Mr. Mallon, 24 months) of subsidized COBRA benefits; and (vi)(6) outplacement assistance benefits.

In addition, in the event of a change of control termination, each executive severance agreement provides for acceleration of all outstanding equity awards subject solely to time-based vesting as of the later of (1) the termination date or (2) the change of control. Further, the exercisability of any outstanding vested stock options held by the named executive officer as of the termination date (including any vested options to purchase Cyclerion common stock granted in connection with the Separation in substitution for or replacement of vested options to purchase Ironwood Class A common stock) would be extended through the earlier of 24 months (for Dr. Hecht,Mr. Mallon, 36 months) following the termination date (or, if later the date that was three months following the change of control) or the stock option's final expiration date.

Under each executive severance agreement, a "change of control termination" consists of an involuntary termination without "cause" or a "constructive termination" (each as defined in the agreement), in either event during the period commencing six months prior to the earlier of (1) the date that Ironwood first publicly announces it is conducting negotiations leading to a change of control, or (2) the date that Ironwood enters into a definitive agreement that would result in a change of control, and ending on the earlier of (i)(A) the date on which Ironwood announces that the definitive agreement has been terminated or the negotiations have been abandoned or (ii)(B) the date that is 24 months after the change of control. Under each executive severance agreement, a change of control occurs when: (i)(I) any person becomes, pursuant to a transaction or a series of transactions not approved by the Ironwood board of directors, the beneficial owner, directly or indirectly, of Ironwood securities representing more than 50% of the total voting power; (ii)(II) a merger or consolidation of Ironwood occurs, whether or not approved by the Ironwood board of directors, which results in the holders of Ironwood's voting securities holding less than 50% of the combined voting power of the surviving entity immediately after such merger or consolidation; (iii)(III) the sale or disposition of more than two-thirds of the assets of Ironwood; or (iv)(IV) the date a majority of members of the Ironwood board of directors is replaced during any 12-month period by directors whose appointment or election was not endorsed by a majority of members of the Ironwood board of directors before the date of the appointment or election.

The benefits described above for our named executive officers are only payable if the named executive officer complies with all of Ironwood's rules and policies, executes a separation agreement that includes a release of claims and complies with his or her post-employment non-disclosure, non-competition and non-solicitation obligations. The executive severance agreements further provide that in connection with the sale of all or substantially all of the assets of Ironwood, Ironwood would cause the acquirer of such assets to assume the arrangements.

    Treatment of Equity in the Event of Death

For all employees, including our named executive officers, outstanding stock option and RSU awards subject solely to time-based vesting accelerate in full in the event of the death of the award holder. This term applies to all outstanding time-based stock option and RSU awards made under our equity incentive plans, including the 20102019 Plan. Further, ourOur current form of stock option and RSU


Table of Contents

agreements for awards issued under our 20102019 Plan include similar provision for the acceleration of unvested time-based awards upon the death of an award holder, including our named executive officers. In addition, the post-termination exercise window of all vested stock options held by a participant that were granted under our Amended and Restated 2005 Stock Incentive Plan, 2010 Plan and 20102019 Plan is extended to one year (or the stock option's final expiration date, if earlier) following the participant's termination of employment by reason of his or her death.

    Separation Agreement

    In connection with her resignation in February 2020, Ms. Gilbert entered into a separation agreement with the company, which agreement generally served to implement the terms of Ms. Gilbert's existing severance agreement.

    The separation agreement, which included a general release of claims, provided that, in exchange for Ms. Gilbert's signing and not revoking the separation agreement within the period set forth therein, the company would provide

    2020  Proxy Statement    59


    Table of Contents

    GRAPHIC

    Ms. Gilbert with the Non-Equity Severance Benefits and the Equity Severance Benefits, in each case as defined above, with the lump-sum payment described in item (i) above equal to Ms. Gilbert's annual base salary of $480,000 (plus up to six months of salary continuation as described above), and the lump-sum payments described in items (ii)-(iv) above equal to the sum of the following: (A) $340,080 (representing Ms. Gilbert's annual bonus for 2019 determined based on actual performance); (B) $38,111 (representing Ms. Gilbert's pro-rated amount of annual target bonus for 2020); and (C) $240,000 (representing Ms. Gilbert's annual target bonus for 2020). The estimated aggregate cost associated with providing Ms. Gilbert with outplacement assistance benefits and 12 months of contributions towards the cost of COBRA coverage is $60,000 and approximately $24,000, respectively. With respect to the Equity Severance Benefits provided to Ms. Gilbert, the number of unvested Ironwood equity awards that were accelerated as described above were 115,571 stock options and 56,736 RSUs and the number of unvested equity awards that were not subject to the accelerated vesting described above but that will remain outstanding (but will not continue to vest) and will vest immediately if, within the 24-month period following the separation date, the company enters into a definitive agreement that would result in a change of control were 61,513 stock options and 35,258 RSUs. In addition, under her separation agreement, the company will not seek reimbursement from Ms. Gilbert for the value of certain conference attendance registration fees following the separation date, the total value of which is not expected to exceed $2,500.

    By executing the separation agreement, Ms. Gilbert acknowledged and reaffirmed her obligations under her employee proprietary information and inventions and noncompetition agreement, including her agreement to (1) protect the company's confidential information, as well as confidential information acquired during employment of any third parties, for the term of her employment and perpetually thereafter; (2) assign to the company all right, title and interest in and to any inventions made during the course of employment; and (3) during the term of employment and for one year thereafter, refrain from (A) engaging in any business activity which is in competition with Ironwood's business, (B) soliciting or doing business with any customer or potential customer of the company, and (C) employing or permitting any future employer or organization under her control to employ any person who at any time during her employment was an agent, representative or consultant of Ironwood.

    Potential Payments Upon Termination or Change of Control

Except as described in this proxy statement, there are currently no other agreements or arrangements pursuant to which our named executive officers would receive severance benefits in the event of a separation from Ironwood. The following table presents our estimate of the amount of severance benefits to which each of our named executive officers would be entitled if a termination occurred on December 31, 20182019 under the circumstances set forth in the column headings. The closing price of our Class A common stock as listed on the Nasdaq Global Select Market on December 31, 20182019 was $10.36

60    Ironwood


Table of Contents

GRAPHIC

$13.31 per share. Drs. Hecht and Currie are not included in the table below because they transitioned to Cyclerion in April 2019 in connection with the Separation.

Name
 Executive Payments
and Benefits
upon Termination
 Involuntary
Termination
without Cause or a
Constructive
Termination(1)
 Termination
Following
Change of
Control
 Death(2) 

Peter M. Hecht, Ph.D. 

 Cash Severance $150,000 $200,000 $ 

 Non-Equity Incentive Plan Compensation $125,000 $150,000 $ 

 Equity Acceleration          

 Options $28,925(4)$28,925(4)$28,925 

 RSUs $ $ $ 

 Other Benefits(5) $92,517 $92,517 $ 
          

 Total $396,442 $471,442 $28,925 

Gina Consylman

 

Cash Severance(3)

 
$

622,500
 
$

622,500
 
$

 

 Non-Equity Incentive Plan Compensation $415,000 $518,750 $ 

 Equity Acceleration       $ 

 Options $975(4)$975(4)$975 

 RSUs $639,906(4)$846,920(4)$846,920 

 Other Benefits(5) $83,344 $83,344 $ 

 Total $1,761,725 $2,072,489 $847,895 

Mark G. Currie, Ph.D. 

 

Cash Severance(3)

 
$

727,500
 
$

727,500
 
$

 

 Non-Equity Incentive Plan Compensation $485,000 $606,250 $ 

 Equity Acceleration          

 Options $7,638(4)$7,638(4)$7,638 

 RSUs $180,968(4)$180,968(4)$180,968 

 Other Benefits(5) $70,790 $70,790 $ 
          

 Total $1,471,896 $1,593,146 $188,606 

Thomas A. McCourt

 

Cash Severance(3)

 
$

697,500
 
$

697,500
 
$

 

 Non-Equity Incentive Plan Compensation $465,000 $581,250 $ 

 Equity Acceleration          

 Options $5,688(4)$5,688(4)$5,688 

 RSUs $460,419(4)$596,985(4)$596,985 

 Other Benefits(5) $69,615 $69,615 $ 

 Total $1,698,222 $1,951,038 $602,673 

William Huyett

 

Cash Severance(3)

 
$

697,500
 
$

697,500
 
$

 

 Non-Equity Incentive Plan Compensation $465,000 $581,250 $ 

 Equity Acceleration          

 Options $ $ $ 

 RSUs $364,206(4)$561,377(4)$561,377 

 Other Benefits(5) $58,125 $58,125 $ 
          

 Total $1,584,831 $1,898,252 $561,377 

    Involuntary
Termination
without
Cause or a
Constructive
Termination(1)
  Termination
Following a
Change of
Control
  Death(2)
 

Mark Mallon

 Cash Severance $1,125,000 $1,500,000  

 Non-Equity Incentive Plan Compensation $1,406,250 $1,687,500  

 Equity Acceleration(4)    

     Options $328,843 $450,986 $450,986 

     RSUs $2,417,828 $4,144,854 $4,144,854 

 Other Benefits(5) $96,234 $96,234  

 Total $5,374,155 $7,879,574 $4,595,840 

Gina Consylman

 Cash Severance(3) $720,000 $720,000    

 Non-Equity Incentive Plan Compensation $480,000 $600,000    

 Equity Acceleration(4)          

     Options $123,239 $163,337 $163,337 

     RSUs $1,673,826 $1,789,583 $1,789,583 

 Other Benefits(5) $96,234 $96,234    

 Total $3,093,299 $3,369,154 $1,952,920 

Halley E. Gilbert*

 Cash Severance(3) $720,000 $720,000  

 Non-Equity Incentive Plan Compensation $480,000 $600,000  

 Equity Acceleration(4)    

     Options $128,191 $168,795 $168,795 

     RSUs $1,801,069 $1,906,138 $1,906,138 

 Other Benefits(5) $96,234 $96,234  

 Total $3,225,494 $3,491,167 $2,074,933 

Thomas A. McCourt

 Cash Severance(3) $780,000 $780,000    

 Non-Equity Incentive Plan Compensation $624,000 $780,000    

 Equity Acceleration(4)          

     Options $327,868 $431,435 $431,435 

     RSUs $1,831,536 $2,098,122 $2,098,122 

 Other Benefits(5) $73,171 $73,171    

 Total $3,636,575 $4,162,728 $2,529,557 

* Ms. Gilbert resigned from the company effective February 28, 2020. Information on separation payments and benefits provided to Ms. Gilbert in connection with her resignation is available elsewhere in this proxy statement under the captionNamed Executive Officer Severance Arrangements—Separation Agreement.

(1)

Represents amounts payable under the terms of the named executive officer severance arrangements. Non equityNon-equity incentive plan compensation payment amount assumes no bonus amounts for 20182019 have been paid to the

Table of Contents

    executive as of December 31, 2018,2019, and that all 20172018 bonus amounts have been paid as of such date, in each case, as would be consistent with Ironwood's historical practice.

(2)

With respect to options, reflects the in-the-money value of the unvested portion of such named executive officer's options that have vesting provisions based solely on time, and not performance milestones.milestones, and that would be fully accelerated, in each case, in accordance with the terms of the award agreements issued under our equity incentive plans. The value is calculated by multiplying the amount (if any) by which $10.36,$13.31, the closing price of our Class A common stock on the Nasdaq Global Select Market on December 31, 2018,2019, exceeds the exercise price of the option by the number of shares subject to the accelerated portion of the option.

With respect to RSUs, the value is calculated by multiplying the number of unvested RSUs with vesting provisions based solely on time that would be fully accelerated (if any) by $10.36,$13.31, the closing price of our Class A common stock on the Nasdaq Global Select Market on December 31, 2018.2019, in accordance with the terms of the award agreements issued under our equity incentive plans.

2020  Proxy Statement    61


Table of Contents

GRAPHIC

(3)

With respect to involuntary termination without cause or a constructive termination, includes the value of the payment of an additional amount equal to six months of base salary for all named executive officers (other than Dr. Hecht)Mr. Mallon) in the event he or she does not obtain full-time employment within six months following the one year anniversary of his or her termination date.

(4)

With respect to options, reflects the in-the-money value of the unvested portion of such named executive officer's options that have vesting provisions based solely on time, and not performance milestones, and that would be accelerated, in each case, in accordance with the terms of our severance arrangementsagreements with each executive officer. The value is calculated by multiplying the amount (if any) by which $10.36,$13.31, the closing price of our Class A common stock on the Nasdaq Global Select Market on December 31, 2018,2019, exceeds the exercise price of the option by the number of shares subject to the accelerated portion of the option.

With respect to RSUs, the value is calculated by multiplying the number of unvested RSUs with vesting provisions based solely on time that would be accelerated (if any) by $10.36,$13.31, the closing price of our Class A common stock on the Nasdaq Global Select Market on December 31, 2018,2019, in each case, in accordance with the terms of our severance arrangements with each executive officer.

(5)

Includes outplacement assistance benefits and subsidized COBRA benefits. With respect to involuntary termination without cause or a constructive termination, also includes the value of the payment of an additional amount equal to six months of subsidized COBRA benefits for all named executive officers (other than Dr. Hecht)Mr. Mallon) in the event he or she is not eligible to participate in the group medical plan of another employer following the one year anniversary of his or her termination date.

CEO Pay Ratio

Under the Dodd-Frank Wall Street Reform and Consumer Protection Act, we are required to disclose the median of the annual total compensation of our employees, the annual total compensation of our principal executive officer, Dr. Hecht, and the ratio of these two amounts.

Both Dr. Hecht and Mr. Mallon served as our chief executive officer during fiscal year 2019. In accordance with Instruction 10 to Item 402(u) of Regulation S-K, we have elected to use Mr. Mallon's compensation for purposes of this pay ratio disclosure as Mr. Mallon was serving as our chief executive officer on December 31, 2019, the date selected by us to identify our median employee. Although we used Mr. Mallon's total 2019 compensation as reported in theSummary Compensation Table for the purposes of this pay ratio disclosure, due to certain one-time cash and equity awards granted to compensate Mr. Mallon, in part, for outstanding equity he forfeited by leaving his previous employer, Mr. Mallon's 2019 compensation is not representative of our expectations for Mr. Mallon's annual compensation on a go-forward basis. For 2018,purposes of computing Mr. Mallon's compensation for this pay ratio disclosure, we did not annualize the base salary paid to Mr. Mallon for the period in 2019 in which he served as our chief executive officer because his salary was unchanged from the salary his received in 2019 as a senior advisor to our board of directors. Moreover, the cash bonus paid to Mr. Mallon in 2020 for 2019 performance was not pro-rated for the period of service as our chief executive officer because Mr. Mallon was employed by Ironwood throughout 2019.

For 2019, our last completed fiscal year:

    The estimated median of the annual total compensation of all employees of our company (other than Dr. Hecht)Mr. Mallon) was $194,750;$202,151; and

    Dr. Hecht'sMr. Mallon's annual total compensation, as reported in theSummary Compensation Table included elsewhere in this proxy statement, was $5,160,116.$10,068,800.

Based on this information for 2018,2019, we estimate that the ratio of the annual total compensation of Dr. HechtMr. Mallon to the median annual total compensation of all employees was 2650 to 1. We believe this pay ratio is a reasonable estimate calculated in a manner consistent with SEC rules based on our payroll and employment records, and the methodology described below. Because the SEC rules for identifying the median of the annual total compensation of our employees and calculating the pay ratio based on that employee's annual total compensation allow companies to adopt a variety of methodologies, to apply certain exclusions, and to make reasonable estimates and assumptions that reflect their employee populations and compensation practices, the pay ratio reported by other companies may not be comparable to the pay ratio for Ironwood, as other companies have employees based in different locations (including other countries), have different business models and employee needs, have different employee populations and compensation practices and may utilize different methodologies, exclusions, estimates and assumptions in calculating their pay ratios.


62    Ironwood


Table of Contents

GRAPHIC

To identify the median of the annual total compensation of all our employees, as well as to determine the annual total compensation of our median employee and Dr. Hecht,Mr. Mallon, we took the following steps:

    As a result of significant changes to our employee population in 2018,2019 on account of the Separation, we determined that it was appropriate to update the methodology by which we determine our median employee and to re-identify our median employee. We determined that, as of December 31, 2018,2019, our employee population consisted of approximately 514317 individuals, with all of these individuals located in the United States. This population consisted of our full- and part-time employees. We moved to ause December 31, 20182019 as an identification date because it is closerclose to the date of our annual proxy statement filing and is consistent with year-end financial reporting and other reporting dates used in this proxy statement. TheUsing a year-end identification date will enablealso enables us to make such identification in a reasonably efficient and economical manner.

    To identify the "median employee" from our employee population, we compareddetermined to use the amountdollar value of salary and wages (including cash bonuses and incentives)total compensation, as defined in Item 402(c)(2)(x) of Regulation S-K, as our consistently applied compensation measure. To calculate the dollar value of total compensation, we started with the gross earnings of our employees as reflected in our payroll records for 20182019 as of the identification date, and as reportable to the Internal Revenue Service on Form W-2. In addition, since we widely distribute annualWe subtracted 2019 equity awards to our employees as part of our owner-oriented compensation philosophy, we includedearnings from stock option exercises and RSU vesting and replaced them with the grant date fair value of equity awards granted in 2019. We subtracted 2018 annual bonuses (paid in 2019) and replaced them with 2019 annual bonus awards (paid in 2020). We also added the compensation measure.
    company's 401(k) matching contribution and included all other amounts reported pursuant to Item 402(c)(2)(ix) of Regulations S-K. For employees hired during 2019, we annualized base salary and 2019 bonus amounts, but not the value of equity granted in 2019 as new hire awards are made on a one-time basis.
    We identified our median employee using this compensation measure, which was consistently applied to all our employees included in the calculation.

    Since all our employees are located in the United States, as is Dr. Hecht,Mr. Mallon, we did not make any cost-of-living adjustments in identifying the "median employee."

    Once we identified our median employee, we combined all of the elements of such employee's compensation for 2018 in accordance with applicable SEC rules, resulting in annual total compensation of $194,750. The difference between such employee's salary and wages, bonuses, and the grant date fair value of the employee's equity grants, and the employee's annual total compensation represents the estimated value of such employee's transportation and fitness stipends and 401(k) matching contributions.

    With respect to the annual total compensation of our CEO, we used the amount reported in the "Total" column of theSummary Compensation Table for 2018.2019.

2020  Proxy Statement    63


Table of Contents

GRAPHIC

Compensation Committee Report

We have:

    1.
    reviewed and discussed with management theCompensation Discussion and Analysis found herein; and

    2.
    based on the review and discussions referred to in paragraph (1) above, we recommended to the board of directors that theCompensation Discussion and Analysis be included in the company's proxy statement on Schedule 14A for filing with the SEC.

 

 

By the Compensation and HR Committee,

 

 

Edward P. OwensAndrew Dreyfus, Chair
Jon R. Duane
Marla L. Kessler

64    Ironwood


Table of Contents


PROPOSAL NO. 2—ADVISORY VOTE ON
NAMED EXECUTIVE OFFICER
COMPENSATION
GRAPHIC


Table of Contents

GRAPHIC

Our board recommends that you approve the
compensation of our named executive officers as
disclosed in this proxy statement.

Proposal No. 2

At our 20192020 annual meeting, we are providing our stockholders with the opportunity to cast an advisory (non-binding) vote on named executive officer compensation, or a "say-on-pay" vote. This is a non-binding vote on the compensation of our "named executive officers," as described in theCompensation Discussion and Analysis section, the tabular disclosure regarding such compensation, and the accompanying narrative disclosure, all as set forth in this proxy statement.

The objectivesobjective of our compensation policies areis to provide compensation and incentives that align employee actions and motivations with the interests of our stockholders,stockholders; attract, retain, motivate and reward outstanding talent across our companyIronwood through well-communicated programs that are aligned with our core valuesvision and business mission,mission; and support a positive company culture. In 2018,2019, the compensation program for our named executive officers consisted principally of base salary, cash bonus and long-term equity incentive compensation in the form of stock options and restricted stock units. While we offer reasonably competitive base salaries and cash bonuses, our compensation program is weighted toward long-term equity incentive compensation as opposed to short-term or cash-based compensation. We believe this better aligns the interests of our executivesnamed executive officers and our stockholders and serves to further focus our executivesnamed executive officers on the creation of long-term stockholder value. If we achieve our corporate goals over the long term, we expect our stock price to reflect our performance and the equity awards currently held by our named executive officers to become an even more significant component of overall compensation. Our compensation and HR committee believes that this approach to executive compensation links compensation directly to continuous improvements in corporate performance and, ultimately our stock price, orand demonstrates our "pay for performance."performance" compensation philosophy.

Our previous say-on-pay vote was at our 20182019 annual meeting and was approved by more than 95%approximately 87% of the votes cast on such matter. Under the Dodd-Frank Wall Street Reform and Consumer Protection Act, as well as the provisions of Section 14A of the Exchange Act, we must hold the advisory (non-binding) vote on named executive officer compensation at least once every three years. Based on the recommendation of our stockholders in 2017, our board of directors determined to provide our stockholders the opportunity to vote (on an advisory basis) on named executive officer compensation on an annual basis to allow our stockholders to provide us with regular, timely and direct input on our executive compensation philosophy, policies and practices as disclosed in the proxy statement each year. We believe this practice allows us to further align our compensation programs with our stockholders' interests as stockholder feedback may be taken into consideration as part of the compensation review process.

Vote Required

Because this proposal seeks a non-binding, advisory vote, there is no "required vote" that would constitute approval. However, our board of directors, including our compensation and HR committee, values the opinions of our stockholders and, to the extent there are a substantial number of votes cast against the executive officer compensation as disclosed in this proxy statement, we will consider our stockholders' concerns and evaluate which actions may be appropriate to address those concerns. Broker nominees do not have discretion to vote on this proposal without your instruction; if you do not instruct your broker nominee how to vote on this proposal, your broker nominee will not vote your shares with respect to this proposal. Any shares that are not voted, whether by abstention, broker non-votes or otherwise, will not affect the outcome of this proposal.


66    Ironwood


Table of Contents

GRAPHIC
Our Stockholders

Security Ownership of Certain Beneficial Owners and Management

The following table sets forth certain information with respect to the beneficial ownership of our Class A common stock at March 31, 2020 for:

    each person whom we know beneficially owns more than five percent of our Class A common stock;

    each of our directors;

    each of our named executive officers; and

    all of our current directors and executive officers as a group.

The number of shares beneficially owned by each stockholder is determined under rules issued by the SEC. Under these rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power. Each of the stockholders listed has sole voting and investment power with respect to the shares beneficially owned by the stockholder unless noted otherwise, subject to community property laws where applicable.

The percentage of Class A common stock beneficially owned by each person is based on 159,368,126 shares of Class A common stock outstanding on March 31, 2020. Shares of Class A common stock that may be acquired within 60 days following March 31, 2020 pursuant to the exercise of options or the vesting of RSUs, are included in the holdings of each stockholder, as applicable, and are deemed to be outstanding for the purpose of computing the percentage ownership of such holder. Such amounts, however, are not included in the holdings of any other stockholder in the table below and are not deemed to be outstanding for computing the percentage ownership of any other holder shown in the table below. Beneficial ownership representing less than one percent is denoted with an "*."

2020  Proxy Statement    67


Table of Contents

GRAPHIC

Unless otherwise indicated, the address for each of the stockholders in the table below is c/o Ironwood Pharmaceuticals, Inc., 100 Summer Street, Suite 2300, Boston, Massachusetts 02110.

Name of Beneficial Owner

  Number of Shares
of our Class A
Common Stock
 Percentage

Named Executive Officers and Directors

    

Mark Mallon(1)

  275,129 *

Peter M. Hecht(2)

 5,285,772 3.3%

Gina Consylman(3)

  257,100 *

Halley E. Gilbert(4)

 779,295 *

Thomas A. McCourt(5)

  1,088,479 *

Andrew Dreyfus

 86,938 *

Mark G. Currie(6)

  1,374,124 *

Julie H. McHugh

 109,337 *

Lawrence S. Olanoff

  58,259 *

Edward P. Owens

 182,234 *

Jon R. Duane

  25,701 *

Marla L. Kessler

 25,701 *

Catherine Moukheibir

  25,701 *

All current executive officers and directors as a group (14 persons)(7)

 3,843,894 2.4%
​ ​ 

5% Security Holders

     

Wellington Management Group LLP(8)

 21,777,701 13.7%

Brown Capital Management, LLC(9)

  17,901,053 11.2%

The Vanguard Group(10)

 16,638,941 10.4%

BlackRock, Inc.(11)

  13,541,545 8.5%

Sarissa Capital Management LP(12)

 12,493,000 7.8%

FMR LLC (Fidelity)(13)

  11,353,494 7.1%

UBS Group AG(14)

 11,181,451 7.0%

Janus Henderson Group PLC(15)

  8,289,895 5.2%

(1)  Includes (i) 205,260 shares of Class A common stock issuable to Mr. Mallon upon the exercise of options that are exercisable within 60 days following March 31, 2020 and (ii) 51,719 restricted stock units that vest on May 7, 2020.

(2)  Includes 3,068,406 shares of Class A common stock issuable to Dr. Hecht upon the exercise of options that are exercisable within 60 days following March 31, 2020.

68    Ironwood


Table of Contents

GRAPHIC

(3)  Includes 187,948 shares of Class A common stock issuable to Ms. Consylman upon the exercise of options that are exercisable within 60 days following March 31, 2020.

(4)  Includes 639,572 shares of Class A common stock issuable to Ms. Gilbert upon the exercise of options that are exercisable within 60 days following March 31, 2020.

(5)  Includes (i) 1,019,437 shares of Class A common stock issuable to Mr. McCourt upon the exercise of options that are exercisable within 60 days following March 31, 2020 and (ii) 5,713 restricted stock units that vest on May 7, 2020.

(6)  Includes 824,582 shares of Class A common stock issuable to Dr. Currie upon the exercise of options that are exercisable within 60 days following March 31, 2020.

(7)  Includes (i) 2,461,450 shares of Class A common stock issuable upon the exercise of options that are exercisable within 60 days following March 31, 2020 and (ii) 61,547 restricted stock units that vest on May 7, 2020.

(8)  Based upon the information provided by Wellington Management Group LLP, or Wellington, Wellington Group Holdings LLP, or Wellington Group, Wellington Investment Advisors Holdings LLP, or Wellington Investment, and Wellington Management Company LLP, or Wellington Management and, collectively with Wellington, Wellington Group and Wellington Investment, the Wellington Entities, in a Schedule 13G/A filed on January 28, 2020, reporting as of December 31, 2019. According to this Schedule 13G/A, (i) Wellington has sole voting and sole dispositive power with respect to none of these shares, shared voting power with respect to 20,301,618 of these shares, and shared dispositive power with respect to all of these shares, (ii) Wellington Group has sole voting and sole dispositive power with respect to none of these shares, shared voting power with respect to 20,301,618 of these shares, and shared dispositive power with respect to all of these shares, (iii) Wellington Investment has sole voting and sole dispositive power with respect to none of these shares, shared voting power with respect to 20,301,618 of these shares, and shared dispositive power with respect to all of these shares, and (iv) Wellington Management has sole voting and sole dispositive power with respect to none of these shares, shared voting power with respect to 19,717,128 of these shares, and shared dispositive power with respect to 19,751,144 of these shares. The address of the Wellington Entities is c/o Wellington Management Company LLP, 280 Congress Street, Boston, MA 02210.

(9)  Based upon the information provided by Brown Capital Management, LLC, or Brown Capital, and The Brown Capital Management Small Company Fund, or Brown Small Fund and collectively with Brown Capital, the Brown Capital Entities, in a Schedule 13G/A filed on February 14, 2020, reporting as of December 31, 2019. According to this Schedule 13G/A, (i) Brown Capital has sole voting power with respect 12,045,996 of these shares, sole dispositive power with respect to all of these shares, and shared voting power and shared dispositive power with respect to none of these shares, and (ii) Brown Capital Small Fund has sole voting and sole dispositive power with respect to 9,980,218 of these shares and shared voting and shared dispositive power with respect to none of these shares. The address of the Brown Capital Entities is 1201 N. Calvert Street, Baltimore, MD 21202.

(10)  Based upon the information provided by The Vanguard Group, or Vanguard, in a Schedule 13G/A filed on February 12, 2020, reporting as of December 31, 2019. According to this Schedule 13G/A, Vanguard has sole voting power with respect to 322,642 of these shares, sole dispositive power with respect to 16,309,201 of these shares, shared voting power with respect to 24,865 of these shares and shared dispositive power with respect to 329,740 of these shares. The address of Vanguard is 100 Vanguard Blvd., Malvern, PA 19355.

(11)  Based upon the information provided by BlackRock, Inc., or BlackRock, in a Schedule 13G/A filed on February 5, 2020, reporting as of December 31, 2019. According to this Schedule 13G/A, Blackrock has sole voting power with respect to 13,084,463 of these shares, sole dispositive power with respect to all of these shares, and shared voting and shared dispositive power with respect to none of these shares. The address of BlackRock is 55 East 52nd Street, New York, NY 10055.

(12)  Based upon the information provided by Sarissa Capital Management LP, or Sarissa, Alexander J. Denner, Ph.D., Sarissa Capital Offshore Master Fund LP, or Sarissa Capital Offshore, Sarissa Capital Catapult Fund LLC, or Sarissa Capital Catapult, Sarissa Capital Hawkeye Fund LP, or Sarissa Capital Hawkeye, and Sarissa Capital Athena Fund Ltd, or Sarissa Capital Athena and, collectively with Sarissa, Dr. Denner, Sarissa Capital Offshore, Sarissa Capital Catapult and Sarissa Capital Hawkeye, the Sarissa Holders, in a Schedule 13D/A filed on February 26, 2020, reporting as of February 25, 2020. According to this Schedule 13D/A, (i) Sarissa has sole voting and sole dispositive power with respect to 1,357,215 of these shares and shared voting and shared dispositive power with respect to 11,135,785 of these shares, (ii) Dr. Denner has sole voting and sole dispositive power with respect to none of these shares and shared voting and shared dispositive power with respect to all of these shares, (iii) Sarissa Capital Offshore has sole voting and sole dispositive power with respect to 5,682,660 of these shares and shared voting and shared dispositive power with respect to none of these shares, (iv) Sarissa Capital Catapult has sole voting and sole dispositive power with respect to 1,948,655 of these shares and shared voting and shared dispositive power with respect to none of these shares, (v) Sarissa Capital Hawkeye has sole voting and sole dispositive power with respect to 1,465,765 of these shares and shared voting and shared dispositive power with respect to none of these shares, and (vi) Sarissa Capital Athena has sole voting and sole dispositive power with respect to 2,038,705 of these shares and shared voting and shared dispositive power with respect to none of these shares, The address of the Sarissa Holders is c/o Sarissa Capital Management LP, 660 Steamboat Road, Greenwich, CT 06830.

(13)  Based upon the information provided by FMR LLC, or FMR, and Abigail P. Johnson in a Schedule 13G/A filed on February 7, 2020, reporting as of December 31, 2019. According to this Schedule 13G/A, (i) FMR has sole voting power with respect to 2,874,977 of these shares, sole dispositive power with respect to all of these shares, and neither shared voting nor shared dispositive power with respect to these shares, and (ii) Ms. Johnson has neither sole nor shared voting power with respect to these shares, sole dispositive power with respect to all of these shares, and shared dispositive power with respect to none of these shares. The address of FMR and Ms. Johnson is 245 Summer Street, Boston, MA 02210.

(14)  Based upon the information provided by UBS Group AG, or UBS, in a Schedule 13G/A filed on February 12, 2020, reporting as of December 31, 2019. According to this Schedule 13G, UBS has sole voting power with respect to 9,912,172 of these shares, shared dispositive power with respect to all of these shares, and shared voting power and sole dispositive power with respect to none of these shares. The address of UBS is Bahnhofstrasse 45, Zurich, Switzerland.

(15)  Based upon the information provided by Janus Henderson Group PLC, or Janus, in a Schedule 13G filed on February 14, 2020, reporting as of December 31, 2019. According to this Schedule 13G, Janus has sole voting and sole dispositive power with respect to none of these shares and shared voting and shared dispositive power with respect to all of these shares. The address of Janus is c/o Janus Henderson Group plc, 201 Bishopsgate EC2M 3AE, United Kingdom.

2020  Proxy Statement    69


Table of Contents

GRAPHIC
Certain Relationships and
Related Person Transactions

Since January 1, 2019, except as described below, there has not been, nor is there currently proposed, any transaction or series of similar transactions to which we were or are a party in which the amount involved exceeded or exceeds $120,000 and in which any of our directors, executive officers, holders of more than 5% of any class of our voting securities, or any member of the immediate family of any of the foregoing persons, had or will have a direct or indirect material interest, other than compensation arrangements with directors and executive officers, which, with respect to our directors and named executive officers are described under the captionsOur Board of Directors—How We Are Paid andExecutive Compensation appearing elsewhere in this proxy statement.

Indemnification Agreements

We have entered into indemnification agreements with each of our current directors and certain of our officers. These agreements require us to indemnify these individuals to the fullest extent permitted under Delaware law against liabilities that may arise by reason of their service to us, and to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified. We intend to enter into indemnification agreements with our future directors and executive officers.

The Separation

On April 1, 2019, we completed the Separation. The Separation was effected by means of a distribution of all of the outstanding shares of common stock of Cyclerion through a dividend in-kind of Cyclerion's common stock, with no par value, to our stockholders of record as of the close of business on March 19, 2019. In connection with the Separation, we and Cyclerion entered into certain agreements that effected the separation of Cyclerion's business from us and govern our relationship with Cyclerion after the Separation. The following is a summary of the terms of the material agreements that we have entered into with Cyclerion in connection with the Separation. Dr. Hecht, our former chief executive officer, is chief executive officer of Cyclerion and Dr. Currie, our former senior vice president, chief scientific officer and president of R&D, is currently president and chief scientific officer of Cyclerion, as well as a member of our board of directors.

Separation Agreement

In connection with the Separation, Ironwood entered into a separation agreement with Cyclerion, dated as of March 30, 2019, that, among other things, set forth our agreements with Cyclerion regarding the principal actions to be taken in connection with the Separation, including the distribution detailed above. The separation agreement identified assets to be transferred, liabilities to be assumed and contracts to be assigned to each of Ironwood and Cyclerion as part of the Separation, and it provided for when and how these transfers, assumptions and assignments would occur. The separation agreement was intended to provide for those transfers of assets and assumptions of liabilities that were necessary so that after the Separation, Ironwood and Cyclerion would have the assets necessary to operate their respective businesses and retain or assume the liabilities related to those assets. Each of Ironwood and Cyclerion agreed to releases, with respect to pre-distribution claims, and cross indemnities, with respect to post-distribution claims, that, except as otherwise provided in the separation agreement, were principally designed to place financial responsibility for the obligations and liabilities allocated to Ironwood under the separation agreement with Ironwood and financial responsibility for the obligations and liabilities allocated to Cyclerion under the separation agreement with Cyclerion.

70    Ironwood


Table of Contents

GRAPHIC

Ironwood and Cyclerion are also each subject to two-year non-solicit and non-hire restrictions. In addition, the parties agreed to certain non-competition restrictions, including Ironwood's agreement not to engage, for three years following the Separation, in the business of discovering, researching, developing, importing, exporting, manufacturing, marketing, distributing, promoting or selling any pharmaceutical product (a) for the diagnosis, prevention or treatment of diabetic nephropathy, heart failure with preserved ejection fraction or sickle cell disease or (b) that contains one or more sGC stimulators.

Development Agreement

We entered into a development agreement with Cyclerion pursuant to which Cyclerion provides us with certain research and development services with respect to certain of our products and product candidates, including without limitation MD-7246 (linaclotide delayed release) and IW-3718. Such research and development activities are governed by a joint steering committee comprised of representatives from both Cyclerion and Ironwood. We pay Cyclerion fees for such research and development services as mutually agreed upon by us and Cyclerion as provided under this development agreement with certain allowances for specified overages. As of March 31, 2020, we have incurred approximately $5.5 million under this agreement.

Transition Services Agreements

Ironwood Transition Services

Prior to the Separation, we provided Cyclerion with significant corporate and shared services and resources related to corporate functions such as finance, human resources, internal audit, research and development, financial reporting and information technology, which we refer to collectively as the "Ironwood Services." Pursuant to this agreement, each of the Ironwood Services was to continue for an initial term of up to two years (as applicable), unless earlier terminated or extended according to the terms of the transition services agreement. We and Cyclerion agreed to terminate this agreement effective March 31, 2020. We earned approximately $313,000 in total fees for the Ironwood Services under this agreement, which fees were based on our cost of providing the Ironwood Services.

Cyclerion Transition Services

We also entered into a second transition services agreement whereby Cyclerion provided certain finance, procurement and facilities services to us, which we refer to herein collectively as the "Cyclerion Services." Pursuant to this agreement, each of the Cyclerion Services were available to us for a term of one year. We incurred approximately $105,000 in total fees for the Cyclerion Services under this agreement, which fees were based on Cyclerion's cost of providing the Cyclerion Services.

Intellectual Property License Agreement

We entered into an intellectual property license agreement with Cyclerion pursuant to which each party granted a license to the other party to certain know-how. We granted Cyclerion a perpetual, worldwide, non-exclusive, royalty-free, fully paid-up license to certain know-how to allow Cyclerion to use such know-how in connection with Cyclerion's ongoing and future research and development activities related to sGC stimulator products in any field. Cyclerion granted us a perpetual, worldwide, non-exclusive, royalty-free, fully paid-up license to certain know-how for use outside of the research and development of sGC stimulator products, including in our existing products and product candidates. Such licenses between the parties generally allow current or future uses of the know-how in connection with each party's respective fields.

2020  Proxy Statement    71


Table of Contents

GRAPHIC

Tax Matters Agreement

We entered into a tax matters agreement with Cyclerion that governs Ironwood's and Cyclerion's respective rights, responsibilities and obligations with respect to taxes (including taxes arising in the ordinary course of business and taxes, if any, incurred as a result of any failure of the distribution of Cyclerion common stock to Ironwood stockholders and certain related transactions to qualify as tax-free for U.S. federal income tax purposes), tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings and assistance and cooperation in respect of tax matters.

The tax matters agreement imposed certain restrictions on Cyclerion and its subsidiaries (including restrictions on share issuances, business combinations, sales of assets and similar transactions) designed to preserve the tax-free status of the distribution and certain related transactions. The tax matters agreement also provided special rules that allocate tax liabilities in the event the distribution, together with certain related transactions, is not tax-free. In general, under the tax matters agreement, each party is expected to be responsible for any taxes imposed on Ironwood or Cyclerion that arise from the failure of the distribution, together with certain related transactions, to qualify as a transaction that is generally tax-free, for U.S. federal income tax purposes, under Sections 355 and 368(a)(1)(D) and certain other relevant provisions of the Code, to the extent that the failure to so qualify is attributable to an acquisition of stock or assets of, or certain actions, omissions or failures to act of, such party. If both Cyclerion and Ironwood are responsible for such failure, liability will be shared according to relative fault. U.S. tax otherwise resulting from the failure of the distribution, together with certain related transactions, to qualify as a transaction that is tax-free generally is the responsibility of Ironwood.

Employee Matters Agreement

We entered into an employee matters agreement with Cyclerion, which allocated assets, liabilities and responsibilities relating to the employment, compensation, and employee benefits of Ironwood and Cyclerion employees, and other related matters in connection with the Separation, including the treatment of outstanding incentive equity awards and certain retirement and welfare benefit obligations. The employee matters agreement generally provided that, unless otherwise specified, Cyclerion is responsible for liabilities associated with employees who transferred to Cyclerion and employees whose employment terminated prior to the Separation but who primarily supported the Cyclerion business, whether incurred prior to or after the Separation, and Ironwood is responsible for liabilities associated with other employees, including employees retained by Ironwood.

The Private Placement

On February 25, 2019, Cyclerion, which was Ironwood's wholly owned subsidiary at the time, and various investors entered into an amended and restated common stock purchase agreement pursuant to which these investors agreed to make an aggregate cash investment in Cyclerion. These investors included the following, each of whom was either an Ironwood director, an Ironwood executive officer, an immediate family member of an Ironwood director or executive officer, an entity related to such a director, executive officer or immediate family member, or beneficially owned at least 5% of Ironwood's Class A common stock: accounts managed by direct or indirect subsidiaries of FMR LLC, a donor advised fund created by Dr. Hecht, Dr. Currie and certain members of Dr. Hecht's immediate family, including through a trust or donor advised fund. Pursuant to this agreement, accounts managed by direct or indirect subsidiaries of FMR LLC agreed to invest up to $17,500,004, the donor advised fund created by Dr. Hecht agreed to invest up to $34,000,000, Dr. Currie agreed to invest up to $4,000,000 and Dr. Hecht's immediate family agreed to invest up to $6,800,000 in the aggregate. This investment closed on April 2, 2019.

Procedures for Related Party Transactions

Under our code of business conduct and ethics, our employees, officers and directors are discouraged from entering into any transaction that may create or give the appearance of a conflict of interest. In addition, they must report any potential conflict of interest, including related party transactions, to certain members of our management or the chair of our audit committee. Pursuant to its charter, our audit committee must approve any related party transactions, including those transactions involving our directors. In approving or rejecting a proposed transaction, the audit committee considers the relevant facts and circumstances available to and deemed relevant by the audit committee, including the material terms of the transaction, risks, benefits, costs, availability of other comparable services or

72    Ironwood


Table of Contents

GRAPHIC

products and, if applicable, the impact on a director's independence. Our audit committee will approve only those transactions that, in light of known circumstances, are in, or are not inconsistent with, our best interests, as our audit committee determines in the good faith exercise of its discretion. A copy of our code of business conduct and ethics and our audit committee charter are available through the Investors section of our website atwww.ironwoodpharma.com, under the heading Corporate Governance.

2020  Proxy Statement    73


Table of Contents


PROPOSAL NO. 3—AMENDMENT TO OUR
CERTIFICATE OF INCORPORATION TO
DECLASSIFY THE BOARD OF DIRECTORS
GRAPHIC


Our board recommends that you approve the
amendment to our certificate of incorporation
to declassify the board of directors

        Currently, our Eleventh Amended and Restated Certificate of Incorporation, or Certificate of Incorporation, provides for a classified board of directors divided into three classes of directors, with each class elected for a three-year term. The classification of the board of directors results in staggered elections, with each class of directors standing for election every third year. One class consists of members whose terms expire upon the election and qualification of their successors at the 2019 Annual Meeting, or the Class III directors, one class consists of members whose terms expire at the 2020 annual meeting of stockholders, or the Class I directors, and one class consists of members whose terms expire at the 2021 annual meeting of stockholders, or the Class II directors.

        After careful consideration, the board of directors has determined that it is advisable and in the best interests of the company and its stockholders to amend our Certificate of Incorporation to declassify the board of directors to allow our company's stockholders to vote on the election of the entire board of directors on an annual basis, rather than on a staggered basis.

        The general description of the proposed amendment to our Certificate of Incorporation set forth in this Proposal 3 is qualified in its entirety by reference to the text thereof, which is attached as Appendix A to this proxy statement. Additions to our Certificate of Incorporation are indicated by bolded underlined text and deletions are indicated by strikethroughs.

Declassification of the Board of Directors

        If this Proposal 3 is approved by Ironwood's stockholders at the annual meeting, the declassification of the board of directors will be phased in as follows:

    at the 2020 annual meeting of stockholders, the Class I directors will stand for election for a one-year term;

    at the 2021 annual meeting of stockholders, the Class I and Class II directors will stand for election for a one-year term; and

    at the 2022 annual meeting of stockholders, and at each annual meeting of stockholders thereafter, all directors will stand for election for one-year terms.

        Under the proposed amendment, the annual election of directors will be phased in gradually to assure a smooth transition. If this Proposal 3 is approved by the requisite vote of Ironwood's stockholders, any director elected to fill a vacancy that did not arise from an increase in the size of the board of directors will hold office for the term that remains for the applicable vacating director, and any director elected to fill a vacancy that resulted from an increase in the size of the board of directors will be elected to serve until the next annual meeting of stockholders. As required by Delaware law, the amendment also reflects that, once the board of directors is declassified, stockholders may remove directors with or without cause.

        If this Proposal 3 is not approved by the requisite vote of Ironwood's stockholders, the board of directors will remain classified, with each class of directors serving a term expiring at the annual meeting of stockholders held in the third year following the year of their election.


Table of Contents

        If this Proposal 3 is passed by the requisite vote of Ironwood's stockholders, it will become effective when we file the amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware, which we intend to do promptly following the annual meeting.

Considerations of the Board of DirectorsGRAPHIC

        Since our initial public offering, we have had a classified board structure in which directors have been divided into three classes and one class is elected each year to serve a three-year term. The board of directors has historically believed that this classified board structure promotes continuity and stability of strategy, ensures that a potential acquirer in a takeover situation negotiates with the board of directors, and facilitates the ability of the board of directors to focus on creating long-term stockholder value. The board of directors is aware that the current trend in corporate governance is leading away from classified boards in favor of electing all directors annually and also recognizes that a classified board structure may reduce directors' accountability to stockholders because such a structure does not enable stockholders to express a view on each director's performance by means of an annual vote. Moreover, many institutional investors believe that the election of directors is the primary means for stockholders to influence corporate governance policies and to increase accountability for implementing those policies.

        In determining whether to support declassification of the board of directors, the board of directors carefully considered the advantages and disadvantages of the current classified board structure and has determined that it is advisable and in the best interests of Ironwood and its stockholders to declassify the board of directors.

Vote Required

        The approval of this proposal requires a majority of our outstanding common stock as of the record date. Broker nominees do not have discretion to vote on this proposal without your instruction; if you do not instruct your broker nominee how to vote on this proposal, your broker nominee will deliver a broker non-vote. Any shares that are not voted, whether by abstention, broker non-votes, or otherwise, will have the same effect as a vote against this proposal.

THE BOARD RECOMMENDS THAT THE STOCKHOLDERS VOTEFOR THE ADOPTION OF THE PROPOSED AMENDMENT TO OUR CERTIFICATE OF INCORPORATION TO PROVIDE FOR THE ANNUAL ELECTION OF DIRECTORS.


Table of Contents


PROPOSAL NO. 4—APPROVAL OF OUR 2019 EQUITY INCENTIVE PLAN

Our board recommends that you
vote to approve the adoption of our
2019 Equity Incentive Plan.

Proposal No. 3

        We are asking stockholders to approve the Ironwood Pharmaceuticals, Inc. 2019 Equity Incentive Plan, or the 2019 Plan. Our board of directors, upon the recommendation of the compensation and HR committee, approved the 2019 Plan, subject to stockholder approval, to replace our Amended and Restated 2010 Employee, Director and Consultant Equity Incentive Plan, or the 2010 Plan, on the date the 2019 Plan is approved by our stockholders, or the Effective Date. Upon the Effective Date, we will no longer make grants under the 2010 Plan. The material features of the 2019 Plan are described underSummary of the 2019 Plan below.

        We believe that the 2019 Plan will advance the interests of our stockholders and is consistent with principles of good corporate governance, including the following:

    Removal of Evergreen Provision.  The 2019 Plan does not continue the "evergreen" feature of the 2010 Plan, which provides for an annual increase to the number of shares available under the plan based on a pre-determined formula.

    Limits on Share Recycling.  Shares underlying awards issued under the 2019 Plan will not be recycled into the share pool if they are surrendered in satisfaction of tax withholding obligations or the exercise, base or purchase price of an award. In addition, shares underlying stock appreciation rights, or SARs, any portion of which are settled in shares, and shares underlying awards that are settled in cash, expire, become exercisable, terminate, or are forfeited to or repurchased by the company will not be recycled into the share pool.

    Limitations on Awards.  The 2019 Plan limits the number of stock options, SARs and other stock-based awards that may be granted to plan participants each calendar year. The 2019 Plan also limits the total compensation that may be granted or paid, as applicable, to non-employee directors during any calendar year.

    No Discounted Stock Options or SARs.  All stock options and SARs granted under the 2019 Plan must have an exercise price that is not less than the fair market value of a share of our common stock on the date of grant.

    No Repricing.  Other than in connection with certain corporate transactions or changes to our corporate structure, the 2019 Plan prohibits the repricing of stock options or SARs without obtaining stockholder approval.

    Dividends and Dividend Equivalents.  Dividends and dividend equivalents on stock-based awards other than stock options or SARs will be subject to service- or performance-based risks of forfeiture and are subject to the same risk of forfeiture as the underlying awards. Dividend equivalents granted under the 2019 Plan will not be paid on stock options or SARs.

Reasons for Seeking Stockholder Approval

        Our board of directors believes that our company's success and long-term progress are dependent upon attracting and incentivizing qualified individuals who can serve as directors, officers, employees, consultants, and advisers, and aligning the interests of such individuals with those of our stockholders. Our board of directors approved the 2019 Plan because it believes that this plan gives us the flexibility to continue to use various forms of incentive awards, including stock options and restricted stock units, as part of our company's overall compensation programs.


Table of Contents

        With input from Pearl Meyer & Partners, LLC, or PM, the independent compensation consultant to the compensation and HR committee, our board of directors determined the number of shares that should be available under the 2019 Plan so that we may continue to grant equity awards in line with our historical practices for approximately two to three years.

        In setting the size of the share pool under the 2019 Plan at 10,000,000 shares, which is smaller than the share pool remaining available to grant under the 2010 Plan, our board of directors considered the historical amounts of equity awards granted by the company in the last three years, the total number of shares of our common stock underlying equity awards outstanding as of December 31, 2018, as further shown in the chart below, and the expected number of eligible plan participants following the Seperation. Based on an analysis by PM of the remaining shares available under the 2010 Plan (which was 10,692,400 as of April 2, 2019), the number of shares of our common stock underlying equity awards outstanding under the 2010 Plan, our historic and projected burn rate, current and proposed plan features, including the elimination of the evergreen feature that was included in our 2010 Plan, the equity plan guidelines established by proxy advisory firms and the impact of the Separation, the board of directors approved the 2019 Plan and the share pool authorized under it to ensure that we continue to have the ability to provide competitive levels of equity compensation.

        If the 2019 Plan is not approved by our stockholders, the 2019 Plan will not become effective, the 2010 Plan will expire on December 17, 2019, and we will no longer be able to grant equity awards to our employees and other service providers following such date. We believe that the inability to grant equity awards will materially affect our ability to attract and retain key talent. We also believe that the terms of the 2019 Plan, including its share pool, are reasonable, appropriate, and in the best interests of our stockholders.

Existing Equity Plan Information

        The table below sets forth information with regard to securities authorized for issuance under our equity compensation plans as of December 31, 2018, and reflects the conversion of our Class B common stock to Class A common stock, which was effective December 31, 2018. As of December 31, 2018, we had two active equity compensation plans, both of which were approved by our stockholders:

    Our 2010 Plan; and

    Our Amended and Restated 2010 Employee Stock Purchase Plan.

        In addition, although we no longer grant awards under our Amended and Restated 2005 Stock Incentive Plan, there remain awards outstanding that were granted under this plan.

Plan category
 Number of securities to
be issued upon exercise
of outstanding options,
warrants and rights(1)
 Weighted-average
exercise price of
outstanding options,
warrants and rights(2)
 Number of securities
remaining available for
future issuance under equity
compensation plans
(excluding securities
reflected in column (a))
 
 
 (a)
 (b)
 (c)
 

Equity compensation plans approved by security holders

  23,515,345 $13.47  16,712,852 

Equity compensation plans not approved by security holders

       

Total

  23,515,345 $13.47  16,712,852 

(1)
Amount includes the number of shares subject to issuance upon exercise of 20,457,537 outstanding stock options and vesting of 3,057,808 RSUs.

Table of Contents

(2)
Amount includes all outstanding stock options but does not include RSUs, which do not have an exercise price.

Summary of the 2019 Plan

        The following is a brief summary of the material features of the 2019 Plan. A copy of the 2019 Plan is attached as Appendix B to this proxy statement, and we urge stockholders to read it in its entirety. The following summary is qualified in its entirety by reference to the full text of the 2019 Plan.

        Purpose.    The purpose of the 2019 Plan is to advance the interests of the company by providing for the grant to participants of stock, stock-based and other incentive awards, all as more fully described below.

        Administration.    The 2019 Plan is administered by our compensation and HR committee, which has the discretionary authority to, among other things, interpret the 2019 Plan, determine eligibility for and grant awards, determine, modify or waive the terms and conditions of any award, determine the form of settlement of awards, prescribe forms, rules and procedures relating to the 2019 Plan and awards and otherwise do all things necessary or desirable to carry out the purposes of the 2019 Plan. Determinations of the compensation and HR committee under the 2019 Plan will be conclusive and bind all persons. The compensation and HR committee may delegate certain of its powers under the 2019 Plan to, among others, one or more of its members or members of our board of directors. As used herein, the term compensation and HR committee refers to our compensation and HR committee or its authorized delegates, as applicable.

        Eligibility.    Employees, directors of and consultants and advisors to the company and its subsidiaries are eligible to participate in the 2019 Plan. Eligibility for stock options intended to be incentive stock options, or ISOs, is limited to employees of the company or certain affiliates. As of April 2, 2019, we estimate that approximately 331 employees and 8 non-employee directors would be eligible to participate in the 2019 Plan.

        Authorized Shares.    Subject to adjustment as described below, the maximum number of shares of our common stock that may be delivered in satisfaction of awards under the 2019 Plan is 10,000,000 shares, plus any shares that are subject to awards under the company's Amended and Restated 2005 Stock Incentive Plan or the company's Amended and Restated 2010 Employee, Director and Consultant Equity Incentive Plan that are forfeited, expired or are cancelled without the delivery of shares of stock, or the Share Pool. The following rules apply in respect of the Share Pool:

    All shares underlying a stock appreciation right, any portion of which is settled in shares of our common stock, will reduce the Share Pool.

    All shares withheld in payment of the exercise price or purchase price of an award or in satisfaction of tax withholding obligations will reduce the Share Pool.

    Shares underlying awards that are settled in cash will reduce the Share Pool.

    Shares underlying award issued under the 2019 Plan that expire, become unexercisable, or terminate or that are forfeited to or repurchased by the company without the issuance of Stock will reduce the Share Pool.

    Shares delivered under awards granted in substitution for awards of an acquired company that are converted, replaced or adjusted in connection with the acquisition, or Substitute Awards, will not reduce the Share Pool.

    The Share Pool will not be increased by any shares of stock delivered under the 2019 Plan that are subsequently repurchased using proceeds directly attributable to stock option exercises.

Table of Contents

Shares that may be delivered under the 2019 Plan may either be (i) authorized but unissued shares of common stock or (ii) previously issued shares of common stock acquired by the company. The closing price of our common stock as reported on the Nasdaq Market on April 2, 2019 was $12.31 per share.

    ��   Individual Limits.    With respect to any person in any calendar year, the maximum number of shares for which stock options may be granted, the maximum number of shares subject to SARs that may be granted, and the maximum number of shares subject to awards other than stock options, SARs and awards that may be paid or settled in cash that may be granted is, in each case, 2,000,000 shares.

        Director Limits.    The aggregate value of all compensation granted or paid to any non-employee director with respect to any calendar year, including awards under the 2019 Plan and other compensation paid by the company for the director's service to our board of directors, may not exceed $600,000.

        Types of Awards.    The 2019 Plan provides for the grant of stock options, SARs, restricted and unrestricted stock and stock units, performance awards, and other awards that are convertible into or otherwise based on our common stock. Dividend equivalents may also be provided in connection with awards under the 2019 Plan.

    Stock Options and SARs.  Our compensation and HR committee may grant stock options, including ISOs, and SARs. A stock option is a right entitling the holder to acquire shares of our common stock upon payment of the applicable exercise price. A SAR is a right entitling the holder upon exercise to receive an amount (payable in cash or shares of equivalent value) equal to the excess of the fair market value of the shares subject to the right over the base value from which appreciation is measured. The exercise price of each stock option, and the base value of each SAR, granted under the 2019 Plan may not be less than 100% of the fair market value of the shares of our common stock subject to such stock option or SAR on the date of grant (or 110% in the case of certain ISOs). Each stock option and SAR will have a maximum term that does not exceed ten years from the date of grant (or five years, in the case of certain ISOs).

    Restricted and Unrestricted Stock and Stock Units.  Our compensation and HR committee may grant awards of stock, stock units, restricted stock and restricted stock units. A stock unit is an unfunded and unsecured promise, denominated in shares, to deliver shares or cash measured by the value of shares in the future, and a restricted stock unit is a stock unit that is subject to the satisfaction of specified performance or other vesting conditions. Restricted stock is stock subject to restrictions requiring that it be redelivered or offered for sale to us if specified service- or performance-based conditions are not satisfied.

    Performance Awards.  Our compensation and HR committee may grant performance awards, which are awards subject to performance criteria.

    Other Stock- and Cash-Based Awards.  Our compensation and HR committee may grant other incentives payable in cash or in shares of our common stock, subject to such terms and conditions as are determined by our compensation and HR committee.

    Substitute Awards.  Our compensation and HR committee may grant Substitute Awards, which may have terms and conditions that are inconsistent with the terms and conditions of the 2019 Plan.

        Vesting; Terms of Awards.    Our compensation and HR committee determines the terms of all awards granted under the 2019 Plan, including the time or times when an award vests or becomes exercisable, the terms on which awards will remain exercisable and the effect of termination of a participant's employment or service on outstanding awards. Our compensation and HR committee may at any time accelerate the vesting or exercisability of an award.


Table of Contents

        No Repricing.    Other than in connection with certain corporate transactions or changes to our capital structure, stock options and SARs granted under the 2019 Plan may not be amended to reduce the exercise price or base value of the stock option or SAR, cancelled and exchanged for stock options or SARs with an exercise price or base value that is less than the exercise price or base value of the original stock option or SAR, or cancelled when the exercise price or base value of the stock option or SAR is greater than the fair market value of a share of our common stock on the date of such cancellation in exchange for cash or other consideration, in each case, without stockholder approval.

        Transferability of Awards.    Except as our compensation and HR committee may otherwise determine, awards may not be transferred other than by will or by the laws of descent and distribution.

        Performance Criteria.    The 2019 Plan provides for grants of performance awards subject to "performance criteria," which may relate to any, or any combination of, the following (measured either absolutely or comparatively (including, without limitation, by reference to an index or indices or the performance of one or more companies) and determined either on a consolidated basis or, as the context permits, on a divisional, subsidiary, line of business, project or geographical basis or in combinations thereof), among any other criteria determined by our compensation and HR committee: achievement of research, clinical trial or other drug development objectives; achievement of regulatory objectives; achievement of manufacturing and/or supply chain or other operational objectives; sales; revenues; assets; expenses; earnings before or after deduction for all or any portion of interest, taxes, depreciation, or amortization, whether or not on a continuing operations or an aggregate or per share basis; return on equity, investment, capital or assets; one or more operating ratios; borrowing levels, leverage ratios or credit rating; market share; capital expenditures; cash flow; stock price; stockholder return; sales of particular products or services; customer acquisition or retention; acquisitions and divestitures (in whole or in part); joint ventures, licenses, collaborations and strategic alliances; spin-offs, split-ups and the like; reorganizations; recapitalizations, restructurings, financings (issuance of debt or equity) or refinancings; or any other objectives determined by our compensation and HR committee. Performance criteria and any related targets need not be based on an increase, a positive or improved result or avoidance of loss. Our compensation and HR committee may provide that one or more of the "performance criteria" specified above will be adjusted to reflect events (including, but not limited to, the impact of charges for restructurings, discontinued operations, mergers, acquisitions, extraordinary items, and other unusual or non-recurring items, and the cumulative effects of tax or accounting changes, each as defined by U.S. generally accepted accounting principles) occurring during the applicable performance period that affect the applicable performance criterion or criteria.

        Effect of Certain Transactions.    In the event of a consolidation, merger or similar transaction in which the company is not the surviving corporation, the sale of all or substantially all of the company's assets or common stock, or a dissolution or liquidation of the company, our compensation and HR committee may, with respect to outstanding awards, provide for:

    The assumption, continuation or substitution of some or all awards or any portion thereof by the acquirer or surviving entity;

    The cash payment in respect of some or all awards or any portion thereof equal to the difference between the fair market value of the shares subject to the award and its exercise or purchase price, if any, on such terms and conditions as our compensation and HR committee determines; and/or

    The acceleration of exercisability or delivery of shares in respect of some or all awards or any portion thereof.

        In the case of shares of restricted stock, our compensation and HR committee may require that any amounts delivered, exchanged or otherwise paid in respect of those shares in connection with the


Table of Contents

transaction be placed in escrow or otherwise made subject to restrictions determined by our compensation and HR committee.

        Adjustment Provisions.    In the event of a stock dividend, stock split or combination of shares (including a reverse stock split), recapitalization or other change in our capital structure, our compensation and HR committee will make appropriate adjustments to the maximum number of shares that may be delivered under the 2019 Plan; the individual award limits; the number and kind of securities subject to, and, if applicable, the exercise or purchase price of, outstanding awards; and any other provisions affected by such event.

        Clawback.    Our compensation and HR committee may provide that outstanding awards and proceeds from the disposition of awards or stock acquired under awards will be subject to forfeiture and disgorgement to the company, with interest and other related earnings, if the participant violates any restrictive covenants by which the participant is bound or any applicable company policy that provides for such forfeiture or disgorgement, or to the extent required by law or applicable stock exchange listing standards and any related company policy.

        Effective Date, Amendments and Termination.    Our board of directors adopted the 2019 Plan on April 10, 2019, subject to approval by our stockholders. If the 2019 Plan is approved by our stockholders, the 2019 Plan will become effective as of the date of such approval. No awards will be granted after the tenth anniversary of the date the 2019 Plan was adopted by our board of directors. Our compensation and HR committee may at any time amend the 2019 Plan or any outstanding award and may at any time terminate the 2019 Plan as to future grants. However, except as expressly provided in the 2019 Plan, our compensation and HR committee may not alter the terms of an award so as to materially and adversely affect a participant's rights without the participant's consent (unless our compensation and HR committee expressly reserved the right to do so at the time the award was granted). Any amendments to the 2019 Plan will be conditioned on stockholder approval to the extent required by law or applicable stock exchange requirements.

Certain Federal Income Tax Consequences

        The following discussion summarizes certain federal income tax consequences associated with certain awards granted under the 2019 Plan under the law as in effect on the date of this proxy statement. The summary does not purport to cover federal employment tax or other U.S. federal tax consequences that may be associated with the 2019 Plan, nor does it cover state, local or non-U.S. taxes.

        ISOs.    In general, an optionee realizes no taxable income upon the grant or exercise of an ISO. However, the exercise of an ISO may result in an alternative minimum tax liability to the optionee. With certain exceptions, a disposition of shares purchased under an ISO within two years from the date of grant or within one year after exercise produces ordinary income to the optionee (and a deduction to company) equal to the value of the shares at the time of exercise less the exercise price. Any additional gain recognized in the disposition is treated as a capital gain for which company is not entitled to a deduction. If the optionee does not dispose of the shares until after the expiration of these one- and two-year holding periods, any gain or loss recognized upon a subsequent sale is treated as a long-term capital gain or loss for which the company is not entitled to a deduction.

        NSOs.    In general, in the case of an NSO, the optionee has no taxable income at the time of grant but realizes income in connection with the exercise of the option in an amount equal to the excess (at the time of exercise) of the fair market value of the shares acquired upon exercise over the exercise price; a corresponding deduction is available to the company. Upon a subsequent sale or exchange of the shares, any recognized gain or loss after the date of exercise is treated as a capital gain or loss for which the company is not entitled to a deduction.


Table of Contents

        In general, an ISO that is exercised by the optionee more than three months after termination of employment is treated as an NSO. ISOs are also treated as NSOs to the extent they first become exercisable by an individual in any calendar year for shares having a fair market value (determined as of the date of grant) in excess of $100,000.

        SARs.    In general, the grant of a SAR does not itself result in taxable income, nor does taxable income result merely because a SAR becomes exercisable. In general, a participant who exercises a SAR for shares of stock or receives payment in cancellation of a SAR will have ordinary income equal to the amount of any cash and the fair market value of any stock received. A corresponding deduction is generally available to the company.

        Unrestricted Stock Awards.    A participant who purchases or is awarded unrestricted stock generally has ordinary income equal to the excess of the fair market value of the shares at that time over the purchase price, if any, and a corresponding deduction is generally available to the company.

        Restricted Stock Awards.    A participant who is awarded or purchases shares subject to a substantial risk of forfeiture generally does not have income until the risk of forfeiture lapses. When the risk of forfeiture lapses, the participant has ordinary income equal to the excess of the fair market value of the shares at that time over the purchase price, if any, and a corresponding deduction is generally available to the company. However, a participant may make an election under Section 83(b) of the Code to be taxed on restricted stock when it is acquired rather than later, when the substantial risk of forfeiture lapses. A participant who makes an effective 83(b) election will realize ordinary income equal to the fair market value of the shares as of the time of acquisition less any price paid for the shares. A corresponding deduction will generally be available to the company. If a participant makes an effective 83(b) election, no additional income results by reason of the lapsing of the restrictions.

        For purposes of determining capital gain or loss on a sale of shares awarded under the 2019 Plan, the holding period in the shares begins when the participant recognizes taxable income with respect to the transfer. The participant's tax basis in the shares equals the amount paid for the shares plus any income realized with respect to the transfer. However, if a participant makes an effective 83(b) election and later forfeits the shares, the tax loss realized as a result of the forfeiture is limited to the excess of what the participant paid for the shares (if anything) over the amount (if any) realized in connection with the forfeiture.

        Restricted Stock Units.    In general, the grant of a restricted stock unit does not itself result in taxable income. Instead, the participant is generally taxed upon vesting (and a corresponding deduction is generally available to the company), unless he or she has made a proper election to defer receipt of the shares (or cash if the award is cash settled) under Section 409A of the Code. If the shares delivered are restricted for tax purposes, the participant will instead be subject to the rules described above for restricted stock.

        Certain Change in Control Payments.    Under Section 280G of the Code, the vesting or accelerated exercisability of options or the vesting and payments of other awards in connection with a change in control of a corporation may be required to be valued and taken into account in determining whether participants have received compensatory payments, contingent on the change in control, in excess of certain limits. If these limits are exceeded, a substantial portion of amounts payable to the participant, including income recognized by reason of the grant, vesting or exercise of awards may be subject to an additional 20% federal tax and may be non-deductible to the company.

New Plan Benefits

        The future benefits or amounts that would be received under the 2019 Plan by executive officers, non-executive directors and non-executive officer employees are discretionary and are therefore not determinable at this time.


Table of Contents

Vote Required

        The approval of this proposal requires a majority of the votes cast for or against the proposal. Abstentions and broker non-votes will not affect the outcome of this proposal. Broker nominees do not have discretion to vote on this proposal without your instruction; if you do not instruct your broker nominee how to vote on this proposal, your broker nominee will deliver a broker non-vote. Any shares that are not voted, whether by abstention, broker non-votes, or otherwise, will not affect the outcome of this proposal.


Table of Contents


PROPOSAL NO. 5—RATIFICATION OF OUR SELECTION OF AUDITORS

Our board recommends that you ratify the selection of
Ernst & Young LLP as our auditors for fiscal year 2019.

Our audit committee has appointed Ernst & Young LLP to serve as our auditors for the fiscal year ending December 31, 2019.2020. The firm of Ernst & Young LLP, an independent registered public accounting firm, has audited the books and accounts of Ironwood since 1998 and has audited our financial statements for the years ended December 31, 2019, 2018 2017 and 2016.2017. Detailed disclosure of the audit, audit-related, tax and other fees we paid to Ernst & Young LLP in 20182019 and 20172018 are set forth below. Based on these disclosures and information in the audit committee report beginning on page 2217 of this proxy statement, our audit committee is satisfied that our auditors are sufficiently independent of management to perform their duties properly. Although not legally required to do so, our board of directors considers it desirable to seek, and recommends, stockholder ratification of its selection of auditors for fiscal year 2019.2020.

Representatives of Ernst & Young LLP are expected to attend the virtual annual meeting to answer any questions and they will have the opportunity to make a statement if they wish.

The table below presents aggregate fees for professional audit services rendered by Ernst & Young LLP for the years ended December 31, 20182019 and 20172018 for the audits of our annual financial statements, and fees billed for other services rendered by Ernst & Young LLP during those periods. It is the audit committee's policy that all audit and non-audit services to be performed by Ernst & Young LLP be pre-approved. The audit committee annually reviews and pre-approves the permissible services that may be provided by Ernst & Young LLP to assure the provision of such services does not impair the auditor's independence. In accordance with the pre-approval policy, our management informs the audit committee of each service performed by Ernst & Young LLP pursuant to the pre-approval policy. Requests to provide services that require separate approval by the audit committee are submitted to the audit committee or its designee by both our chief financial officer or chief accounting officer and Ernst & Young LLP. All of the services described in the following fee table were approved in conformity with the audit committee's pre-approval policy.


 2018 2017  2019 2018
 

Audit

 $994,154 $1,027,904  $1,840,900 $994,154 

Audit-related

 $1,564,161 $65,000  $ $1,564,161 

Tax

 $ $  $ $ 

All other

 $6,910 $307,700  $1,735 $6,910 
 $1,842,635 $2,565,225 

 $2,565,225 $1,400,604 

Audit fees for 20182019 and 20172018 were for professional services rendered for the audits of our financial statements and internal controls over financial reporting, including accounting consultation, and reviews of quarterly financial statements, as well as for services that are normally provided in connection with regulatory filings or engagements, including auditor consents. Audit fees for 2019 were significantly higher than they were in 2018 due to services provided in connection with the Separation, including the review and/or audit of discontinued operations, as well as accounting review of certain collaboration and co-promotion agreements and debt-related transactions.

Audit-related fees for 2018 were principally comprised of services provided in connection with the Separation, including the review and/or audit of Cyclerion carveoutcarve-out financial statements. Audit-related fees for 2018 and 2017 includedstatements, as well as accounting consultations associated with the anticipated adoption of new accounting standards. All audit-related fees were approved by the audit committee.

Other services includedin 2019 and 2018 include license fees for a web-based accounting research tool in 2018 and due diligence activities performed during 2017. All other fees were approved by the audit committee.


Table of Contentstool.

Other than the foregoing, Ernst & Young LLP did not provide any other services to us in 20182019 or 2017.2018.

Vote Required

The approval of the proposal to ratify the selection of Ernst & Young LLP as our auditors requires a majority of the votes cast for or against the proposal. Because we believe this matter to be routine, a broker nominee may vote on your behalf if you do not otherwise provide instructions. As a result, we do not expect there will be any broker non-votes on this matter. Abstentions will not affect the outcome of this proposal.

2020  Proxy Statement    75



SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Table of Contents

GRAPHIC
User's Guide

Our board of directors executive officersis soliciting proxies for the 2020 annual meeting of stockholders. This proxy statement explains the agenda, voting information and procedures for the meeting. Please read it carefully. This proxy statement and related materials are first being made available to stockholders on or about April 21, 2020, and the notice of internet availability of proxy materials is first being sent to our stockholders on the same day. All stockholders will also have the ability to access the proxy materials online through the Investors section of our website atwww.ironwoodpharma.com, under the heading Featured Reports.

Who can vote

Only stockholders of record of our Class A common stock at the close of business on April 13, 2020 can vote at the meeting.

Quorum

In order to hold and complete the business of the annual meeting, we must have a majority of the votes entitled to be cast represented at the meeting or by proxy. On our record date, April 13, 2020, we had 159,374,029 shares of our Class A common stock outstanding and entitled to vote. With respect to all matters that will come before the meeting, each share is entitled to one vote.

Notice of internet availability of proxy materials

Pursuant to rules adopted by the SEC, we have elected to provide access to our proxy materials via the internet. Accordingly, we are sending a notice of internet availability of proxy materials to our stockholders. All stockholders will have the ability to access the proxy materials on the website referenced in the notice and to request to receive a printed set of the proxy materials by mail. Instructions on how to access the proxy materials over the internet and how to request a printed copy may be found in the notice. In addition, stockholders may request to receive proxy materials in printed form by mail or electronically by email on an ongoing basis. We encourage stockholders to take advantage of the availability of the proxy materials on the internet or through email to help reduce the environmental impact of our annual meetings.

Voting procedures—stockholders of record and beneficial owners

You are a stockholder of record if your shares of our stock are registered directly in your own name with our transfer agent, Computershare Trust Company, N.A., or Computershare. You are a beneficial owner if a brokerage firm, bank, trustee or other agent, called a "nominee," holds your stock. This is often called ownership in "street name" because your name does not appear in the records of Computershare. If you hold your shares in street name, you should receive a voting instruction form from your broker nominee.

How to vote your shares.

If you are a stockholder of record, there are four ways to vote:

    Online Before the Meeting.  You may vote by proxy via the internet by following the instructions provided on the notice of internet availability of proxy materials or the proxy card. You must have the 16-digit control number that is on either the notice of internet availability of proxy materials or the proxy card when voting.

76    Ironwood


Table of Contents

GRAPHIC
    Online During the Meeting.  You may vote online during the annual meeting through the linkwww.virtualshareholdermeeting.com/IRWD2020. The 16-digit control number provided on your notice of internet availability of proxy materials or proxy card is necessary to access the website. The meeting will begin at 9:00 a.m. Eastern Time (with check-in beginning at 8:45 a.m. Eastern Time) on Wednesday, June 3, 2020.

    By Telephone.  If you request printed copies of the proxy materials by mail and you live in the United States or Canada, you may vote by proxy by calling the toll-free number found on the proxy card. You must have the control number that is on the proxy card when voting.

    By Mail.  If you request printed copies of the proxy materials by mail, you may vote by proxy by filling out the proxy card and sending it back in the envelope provided.

If you are a beneficial owner of shares held in street name, there are four ways to provide voting instructions:

    Online Before the Meeting.  You may provide voting instructions via the internet by following the instructions provided on your voting instruction form. You must have the 16-digit control number that is on the voting instruction form when voting.

    Online During the Meeting.  You may vote online during the annual meeting through the linkwww.virtualshareholdermeeting.com/IRWD2020. The 16-digit control number provided on your voting instruction form is necessary to access the website. The meeting will begin at 9:00 a.m. Eastern Time (with check-in beginning at 8:45 a.m. Eastern Time) on Wednesday, June 3, 2020.

    By Telephone.  You may provide voting instructions by calling the toll-free number found on your voting instruction form. You must have the control number that is on the voting instruction form when voting.

    By Mail.  You may provide voting instructions by filling out the voting instruction form and sending it back in the envelope provided.

How you may revoke your proxy or voting instructions.    If you are a stockholder of record, you may revoke or amend your proxy before it is voted at the annual meeting by writing to us directly in a timely manner "revoking" your earlier proxy, submitting a new proxy in a timely manner with a later date by mail, over the telephone or on the internet, or by attending the meeting and voting. Your last dated proxy timely received prior to or vote cast at the annual meeting will be counted.

What if you receive more than 10%one notice of internet availability of proxy materials, proxy card or voting instruction form?    This means that you may have more than one account at Computershare and/or with a nominee. Your notice of internet availability of proxy materials, proxy card or voting instruction form lists the number of shares you are voting. Please vote the shares on all notices of internet availability of proxy materials, proxy cards and voting instruction forms that you receive.

We recommend you consolidate your holdings under the same name, address and tax identification number, if possible. This will eliminate some duplication of mailings and reduce costs. Please contact your nominee to consolidate accounts, or our transfer agent, Computershare, at (800) 368-5948, as applicable.

2020  Proxy Statement    77


Table of Contents

GRAPHIC

Abstentions and "broker non-votes." If you are a stockholder of record and you vote "abstain" or "withhold" on any matter, your shares will not be voted on that matter and will not be counted as votes cast in the final tally of votes on that matter. However, your shares will be counted for purposes of determining whether a quorum is present. If you are a beneficial owner holding shares through a broker nominee, you may instruct your broker nominee that you wish to abstain from voting on a proposal or withhold authority to vote for one or more nominees for director.

A broker nominee generally may not vote on "non-routine" matters without receiving your specific voting instructions. A "broker non-vote" occurs when a broker nominee holding shares in street name votes shares on some matters at the meeting but not others. Like abstentions, broker non-votes are counted as present and entitled to vote for quorum purposes, but are not counted as votes cast. At the annual meeting, your broker nominee will not be able to submit a vote on the election of directors or the advisory votes on named executive officer compensation unless it receives your specific instructions. If your broker nominee does not receive your specific instructions for these proposals, it will submit a broker non-vote. The broker nominee will, however, be able to vote on the ratification of the selection of our common stockindependent auditors even if it does not receive your instructions, so we do not expect any broker non-votes will exist in connection with such proposal.

Discretionary authority.    If you are required under Section 16(a)a stockholder of record and you properly submit your proxy card without making any specific selections, your shares will be voted on each matter before the annual meeting in the manner recommended by our board of directors. If other matters not included in this proxy statement properly come before the annual meeting, the persons named on the proxy card, or otherwise designated, will have the authority to vote on those matters for you as they determine, to the extent permitted by Rule 14a-4(c)(1) of the Exchange ActAct. If you are a beneficial owner of shares held in street name, please see the discussion above regarding broker non-votes and the rules related to voting by broker nominees.

Vote required

The required vote for each of the proposals expected to be acted upon at the annual meeting is described below.

Proposal No. 1—Election of Class I Directors:
the three nominees for director with the highest number of affirmative votes will be elected as directors to serve for one-year terms and until their successors are duly elected and qualified or until their death, resignation or removal. Because there is no minimum vote required, abstentions and broker non-votes will not affect the outcome of this proposal.

Proposal No. 2—Advisory (non-binding) Vote on Named Executive Officer Compensation, or "Say-on-Pay":
because this proposal calls for a non-binding, advisory vote there is no "required vote" that would constitute approval. However, our board of directors, including our compensation and HR committee, values the opinions of our stockholders and, to the extent there are a substantial number of votes cast against the named executive officer compensation disclosed in this proxy statement, we will consider our stockholders' concerns and evaluate what actions may be appropriate to address those concerns. Broker nominees do not have discretion to vote on this proposal without your instruction; if you do not instruct your broker nominee how to vote on this proposal, your broker nominee will deliver a broker non-vote. Any shares that are not voted, whether by abstention, broker non-votes or otherwise, will not affect the outcome of this proposal.

Proposal No. 3—Ratification of Auditors:
the approval of this proposal requires a majority of the votes cast for or against the proposal. Abstentions and broker non-votes will not affect the outcome of this proposal. Further, because we believe this matter to be routine, a broker nominee may vote on your behalf if you do not otherwise provide instructions. As a result, we do not expect there will be any broker non-votes on this matter.

Results of the voting.    We expect to announce the preliminary voting results at the annual meeting. The final voting results will be tallied by the inspector of election and published in a Current Report on Form 8-K, which we are required to file reportswith the SEC, within four business days following the annual meeting.

78    Ironwood


Table of ownershipContents

GRAPHIC

Costs of solicitation and changessolicitation participants.    We will pay the costs of soliciting proxies. These costs also include support for the hosting of the virtual meeting. We will solicit proxies by email from stockholders who are our employees or who previously requested to receive proxy materials electronically. Our directors, our officers and our employees also may solicit proxies on our behalf, personally, electronically or by telephone, facsimile or mail or other means, without additional compensation. We may request that brokerage firms, banks and other agents forward proxy materials to beneficial owners and we would reimburse such institutions for their out-of-pocket expenses incurred.

We may also utilize the assistance of third parties in ownershipconnection with our proxy solicitation efforts, and we would compensate such third parties for their efforts. We have engaged one such third party, MacKenzie Partners, to assist in the solicitation of proxies and provide related advice and informational support, for service fees of up to $20,000 and the reimbursement of certain expenses.

Additional Meeting Information

We encourage you to access the meeting prior to the start time. Please allow sufficient time for online check-in, which begins at 8:45 a.m. Eastern Time. You may check your browser's compatibility any time prior to the meeting atwww.virtualshareholdermeeting.com/IRWD2020.

If you have technical difficulties or trouble accessing the virtual meeting, there will be technicians ready to assist you. If you encounter any technical difficulties accessing the virtual meeting during the check-in or meeting time, please call the technical support number that will be posted on the virtual shareholder meeting log in page.

If you want to submit a question you may do so electronically starting at the time of check-in or during the meeting. We will post any appropriate questions received during the meeting and our answers in the Investors section of our securities withwebsite atwww.ironwoodpharma.com as soon as practical after the SEC. Our staff assists our directors and executive officers in preparing ownership reports and reporting ownership changes, and typically files these reports on their behalf. Based on a review of the copies of reports filed by us or by our 10% stockholders and representations that no other reports were required, we believe that during 2018 our directors, executive officers and 10% stockholders complied with all Section 16(a) filing requirements.meeting.

2020  Proxy Statement    79



STOCKHOLDER COMMUNICATIONS, PROPOSALS AND NOMINATIONS FOR DIRECTORSHIPS
Table of Contents

CommunicationsGRAPHIC
Stockholder Communications, Proposals and Nominations for Directorships

Communications

A stockholder may send general communications to our board of directors, any committee of our board of directors or any individual director by directing such communication to General Counsel, Ironwood Pharmaceuticals, Inc., 301 Binney100 Summer Street, Cambridge,Suite 2300, Boston, Massachusetts 02142.02110. All communications will be reviewed by our general counsel and, if requested by the stockholder, forwarded to our board of directors or an individual director, as applicable. Our general counsel reserves the right not to forward to our board of directors or any individual director any abusive, threatening or otherwise inappropriate materials.

Any request for materials or other communications directed to our Secretarysecretary should be sent to: Secretary, Ironwood Pharmaceuticals, Inc., 301 Binney100 Summer Street, Cambridge,Suite 2300, Boston, Massachusetts 02142.02110.

Proposals and Nominations

Proposals and Nominations

Stockholders who wish to present a proposal for inclusion in our proxy materials for our 20202021 annual meeting should follow the procedures prescribed in Rule 14a-8 under the Exchange Act and our bylaws. Those procedures require that we receive a stockholder proposal in writing no later than December 28, 201922, 2020 in order for such proposal to be included in our proxy materials.

Under our bylaws, stockholders who wish to nominate a director or include a proposal in our 20202021 annual meeting of stockholders (but do not wish to include such proposal in our proxy materials) must give us timely notice. To be timely, a notice of director nomination or other proposal for the 20202021 annual meeting of stockholders must be received by us no earlier than March 1, 20205, 2021 and no later than March 31, 2020,April 4, 2021, unless the date of the 20202021 annual meeting of stockholders is more than 30 days from the anniversary date of the 20192020 annual meeting of stockholders, in which event the notice must be received by us on or before 15 days after the day on which the date of the 20202021 annual meeting of stockholders is first disclosed in a public announcement. The notice must contain specified information that is prescribed in our bylaws about you and the director nominee or the proposal, as applicable. If any director nomination or stockholder proposal is submitted after March 31, 2020,April 4, 2021, our bylaws provide that the nomination or the proposal shall be disregarded.


80    Ironwood


Table of Contents


GRAPHIC
SEC FILINGS
Filings

We file annual, quarterly and current reports, as well as other information with the SEC. You can obtain any of them from the SEC at its website atwww.sec.gov or at its Public Reference Room at 100 F Street, N.E., Washington, DC 20549.. The documents are also available from us without charge by requesting them in writing or by telephone from Ironwood Pharmaceuticals, Inc., 301 Binney100 Summer Street, Cambridge,Suite 2300, Boston, Massachusetts 02142,02110, Attention: Corporate Communications, telephone: (617) 621-7722.


Table621-7722, or by visiting the Investors section of Contents


Appendix A

Proposed Amendment to our Certificate of Incorporation

        The proposed amendment to the Company's Certificate of Incorporation would revise Article VII, Sections B and C thereof as shown below (new language is indicated by bolded underlined text, and deletions are indicated by strikethroughs):

B.website atwww.ironwoodpharma.comDirectors; Election; Term of Office.    

    1.
    Until the Company's 2022 annual meeting of stockholders, tThe directors shall be divided into three classes designated as Class I, Class II and Class III, respectively.At the firstClass III directors elected at the 2019 annual meeting of stockholdersfollowing the Effective Time, the term of officeshall have terms expiring at the 2022 annual meeting of stockholders. Notwithstanding the foregoing, at the 2020 annual meeting of stockholders, the successors of the Class I directorsshall expire, and Class I directorswhose terms expire at that meeting shall be elected fora full term of three years. At the secondterms expiring at the 2021 annual meeting of stockholders;following the Effective Time, the term of officeand at the 2021 annual meeting of stockholders, the successorsof the Class II directorsshall expire, and Class IIwhose terms expire at that meeting shall be elected for terms expiring at the 2022 annual meeting of stockholders. Commencing with the 2022 annual meeting of stockholders, the classification of the Board of Directors shall cease, and all directors shall be elected fora full term of three years. At the third annual meeting of stockholders following the Effective Time, the term of office of the Class III directors shall expire, and Class III directors shall be elected for a full term of three years. At eachterms expiring at the next succeeding annual meeting of stockholders., directors shall be elected for a full term of three years to succeed the directors of the class whose terms expire at such annual meeting. Notwithstanding the foregoing,Eeach director shall serve until hisor her successor is duly elected and qualified or until hisor her death, resignation or removal.

    2.
    For so long as the Board of Directors is classified, iIn the event of any increase in the authorized number of directors, the newly created directorships resulting from such increase shall be apportioned by the Board of Directors among the three classes of directors.

    3.
    No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director. Any election of directors by stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote in the election. The directors of the Corporation need not be elected by written ballot unless the By-laws of the Corporation so provide.

C.
Removal. Subject to the preferences applicable to any series of Preferred Stock,for so long as the Board of Directors is classified,the directors of the Corporation may be removed only for cause by the stockholders entitled to vote thereon; thereafter, the directors of the Corporation may be removed with or without cause by the stockholders entitled to vote thereon.

2020  Proxy Statement    81


Table of Contents

Appendix B

2019 Equity Incentive Plan

IRONWOOD PHARMACEUTICALS, INC.
2019 EQUITY INCENTIVE PLAN

1.DEFINED TERMS

Exhibit A, which is incorporated by reference, defines the terms used in the Plan and includes certain operational rules related to those terms.

2.PURPOSE

        The Plan has been established to advance the interests of the Company by providing for the grant to Participants of Stock, Stock-based and other incentive Awards. The Plan is effective as of the Effective Date.

3.ADMINISTRATION

        The Administrator has discretionary authority, subject only to the express provisions of the Plan, to interpret the Plan; determine eligibility for and grant Awards; determine, modify or waive the terms and conditions of any Award; determine the form of settlement of Awards (whether in cash, shares of Stock, or other property); prescribe forms, rules and procedures relating to the Plan and Awards; and otherwise do all things necessary or desirable to carry out the purposes of the Plan. Determinations of the Administrator made under the Plan are conclusive and bind all persons.

4.LIMITS ON AWARDS UNDER THE PLAN

(a)Number of Shares.    Subject to adjustment as provided in Section 7(b), the maximum number of shares of Stock that may be issued in satisfaction of Awards under the Plan is (1) 10,000,000 shares, plus (2) any shares of Stock underlying awards that are forfeited, expired or are cancelled without the delivery of shares of Stock under the Company's Amended and Restated 2005 Stock Incentive Plan or the Company's Amended and Restated 2010 Employee, Director and Consultant Equity Incentive Plan on and following the Effective Date (each, a "Prior Plan Award"). Up to the total number of shares of Stock set forth in the preceding sentence may be issued in satisfaction of ISOs, but nothing in this Section 4(a) will be construed as requiring that any, or any fixed number of, ISOs be awarded under the Plan. Further, (i) any shares of Stock withheld by the Company in payment of the exercise price or purchase price of an Award or Prior Plan Award in satisfaction of tax withholding requirements with respect to an Award or Prior Plan Award, (ii) the full number of shares covered by a SAR any portion of which is settled in Stock (and not only the number of shares of Stock delivered in settlement), and (iii) the number of shares of Stock underlying any Awards or Prior Plan Awards that are settled in cash, expire, become unexercisable, terminate or are forfeited to or repurchased by the Company without the issuance of Stock will not be available for grant under the Plan. For the avoidance of doubt, the number of shares of Stock available for delivery under the Plan will not be increased by any shares of Stock delivered under the Plan that are subsequently repurchased using proceeds directly attributable to Stock Option exercises. The limits set forth in this Section 4(a) will be construed to comply with Section 422.

(b)Substitute Awards.    The Administrator may grant Substitute Awards under the Plan. To the extent consistent with the requirements of Section 422 and the regulations thereunder and other applicable legal requirements (including applicable stock exchange requirements), Stock issued under Substitute Awards will be in addition to and will not reduce the number of shares available for Awards under the Plan set forth in Section 4(a), but, notwithstanding anything in Section 4(a) to the contrary, if any Substitute Award is settled in cash, expires, becomes unexercisable, terminates or is forfeited to or repurchased by the Company without the issuance of Stock, the shares of Stock previously subject to


Table of Contents

such Award will not be available for future grants under the Plan. The Administrator will determine the extent to which the terms and conditions of the Plan apply to Substitute Awards, if at all,provided, however, that Substitute Awards will not be subject to, or counted toward, the per-Participant Award limits described in Section 4(d) below.

(c)Type of Shares.    Stock delivered by the Company under the Plan may be authorized but unissued Stock, treasury Stock or previously issued Stock acquired by the Company. No fractional shares of Stock will be delivered under the Plan.

(d)Individual Limit.

    (1)   Awards comprising no more than 2,000,000 shares of Stock may be granted to any person under the Plan in any calendar year. In applying the foregoing limit, (i) all Awards granted to the same person in the same calendar year are aggregated and made subject to one limit; (ii) the limit as applicable to Stock Options and SARs refers to the number of shares of Stock underlying those Awards; and (iii) the share limit as applicable to Awards other than Stock Options and SARs refers to the maximum number of shares of Stock that may be delivered, or the value of which could be paid in cash or other property, under an Award or Awards assuming a maximum payout.

    (2)   Notwithstanding the foregoing limit, the aggregate value of all compensation granted or paid to any Director with respect to any calendar year, including Awards granted under the Plan and cash fees or other compensation paid by the Company to such Director outside of the Plan, for his or her services as a Director during such calendar year may not exceed $600,000 in the aggregate, calculating the value of any Awards based on the grant date fair value in accordance with the Accounting Rules, assuming a maximum payout.

5.ELIGIBILITY AND PARTICIPATION

        The Administrator shall select Participants from among Employees and Directors of, and consultants and advisors to, the Company and its subsidiaries. Eligibility for ISOs is limited to individuals described in the first sentence of this Section 5 who are employees of the Company or of a "parent corporation" or "subsidiary corporation" of the Company as those terms are defined in Section 424 of the Code. Eligibility for Stock Options, other than ISOs, and SARs is limited to individuals described in the first sentence of this Section 5 who are providing direct services on the date of grant of the Award to the Company or to a subsidiary of the Company that would be described in the first sentence of Treas. Regs. §1.409A-1(b)(5)(iii)(E).

6.RULES APPLICABLE TO AWARDS

(a)All Awards.

    (1)Award Provisions.    The Administrator shall determine the terms of all Awards, subject to the limitations provided herein. By accepting (or, under such rules as the Administrator may prescribe, being deemed to have accepted) an Award, the Participant will be deemed to have agreed to the terms of the Award and the Plan. Notwithstanding any provision of this Plan to the contrary, Substitute Awards may contain terms and conditions that are inconsistent with the terms and conditions specified herein, as determined by the Administrator.

    (2)Term of Plan.    No Awards may be made after 10 years from the Date of Adoption, but previously granted Awards may continue beyond that date in accordance with their terms.

    (3)Transferability.    Neither ISOs nor, except as the Administrator otherwise expressly provides in accordance with the third sentence of this Section 6(a)(3), other Awards may be transferred other than by will or by the laws of descent and distribution. During a Participant's lifetime, ISOs and, except as the Administrator otherwise expressly provides in accordance with the third sentence of this Section 6(a)(3), SARs and NSOs may be exercised only by the Participant.


Table of Contents

    The Administrator may permit the gratuitous transfer (i.e., transfer not for value) of Awards other than ISOs, subject to applicable securities and other laws and such limitations as the Administrator may impose.

    (4)Vesting.    The Administrator shall determine the time or times at which an Award vests or becomes exercisable and the terms on which a Stock Option or SAR remains exercisable. Without limiting the foregoing, the Administrator may at any time accelerate the vesting or exercisability of an Award, including, but not limited to, in connection with providing consideration for a restrictive covenant, regardless of any adverse or potentially adverse tax or other consequences resulting from such acceleration. Unless the Administrator expressly provides otherwise, the following rules will apply if a Participant's Employment ceases:

      (A)  Except as provided in (B) and (C) below, immediately upon the cessation of the Participant's Employment each Stock Option and SAR that is then held by the Participant or by the Participant's permitted transferees, if any, will cease to be exercisable and will terminate and all other Awards that are then held by the Participant or by the Participant's permitted transferees, if any, to the extent not already vested will be forfeited.

      (B)  Subject to (C) and (D) below, all Stock Options and SARs held by the Participant or the Participant's permitted transferees, if any, immediately prior to the cessation of the Participant's Employment, to the extent then exercisable, will remain exercisable for the lesser of (i) a period of three months or (ii) the period ending on the latest date on which such Stock Option or SAR could have been exercised without regard to this Section 6(a)(4), and will thereupon immediately terminate.

      (C)  Subject to (D) below, all Stock Options and SARs held by a Participant or the Participant's permitted transferees, if any, immediately prior to the cessation of the Participant's Employment due to death or Disability, to the extent then exercisable, will remain exercisable for the lesser of (i) the one-year period ending with the first anniversary of the Participant's cessation of Employment or (ii) the period ending on the latest date on which such Stock Option or SAR could have been exercised without regard to this Section 6(a)(4), and will thereupon immediately terminate. In addition, if the Participant's Employment ceases for any reason other than pursuant to (D) below and in the three months following such cessation of Employment the Participant dies or experiences a Disability, the exercisability of all Stock Options and SARs held by the Participant or the Participant's permitted transferees, if any, will automatically be extended upon such event and will remain exercisable for the lesser of (i) the one-year period ending with the first anniversary of the Participant's cessation of Employment or (ii) the period ending on the latest date on which such Stock Option or SAR could have been exercised without regard to this Section 6(a)(4), and will thereupon immediately terminate.

      (D)  All Stock Options and SARs (whether or not exercisable) held by a Participant or the Participant's permitted transferees, if any, immediately prior to the cessation of the Participant's Employment will immediately terminate upon such cessation of Employment if the termination is for Cause or occurs in circumstances that in the determination of the Administrator would have constituted grounds for the Participant's Employment to be terminated for Cause.

    (5)Recovery of Compensation.    The Administrator may provide in any case that outstanding Awards (whether or not vested or exercisable) and the proceeds from the exercise or disposition of Awards or Stock acquired under Awards will be subject to forfeiture and disgorgement to the Company, with interest and other related earnings, if the Participant to whom the Award was granted violates (i) a non-competition, non-solicitation, no-hire, non-disparagement, confidentiality, invention assignment or other restrictive covenant by which he or she is bound, or (ii) any


Table of Contents

    Company policy applicable to the Participant that provides for forfeiture or disgorgement with respect to incentive compensation that includes Awards under the Plan. In addition, the Administrator may require forfeiture and disgorgement to the Company of outstanding Awards and the proceeds from the exercise or disposition of Awards or Stock acquired under Awards, with interest and other related earnings, to the extent required by law or applicable stock exchange listing standards, including, without limitation, Section 10D of the Exchange Act, or any related Company policy. Each Participant, by accepting or being deemed to have accepted an Award under the Plan, agrees or will be deemed to have agreed to cooperate fully with the Administrator, and to cause any and all permitted transferees of the Participant to cooperate fully with the Administrator, to effectuate any forfeiture or disgorgement required hereunder. Neither the Administrator nor the Company nor any other person, other than the Participant and his or her permitted transferees, if any, will be responsible for any adverse tax or other consequences to a Participant or his or her permitted transferees, if any, that may arise in connection with this Section 6(a)(5).

    (6)Taxes.    The delivery, vesting and retention of Stock, cash or other property under an Award are conditioned upon full satisfaction by the Participant of all tax withholding requirements with respect to the Award. The Administrator shall prescribe such rules for the withholding of taxes with respect to any Award as it deems necessary, including, but not limited to, (a) providing that the Administrator may hold back shares of Stock from an Award, (b) permitting a Participant to tender previously owned shares of Stock in satisfaction of tax withholding requirements, or (c) permitting an authorized broker-dealer to sell shares of Stock subject to an Award and remit the cash proceeds of such sale to the Company to satisfy any tax withholding requirements related to such Award (provided that such arrangements will not result in withholding in excess of the maximum withholding amount consistent with the award being subject to equity accounting treatment under the Accounting Rules).

    (7)Dividends and Dividend Equivalents.    The Administrator may provide for the payment of amounts (on terms and subject to conditions established by the Administrator) in lieu of cash dividends or other cash distributions with respect to Stock subject to an Award whether or not the holder of such Award is otherwise entitled to share in the actual dividend or distribution in respect of such Award; provided, however, that (a) dividends or dividend equivalents relating to an Award that, at the dividend payment date, remains subject to a risk of forfeiture (whether service-based or performance-based) shall be subject to the same risk of forfeiture as applies to the underlying Award and (b) no dividends or dividend equivalents shall be payable with respect to Options or SARs. Any entitlement to dividend equivalents or similar entitlements will be established and administered either consistent with an exemption from, or in compliance with, the requirements of Section 409A. Dividends or dividend equivalent amounts payable in respect of Awards that are subject to restrictions may be subject to such limits or restrictions as the Administrator may impose.

    (8)Rights Limited.    Nothing in the Plan may be construed as giving any person the right to be granted an Award or to continued employment or service with the Company or any of its subsidiaries, or any rights as a stockholder except as to shares of Stock actually issued under the Plan. The loss of existing or potential profit in Awards will not constitute an element of damages in the event of termination of Employment for any reason, even if the termination is in violation of an obligation of the Company or any of its subsidiaries to the Participant.

    (9)Coordination with Other Plans.    Awards under the Plan may be granted in tandem with, or in satisfaction of or substitution for, other Awards under the Plan or awards made under other compensatory plans or programs of the Company or any of its subsidiaries. For example, but without limiting the generality of the foregoing, awards under other compensatory plans or programs of the Company or any of its subsidiaries may be settled in Stock (including, without


Table of Contents

    limitation, Unrestricted Stock) under the Plan if the Administrator so determines, in which case the shares delivered will be treated as awarded under the Plan (and will reduce the number of shares thereafter available under the Plan in accordance with the rules set forth in Section 4).

    (10)Section 409A.

      (A)  Without limiting the generality of Section 11(b) hereof, each Award will contain such terms as the Administrator determines and will be construed and administered, such that the Award either qualifies for an exemption from the requirements of Section 409A or satisfies such requirements.

      (B)  Notwithstanding Section 9 of this Plan or any other provision of this Plan or any Award agreement to the contrary, the Administrator may unilaterally amend, modify or terminate the Plan or any outstanding Award, including but not limited to changing the form of the Award, if the Administrator determines that such amendment, modification or termination is necessary or advisable to avoid the imposition of an additional tax, interest or penalty under Section 409A.

      (C)  If a Participant is deemed on the date of the Participant's termination of Employment to be a "specified employee" within the meaning of that term under Section 409A(a)(2)(B), then, with regard to any payment that is considered nonqualified deferred compensation under Section 409A, to the extent applicable, payable on account of a "separation from service", such payment will be made or provided on the date that is the earlier of (i) the expiration of the six-month period measured from the date of such "separation from service" and (ii) the date of the Participant's death (the "Delay Period"). Upon the expiration of the Delay Period, all payments delayed pursuant to this Section 6(a)(10)(C) (whether they would have otherwise been payable in a single lump sum or in installments in the absence of such delay) will be paid on the first business day following the expiration of the Delay Period in a lump sum and any remaining payments due under the Award will be paid in accordance with the normal payment dates specified for them in the applicable Award agreement.

      (D)  For purposes of Section 409A, each payment made under this Plan will be treated as a separate payment.

      (E)  With regard to any payment considered to be nonqualified deferred compensation under Section 409A, to the extent applicable, that is payable upon a change in control of the Company or other similar event, to avoid the imposition of an additional tax, interest or penalty under Section 409A, no amount will be payable unless such change in control constitutes a "change in control event" within the meaning of Section 1.409A-3(i)(5) of the Treasury Regulations.

(b)Stock Options and SARs.

    (1)Time and Manner of Exercise.    Unless the Administrator expressly provides otherwise, no Stock Option or SAR will be deemed to have been exercised until the Administrator receives notice of exercise in a form acceptable to the Administrator that is signed by the appropriate person and accompanied by any payment required under the Award. Any attempt to exercise a Stock Option or SAR by any person other than the Participant will not be given effect unless the Administrator has received such evidence as it may require that the person exercising the Award has the right to do so.

    (2)Exercise Price.    The exercise price (or the base value from which appreciation is to be measured) of each Award requiring exercise must be no less than 100% (in the case of an ISO granted to a 10-percent stockholder within the meaning of subsection (b)(6) of Section 422, 110%)


Table of Contents

    of the Fair Market Value of the Stock subject to the Award, determined as of the date of grant, or such higher amount as the Administrator may determine in connection with the grant.

    (3)Payment of Exercise Price.    Where the exercise of an Award is to be accompanied by payment, payment of the exercise price must be by cash or check acceptable to the Administrator or, if so permitted by the Administrator and if legally permissible, (i) through the delivery of previously acquired unrestricted shares of Stock, or the withholding of unrestricted shares of Stock otherwise deliverable upon exercise, in either case that have a Fair Market Value equal to the exercise price, (ii) through a broker-assisted exercise program acceptable to the Administrator, (iii) by other means acceptable to the Administrator, or (iv) by any combination of the foregoing permissible forms of payment. The delivery of previously acquired shares in payment of the exercise price under clause (i) above may be accomplished either by actual delivery or by constructive delivery through attestation of ownership, subject to such rules as the Administrator may prescribe.

    (4)Maximum Term.    The maximum term of Stock Options and SARs must not exceed 10 years from the date of grant (or five years from the date of grant in the case of an ISO granted to a 10-percent stockholder described in Section 6(b)(2) above).

    (5)No Repricing.    Except in connection with a corporate transaction involving the Company (which term includes, without limitation, any stock dividend, stock split, extraordinary cash dividend, recapitalization, reorganization, merger, consolidation, split-up, spin-off, combination or exchange of shares) or as otherwise contemplated by Section 7 below, the Company may not, without obtaining stockholder approval, (A) amend the terms of outstanding Stock Options or SARs to reduce the exercise price or base value of such Stock Options or SARs, (B) cancel outstanding Stock Options or SARs in exchange for Stock Options or SARs with an exercise price or base value that is less than the exercise price or base value of the original Stock Options or SARs, or (C) cancel outstanding Stock Options or SARs that have an exercise price or base value greater than the Fair Market Value of a share of Stock on the date of such cancellation in exchange for cash or other consideration.

7.EFFECT OF CERTAIN TRANSACTIONS

(a)Covered Transactions.    Except as otherwise expressly provided in an Award agreement, another agreement between the Company and a Participant, or the Company's Change of Control Severance Plan or otherwise by the Administrator, the following provisions will apply in the event of a Covered Transaction:

    (1)Assumption or Substitution.    If the Covered Transaction is one in which there is an acquiring or surviving entity, the Administrator may provide for (A) the assumption or continuation of some or all outstanding Awards or any portion thereof or (B) the grant of new awards in substitution therefor by the acquiror or survivor or an affiliate of the acquiror or survivor.

    (2)Cash-Out of Awards.    Subject to Section 7(a)(5) below, the Administrator may provide for payment (a "cash-out"), with respect to some or all Awards or any portion thereof, equal in the case of each affected Award or portion thereof to the excess, if any, of (A) the Fair Market Value of one share of Stock times the number of shares of Stock subject to the Award or such portion, over (B) the aggregate exercise or purchase price, if any, under the Award or such portion (in the case of a SAR, the aggregate base value above which appreciation is measured), in each case on such payment terms (which need not be the same as the terms of payment to holders of Stock) and other terms, and subject to such conditions, as the Administrator determines;provided, however, for the avoidance of doubt, that if the exercise or purchase price (or base value) of an


Table of Contents

    Award is equal to or greater than the Fair Market Value of one share of Stock, the Award may be cancelled with no payment due hereunder or otherwise in respect of such Award.

    (3)Acceleration of Certain Awards.    Subject to Section 7(a)(5) below, the Administrator may provide that any Award requiring exercise will become exercisable, in full or in part, and/or that the delivery of any shares of Stock remaining deliverable under any outstanding Award of Stock Units (including Restricted Stock Units and Performance Awards to the extent consisting of Stock Units) will be accelerated, in full or in part, in each case on a basis that gives the holder of the Award a reasonable opportunity, as determined by the Administrator, following exercise of the Award or the delivery of the shares, as the case may be, to participate as a stockholder in the Covered Transaction.

    (4)Termination of Awards upon Consummation of a Covered Transaction.    Except as the Administrator may otherwise determine in any case, each Award will automatically terminate (and in the case of outstanding shares of Restricted Stock, will automatically be forfeited) immediately upon consummation of the Covered Transaction, other than any Award that is assumed or substituted pursuant to Section 7(a)(1) above.

    (5)Additional Limitations.    Any share of Stock and any cash or other property or other award delivered pursuant to Section 7(a)(1), Section 7(a)(2) or Section 7(a)(3) above with respect to an Award may, in the discretion of the Administrator, contain such restrictions, if any, as the Administrator deems appropriate to reflect any performance or other vesting conditions to which the Award was subject and that did not lapse (and were not satisfied) in connection with the Covered Transaction. For purposes of the immediately preceding sentence, a cash-out under Section 7(a)(2) above or an acceleration under Section 7(a)(3) above will not, in and of itself, be treated as the lapsing (or satisfaction) of a performance or other vesting condition. In the case of Restricted Stock that does not vest and is not forfeited in connection with the Covered Transaction, the Administrator may require that any amounts delivered, exchanged or otherwise paid in respect of such Stock in connection with the Covered Transaction be placed in escrow or otherwise made subject to such restrictions as the Administrator deems appropriate to carry out the intent of the Plan.

(b)Changes in and Distributions with Respect to Stock.

    (1)Basic Adjustment Provisions.    In the event of a stock dividend, stock split or combination of shares (including a reverse stock split), recapitalization or other change in the Company's capital structure that constitutes an equity restructuring within the meaning of the Accounting Rules, the Administrator shall make appropriate adjustments to the maximum number of shares of Stock specified in Section 4(a) that may be issued under the Plan and to the maximum share limits described in Section 4(d), and shall make appropriate adjustments to the number and kind of shares of stock or securities underlying Awards then outstanding or subsequently granted, any exercise or purchase prices (or base values) relating to Awards and any other provision of Awards affected by such change.

    (2)Certain Other Adjustments.    The Administrator may also make adjustments of the type described in Section 7(b)(1) above to take into account distributions to stockholders other than those provided for in Section 7(a) and 7(b)(1), or any other event, if the Administrator determines that adjustments are appropriate to avoid distortion in the operation of the Plan, having due regard for the qualification of ISOs under Section 422 and the requirements of Section 409A, to the extent applicable.

    (3)Continuing Application of Plan Terms.    References in the Plan to shares of Stock will be construed to include any stock or securities resulting from an adjustment pursuant to this Section 7.


Table of Contents

8.LEGAL CONDITIONS ON DELIVERY OF STOCK

        The Company will not be obligated to deliver any shares of Stock pursuant to the Plan or to remove any restriction from shares of Stock previously delivered under the Plan until: (i) the Company is satisfied that all legal matters in connection with the issuance and delivery of such shares have been addressed and resolved; (ii) if the outstanding Stock is at the time of delivery listed on any stock exchange or national market system, the shares to be delivered have been registered with the U.S. Securities and Exchange Commission and listed or authorized to be listed on such exchange or system upon official notice of issuance; and (iii) all conditions of the Award have been satisfied or waived. The Company may require, as a condition to the exercise of an Award or the delivery of shares of Stock under an Award, such representations or agreements as counsel for the Company may consider appropriate to avoid violation of the Securities Act of 1933, as amended, or any applicable state or non-U.S. securities law. Any Stock required to be issued to Participants under the Plan will be evidenced in such manner as the Administrator may deem appropriate, including book-entry registration or delivery of stock certificates. In the event that the Administrator determines that stock certificates will be issued to Participants under the Plan or the Shares will be evidenced by book-entry, the Administrator may require that any certificates evidencing Stock issued under the Plan or the book-entry reflecting the issuance of Stock under the Plan bear an appropriate legend reflecting any restriction on transfer applicable to such Stock, and the Company may hold any such certificates pending lapse of the applicable restrictions.

9.AMENDMENT AND TERMINATION

        The Administrator may at any time or times amend the Plan or any outstanding Award for any purpose which may at the time be permitted by law, and may at any time terminate the Plan as to any future grants of Awards;provided, however, that except as otherwise expressly provided in the Plan the Administrator may not, without the Participant's consent, alter the terms of an Award so as to affect materially and adversely the Participant's rights under the Award, unless the Administrator expressly reserved the right to do so at the time the Award was granted. Any amendments to the Plan will be conditioned upon stockholder approval only to the extent, if any, such approval is required by law (including the Code) or applicable stock exchange requirements, as determined by the Administrator.

10.OTHER COMPENSATION ARRANGEMENTS

        The existence of the Plan or the grant of any Award will not affect the Company's right to award a person bonuses or other compensation in addition to Awards under the Plan.

11.MISCELLANEOUS

(a)Waiver of Jury Trial.    By accepting or being deemed to have accepted an Award under the Plan, each Participant waives (or will be deemed to have waived), to the maximum extent permitted under applicable law, any right to a trial by jury in any action, proceeding or counterclaim concerning any rights under the Plan and any Award, or under any amendment, waiver, consent, instrument, document or other agreement delivered or which in the future may be delivered in connection therewith, and agrees that any such action, proceedings or counterclaim will be tried before a court and not before a jury. By accepting or being deemed to have accepted an Award under the Plan, each Participant certifies that no officer, representative, or attorney of the Company has represented, expressly or otherwise, that the Company would not, in the event of any action, proceeding or counterclaim, seek to enforce the foregoing waivers. Notwithstanding anything to the contrary in the Plan, nothing herein is to be construed as limiting the ability of the Company and a Participant to agree to submit disputes arising under the terms of the Plan or any Award made hereunder to binding arbitration or as limiting the ability of the Company to require any eligible individual to agree to submit such disputes to binding arbitration as a condition of receiving an Award hereunder.


Table of Contents

(b)Limitation of Liability.    Notwithstanding anything to the contrary in the Plan, neither the Company, nor any of its subsidiaries, nor the Administrator, nor any person acting on behalf of the Company, any of its subsidiaries, or the Administrator, will be liable to any Participant, to any permitted transferee, to the estate or beneficiary of any Participant or any permitted transferee, or to any other holder of an Award by reason of any acceleration of income, or any additional tax (including any interest or penalties), asserted by reason of the failure of an Award to satisfy the requirements of Section 422 or Section 409A or by reason of Section 4999 of the Code, or otherwise asserted with respect to an Award.

12.ESTABLISHMENT OF SUB-PLANS

        The Administrator may at any time and from time to time establish one or more sub-plans under the Plan (for local-law compliance purposes or other administrative reasons determined by the Administrator) by adopting supplements to the Plan containing, in each case, such limitations on the Administrator's discretion under the Plan, and such additional terms and conditions, as the Administrator deems necessary or desirable. Each supplement so established will be deemed to be part of the Plan but will apply only to Participants within the group to which the supplement applies (as determined by the Administrator).

13.GOVERNING LAW

(a)Certain Requirements of Corporate Law.    Awards will be granted and administered consistent with the requirements of applicable Delaware law relating to the issuance of stock and the consideration to be received therefor, and with the applicable requirements of the stock exchanges or other trading systems on which the Stock is listed or entered for trading, in each case as determined by the Administrator.

(b)Other Matters.    Except as otherwise provided by the express terms of an Award agreement, under a sub-plan described in Section 12 or as provided in Section 13(a) above, the domestic substantive laws of the State of Delaware govern the provisions of the Plan and of Awards under the Plan and all claims or disputes arising out of or based upon the Plan or any Award under the Plan or relating to the subject matter hereof or thereof without giving effect to any choice or conflict of laws provision or rule that would cause the application of the domestic substantive laws of any other jurisdiction.

(c)Jurisdiction.    By accepting (or being deemed to have accepted) an Award, each Participant will be deemed to (a) have submitted irrevocably and unconditionally to the jurisdiction of the federal and state courts located within the geographic boundaries of the United States District Court for the District of Delaware for the purpose of any suit, action or other proceeding arising out of or based upon the Plan or any Award; (b) agree not to commence any suit, action or other proceeding arising out of or based upon the Plan or an Award, except in the federal and state courts located within the geographic boundaries of the United States District Court for the District of Delaware; and (c) waive, and agree not to assert, by way of motion as a defense or otherwise, in any such suit, action or proceeding, any claim that he or she is not subject personally to the jurisdiction of the above-named courts that his or her property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that the Plan or an Award or the subject matter thereof may not be enforced in or by such court.


Table of Contents


EXHIBIT A

Definition of Terms

        The following terms, when used in the Plan, have the meanings and are subject to the provisions set forth below:

"Accounting Rules":    Financial Accounting Standards Board Accounting Standards Codification Topics 505 and 718, as applicable, or any successor provision.

"Administrator":    The Compensation Committee, except that the Compensation Committee may delegate (i) to one or more of its members (or one or more other members of the Board, including the full Board) such of its duties, powers and responsibilities as it may determine; (ii) to one or more officers of the Company the power to grant Awards to the extent permitted by Section 152 or 157(c) of the Delaware General Corporation Law; and (iii) to such Employees or other persons as it determines such ministerial tasks as it deems appropriate. In the event of any delegation described in the preceding sentence, the term "Administrator" will include the person or persons so delegated to the extent of such delegation. Notwithstanding the foregoing, only the Board or the Compensation Committee shall be authorized to grant an Award to any director of the Company or to any "officer" of the Company (as defined by Rule 16a-1 under the Exchange Act).

"Award":    Any or a combination of the following:

              (i)  Stock Options.

             (ii)  SARs.

            (iii)  Restricted Stock.

            (iv)  Unrestricted Stock.

             (v)  Stock Units, including Restricted Stock Units.

            (vi)  Performance Awards.

           (vii)  Awards (other than Awards described in (i) through (vi) above) that are convertible into or otherwise based on Stock.

"Board":    The Board of Directors of the Company.

"Cause":    With respect to a Participant, (i) dishonesty with respect to the Company or any affiliate of the Company, (ii) insubordination, substantial malfeasance or non-feasance of duty, (iii) unauthorized disclosure of confidential information, (iv) breach by a Participant of any provision of any employment, consulting, advisory, nondisclosure, non-competition or similar agreement between the Participant and the Company or any affiliate of the Company, and (v) conduct substantially prejudicial to the business of the Company or any affiliate of the Company; provided, however, that this definition of "Cause" shall be superseded by (a) the definition of "Cause" contained in an agreement between a Participant and the Company or any affiliate of the Company that is in effect at the time of such termination, with respect to that Participant and (b) the definition of "Cause" contained in the Company's Change of Control Severance Benefit Plan to the extent such plan is in effect at the time of such termination, the Participant is a participant in such plan and such termination occurs within the period during which the Participant is eligible for enhanced severance benefits under the Company's Change of Control Severance Benefit Plan. The determination of the Administrator as to the existence of Cause will be conclusive on the Participant and the Company; provided, however, that if the determination is made within the period during which the Participant is eligible for enhanced severance benefits under the Company's Change of Control Severance Benefit Plan, then the determination will be subject to de novo review.


Table of Contents

"Code":    The U.S. Internal Revenue Code of 1986, as from time to time amended and in effect, or any successor statute as from time to time in effect.

"Compensation Committee":    The Compensation and HR Committee of the Board.

"Company":    Ironwood Pharmaceuticals, Inc., a Delaware corporation.

"Covered Transaction":    Any of (i) a consolidation, merger or similar transaction or series of related transactions, including a sale or other disposition of stock, in which the Company is not the surviving corporation or which results in the acquisition of all or substantially all of the Company's then outstanding common stock by a single person or entity or by a group of persons and/or entities acting in concert, (ii) a sale or transfer of all or substantially all the Company's assets, or (iii) a dissolution or liquidation of the Company. Where a Covered Transaction involves a tender offer that is reasonably expected to be followed by a merger described in clause (i) (as determined by the Administrator), the Covered Transaction will be deemed to have occurred upon consummation of the tender offer.

"Date of Adoption":    The earlier of the date the Plan was approved by the Company's stockholders or adopted by the Board, as determined by the Committee.

"Director":    A member of the Board who is not an Employee.

"Disability":    A disability that would entitle a Participant to long-term disability benefits under the Company's long-term disability plan in which the Participant participates. If a Participant does not participate a long-term disability plan of the Company, Disability means a permanent and total disability as defined in Section 22(e)(3) of the Code.

"Effective Date":    The date on which the Plan is first approved by the Company's stockholders.

"Employee":    Any person who is employed by the Company or any of its subsidiaries.

"Employment":    A Participant's employment or other service relationship with the Company or any of its subsidiaries. Employment will be deemed to continue, unless the Administrator expressly provides otherwise, so long as the Participant is employed by, or otherwise is providing services in a capacity described in Section 5 to, the Company or any of its subsidiaries. If a Participant's employment or other service relationship is with any subsidiary of the Company and that entity ceases to be a subsidiary of the Company, the Participant's Employment will be deemed to have terminated when the entity ceases to be a subsidiary of the Company unless the Participant transfers Employment to the Company or any of its remaining subsidiaries. Notwithstanding the foregoing, in construing the provisions of any Award relating to the payment of "nonqualified deferred compensation" (subject to Section 409A) upon a termination or cessation of Employment, references to termination or cessation of employment, separation from service, retirement or similar or correlative terms will be construed to require a "separation from service" (as that term is defined in Section 1.409A-1(h) of the Treasury Regulations) from the Company and from all other corporations and trades or businesses, if any, that would be treated as a single "service recipient" with the Company under Section 1.409A-1(h)(3) of the Treasury Regulations. The Company may, but need not, elect in writing, subject to the applicable limitations under Section 409A, any of the special elective rules prescribed in Section 1.409A-1(h) of the Treasury Regulations for purposes of determining whether a "separation from service" has occurred. Any such written election will be deemed a part of the Plan.

"Exchange Act":    The Securities Exchange Act of 1934, as amended.

"Fair Market Value":    As of a particular date, (i) the closing price for a share of Stock reported on the Nasdaq Stock Market (or any other national securities exchange on which the Stock is then listed) for that date or, if no closing price is reported for that date, the closing price on the immediately preceding date on which a closing price was reported or (ii) in the event that the Stock is


Table of Contents

not traded on a national securities exchange, the fair market value of a share of Stock determined by the Administrator consistent with the rules of Section 422 and Section 409A to the extent applicable.

"ISO":    A Stock Option intended to be an "incentive stock option" within the meaning of Section 422. Each Stock Option granted pursuant to the Plan will be treated as providing by its terms that it is to be an NSO unless, as of the date of grant, it is expressly designated as an ISO.

"NSO":    A Stock Option that is not intended to be an "incentive stock option" within the meaning of Section 422.

"Participant":    A person who is granted an Award under the Plan.

"Performance Award":    An Award subject to Performance Criteria.

"Performance Criteria":    Specified criteria, other than the mere continuation of Employment or the mere passage of time, the satisfaction of which is a condition for the grant, exercisability, vesting or full enjoyment of an Award. A Performance Criterion and any targets with respect thereto need not be based upon an increase, a positive or improved result or avoidance of loss and may be applied to the Participant individually, or to a business unit or division or the Company as a whole and may relate to any or any combination of the following (measured either absolutely or by reference to an index or indices or the performance of one or more companies and determined either on a consolidated basis or, as the context permits, on a divisional, subsidiary, line of business, product or product candidate, project or geographical basis or in combinations thereof), among any other criteria determined by the Administrator: achievement of research, clinical trial or other drug development objectives; achievement of regulatory objectives; achievement of manufacturing and/or supply chain or other operational objectives; sales; revenues; assets; expenses; earnings before or after deduction for all or any portion of interest, taxes, depreciation, or amortization, whether or not on a continuing operations or an aggregate or per share basis; return on equity, investment, capital or assets; one or more operating ratios; borrowing levels, leverage ratios or credit rating; market share; capital expenditures; cash flow; stock price; stockholder return; sales of particular products or services; customer acquisition or retention; acquisitions and divestitures (in whole or in part); joint ventures, licenses, collaborations and strategic alliances; spin-offs, split-ups and the like; reorganizations; recapitalizations, restructurings, financings (issuance of debt or equity) or refinancings; or any other objectives determined by the Administrator. The Administrator may provide that one or more of the Performance Criteria applicable to such Award will be adjusted to reflect events (including, but not limited to, the impact of charges for restructurings, discontinued operations, mergers, acquisitions, extraordinary items, and other unusual or non-recurring items, and the cumulative effects of tax or accounting changes, each as defined by U.S. generally accepted accounting principles) occurring during the applicable performance period that affect the applicable Performance Criterion or Criteria.

"Plan":    The Ironwood Pharmaceuticals, Inc. 2019 Equity Incentive Plan, as from time to time amended and in effect.

"Restricted Stock":    Stock subject to restrictions requiring that it be forfeited, redelivered or offered for sale to the Company if specified service or performance-based conditions are not satisfied.

"Restricted Stock Unit":    A Stock Unit that is, or as to which the delivery of Stock or cash in lieu of Stock is, subject to the satisfaction of specified performance or other vesting conditions.

"SAR":    A right entitling the holder upon exercise to receive an amount (payable in cash or in shares of Stock of equivalent value at the discretion of the Administrator) equal to the excess of the Fair Market Value of the shares of Stock subject to the right over the base value from which appreciation under the SAR is to be measured.

"Section 409A":    Section 409A of the Code.


Table of Contents

"Section 422":    Section 422 of the Code.

"Stock":    Class A common stock of the Company, par value $0.001 per share.

"Stock Option":    An option entitling the holder to acquire shares of Stock upon payment of the exercise price.

"Stock Unit":    An unfunded and unsecured promise, denominated in shares of Stock, to deliver Stock or cash measured by the value of Stock in the future.

"Substitute Awards":    Awards issued under the Plan in substitution for equity awards of an acquired company that are converted, replaced or adjusted in connection with the acquisition.

"Unrestricted Stock":    Stock not subject to any restrictions under the terms of the Award.


 

VOTE BY INTERNET Before The Meeting - Go to www.proxyvote.com UseYou may use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 P.M. Eastern Time the day before the meeting date. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form. IRONWOOD PHARMACEUTICALS, INC. 301 BINNEY100 SUMMER STREET, CAMBRIDGE,SUITE 2300 BOSTON, MA 0214202110 During The Meeting - Go to www.virtualshareholdermeeting.com/IRWD2020 You may also vote during the meeting. Have the information that is printed in the box marked by the arrow available and follow the instructions. ELECTRONIC DELIVERY OF FUTURE PROXY MATERIALS If you would like to reduce the costs incurred by our company in mailing proxy materials, you can consent to receiving all future proxy statements, proxy cards and annual reports electronically via e-mail or the Internet. To sign up for electronic delivery, please follow the instructions above to vote using the Internet and, when prompted, indicate that you agree to receive or access proxy materials electronically in future years. VOTE BY PHONE - 1-800-690-6903 Use any touch-tone telephone to transmit your voting instructions up until 11:59 P.M. Eastern Time the day before the meeting date. Have your proxy card in hand when you call and then follow the instructions. VOTE BY MAIL Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: E75744-P22797D14047-P36525 KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. IRONWOOD PHARMACEUTICALS, INC. The Board of Directors recommends you vote FOR the following: For Withhold For All AllAllExcept To withhold authority to vote for any individual nominee(s), mark "For All Except" and write the number(s) of the nominee(s) on the line below. ! !! 1. Election of Directors Nominees: 01) 02) 03) Andrew Dreyfus Julie H. McHugh Edward P. OwensMark G. Currie, Ph.D. Jon Duane Mark Mallon For Against Abstain The Board of Directors recommends you vote FOR the following proposals: ! ! ! ! ! ! ! ! ! ! ! ! 2. Approval, by non-binding advisory vote, of the compensation paid to the named executive officers. 3. Approval of an amendment to the Company's Certificate of Incorporation to declassify the Board of Directors. 4. Approval of the Company's 2019 Equity Incentive Plan. 5. Ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for 2019.2020. NOTE: In their discretion, the Proxies are authorized to vote upon such other business as may properly come before the meeting or any adjournment or postponement thereof. ! ! Please indicate if you plan to attend this meeting. Yes No Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer. Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date

 

Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: The Notice, Proxy Statement and Annual Report on Form 10-K are available at www.proxyvote.com. E75745-P22797D14048-P36525 IRONWOOD PHARMACEUTICALS, INC. Annual Meeting of Stockholders Thursday, May 30, 2019Wednesday, June 3, 2020 9:00 AM Eastern Time This proxy is solicited by the Board of Directors The stockholder(s) hereby appoint(s) Mark Mallon and Gina Consylman, or either of them, as proxies, each with the power to appoint his or her substitute, and hereby authorize(s) them to represent and to vote, as designated on the reverse side of this ballot, all of the shares of common stock of IRONWOOD PHARMACEUTICALS, INC. that the stockholder(s) is/are entitled to vote at the Annual Meeting of Stockholders to be held at 9:00 AM, Eastern Time on Thursday, May 30, 2019Wednesday, June 3, 2020 via live webcast at Ironwood Pharmaceuticals, Inc., 301 Binney Street, Cambridge, MA 02142,www.virtualshareholdermeeting.com/IRWD2020, and any adjournment or postponement thereof. The stockholder(s) hereby revoke(s) any proxy previously given and acknowledge(s) receipt of the notice and proxy statement for the Annual Meeting of Stockholders. This proxy, when properly executed, will be voted in the manner directed herein. If no such direction is made, this proxy will be voted in accordance with the recommendations of the Board of Directors. Continued and to be signed on reverse side

 

Table of Contents

GRAPHIC


Table of Contents

GRAPHIC